Metabolon and University of Texas Partner in Diabetes Research

Metabolon, a provider of metabolomics-driven biomarker discovery and analysis, has announced that it is collaborating with Ralph DeFronzo and colleagues at The University of Texas Health Science Center at San Antonio.

The partnership will help drive development of Metabolon’s pre-diabetes diagnostic products as well as provide valuable data for insulin resistance and diabetes-related research.

Metabolon will be analyzing samples from various studies conducted by Dr DeFronzo’s team to discover and validate biochemical biomarkers reflective of insulin resistance and beta cell dysfunction.

These biomarkers will be used to help further develop Metabolon’s diagnostic tests in the area of insulin resistance, and how this relates to risk of developing metabolic diseases such as diabetes.

John Ryals, CEO of Metabolon, said: “It is through collaborations like this one with Dr DeFronzo’s team that Metabolon will be able to offer a unique diagnostic test that can help physicians to identify asymptomatic, pre-diabetic patients years before they become diabetic.”

Meaghan Onofrey Named President of MBS/Vox

CommonHealth today announced the promotion of Meaghan Onofrey to president of MBS/Vox, the research consultancy unit of CommonHealth specializing in the analysis of naturally occurring healthcare interactions, including in-office physician-patient dialogue.

CommonHealth (www.commonhealth.com) is the world’s leading healthcare-communications network and a WPP (NASDAQ: WPPGY)(www.wpp.com) company.

Advancing from her previous role as general manager, Ms. Onofrey will oversee the management, operation and long-term planning for MBS/Vox, which includes innovating the group’s unique, reality-based research techniques for analyzing healthcare dialogue and driving strategy for pharmaceutical brands. Already in development are several new offerings, including a hospital-based methodology, and an initiative to address the question of how to drive medication adherence. Additionally, Ms. Onofrey will work with inter-company account teams to maximize client research and strategy offerings.

“In her five years at MBS/Vox, Meaghan has consistently exhibited outstanding leadership and creativity,” said Joe Gattuso, Chief Strategist for CommonHealth and former President of MBS/Vox. “She has played a significant role in many new business wins and in further strengthening our linguistic and marketing teams over the past year, making it our most successful year yet,” he added.

MBS/Vox, founded in 2000, was the first company to look into the exam room and assess physician-patient dialogue. This insight offered a radical shift from traditional market research because of the ability to see how physicians and patients actually talk about pharmaceutical brands and categories in real-life visits. The group has an extensive database of physician-patient interactions, and has published more than twenty-five articles documenting study results.

Ms. Onofrey joined MBS/Vox five years ago with extensive training in medical linguistics. During her five-year tenure, she has worked on more than eighty studies in a diverse assortment of therapeutic categories, including the first study to measure the impact of physician training on office dialogue. She has co-authored twenty publications and designed an array of communications-based tactical programs for her pharmaceutical clients. Ms. Onofrey holds a bachelor’s degree in linguistics and a master’s degree in sociolinguistics, both from Georgetown University.

CommonHealth comprises MBS/Vox, Altum, Carbon, CommonHealth London, CommonHealth Paris, Conectics, Earthborn, EvoLogue, Ferguson, HLS, Noesis, ProCom, Qi and Solara. The organization also maintains numerous partnerships both within and outside of the WPP network of companies.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=802446

 Contact: Beth Paulino or Kerianne McGuire CommonHealth (973) 352-1000  

SOURCE: MBS/Vox

BodyTel’s Blood Glucose Monitoring and Diabetes Management System, GlucoTel, Passes TNO Tests

JACKSONVILLE, Fla., July 23, 2008 (PRIME NEWSWIRE) — BodyTel Scientific Inc. (OTCBB:BDYT), a developer and manufacturer of wireless telemedical systems, announces today that the GlucoTel system has received certification from the Netherlands Organization for Applied Scientific Research TNO (“TNO”) by passing rigorous quality assurance tests. TNO is an independent group founded in 1932 that, among other things, thoroughly tests and inspects medical devices.

“The TNO approval offers consumers the reassurance that a product has been thoroughly tested and periodically monitored by an independent organization. TNO is known throughout Europe for their high standards and its tests are often more rigorous than the requirements for CE Marking,” stated, BodyTel CEO, Stefan Schraps. “Receiving the TNO approval is a testament to the accuracy and quality of the GlucoTel system.”

Dion van de Ven, CEO of TeleHealth Services, BodyTel’s distributor in the Benelux region, commented, “The TNO approval seal will assist us with the introduction of this telemedical solution within medical institutes, as well as assist our efforts in differentiating our product from our competitors. Also, there are already some insurance companies who are considering requiring the TNO certificate in order to have the costs reimbursed by them. Most important for the Benelux market is that the certification gives the quality-image that GlucoTel deserves.”

The GlucoTel system is a complete telemedical blood glucose monitoring and diabetes management system, supporting patients and healthcare professionals in the treatment and control of diabetes and other associated disorders. GlucoTel electronically measures the blood sugar level and then sends it automatically via Bluetooth to the patient’s cell phone. Measured values are automatically transmitted from the cell phone to BodyTel’s online database via mobile Internet connection and stored on a long-term basis in the patient’s secured profile. To facilitate better diabetes management, the patient and any authorized persons, e.g. healthcare professionals or other caregivers, can access the database ‘BodyTel Center’ at www.bodytel.com via the Internet at any time using a secure login.

The GlucoTel system is the first system of its kind that can provide real-time monitoring and management through its optional alarm functions. If defined by the caregiver, the BodyTel Center can create an alert message that can be sent to caregivers such as parents of a diabetic child, thereby informing them immediately of a potential out-of-range result or other unusual behavior like not performing any test within a predefined time frame. The versatility of the system provides all these tools, but use is completely optional and can be enabled or disabled based on patient, caregivers or healthcare professionals’ requirements preventing possible serious complications if action is taken without delay.

About BodyTel

BodyTel is a German-American telehealth company that specializes in telemedical monitoring and management systems for chronic diseases. The company combines its know-how in telecommunications, Internet and medical technology/diagnostics to create new products and services for the changing needs of global health. BodyTel products are designed not only to simplify home monitoring by patients, but also to ease the communication of ‘measured body values’ to healthcare professionals or other caregivers by bridging the gap between the patient and the caregivers instantaneously and in real-time. BodyTel’s products — GlucoTel, PressureTel and WeightTel — are each at different stages of development and approval processes.

Further information can be found at www.bodytel.com.

Forward-Looking Statements

Statements in this news release that are not historical are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,””plans,””anticipates,””believes,””intends,””estimates,””projects,””aims,””potential,””goal,””objective,””prospective,” and similar expressions, or that events or conditions “will,””would,””may,””can,””could” or “should” occur. Forward-looking statements in this news release include: The TNO approval seal will assist us with the introduction of this telemedical solution within medical institutes, as well as assist our efforts in differentiating our product from our competitors. It is important to note that the Company’s actual outcomes may differ materially from those statements contained in this press release. Factors which may delay or prevent these forward looking statements from being realized include, but are not limited to those concerning the timing of regulatory approval or commercialization of its products or the achievement of any other clinical, regulatory or product development milestones or other risk factors and matters set forth in the Company’s Annual Report on Form 10-KSB for the year ended February 28, 2007 and the Company’s periodic reports filed with the SEC. These reports are available on our investor relations website at www.bodytel.com and on the SEC’s website at http://www.sec.gov. BodyTel undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

This news release was distributed by PrimeNewswire, www.primenewswire.com

 CONTACT:  BodyTel Europe GmbH           Michaela Klinger           +49 (0)5621 96776 11           [email protected]            chain relations           Torsten Herrmann           06192/96 166 80           [email protected]            ZA Consulting Inc.           U.S. Investor Relations           David Zazoff           212-505-5976 

WorldDoc, Inc. And D2Hawkeye, Inc. Create Alliance to Improve Early Identification of Care Gaps

WorldDoc, Inc. and D2Hawkeye, Inc. announced today a strategic partnership to develop an enhanced consumer care gap identification system. D2Hawkeye’s wide range of clinical rules to predict individual and aggregate risk within a population will be integrated with WorldDoc’s consumer care management systems. The result will be earlier identification of medical care gaps for individuals with access to WorldDoc’s systems. Healthcare consumers will be further empowered to make better personal health decisions, leading to improved health outcomes and cost control.

The core component of WorldDoc’s consumer care management systems, WorldDoc 24/7, is an intuitive, interactive personal health management application that empowers users to evaluate symptoms, understand their health issues, assess health risks and take steps to decrease those risks. WorldDoc 24/7 collects, analyzes and integrates a user’s medical, prescription and personal health data to provide a comprehensive care management solution that includes personalized medical goals, care gap identification and communication with targeted, actionable treatment suggestions.

“This collaboration will enable consumers to receive personalized information from rules jointly developed by D2Hawkeye and WorldDoc clinicians. With D2Hawkeye as the ‘rules intelligence’ inside our system, we will be able to measure the immediate proactive effect of consumers’ behavior change. As further encouragement, we will be measuring the engagement levels and behavioral change impact over time,” said Rahul Singal, MD, president and CEO of WorldDoc, Inc. “It’s one thing to tell someone what to do; it’s another to determine their intent of action and provide them with meaningful and personal information that helps them reach their goals.”

D2 Hawkeye is a market leader in managing clinical risks and costs through intensive data mining techniques and automating the analytical process. D2Hawkeye will offer WorldDoc’s web-based consumer care management solution to their clients interested in engaging members through a consumer interfacing system.

Chris Kryder, MD, chairman and CEO of D2Hawkeye, is similarly enthusiastic about this important alliance. “Through WorldDoc’s consumer care management systems, we will readily embed our analytical methods in order to pinpoint the evidence-based medical opportunities required for early interventions. The fragmentation of care and information which is so common today has created a huge hole; the combination of WorldDoc’s portal and D2’s rules and predictive analytics fills this hole, and drives proactive engagement of the member. The freer flow of information will unequivocally improve outcomes and reduce costs,” said Kryder.

About WorldDoc, Inc.

WorldDoc Inc. is a leading provider of consumer care management systems to health plans, third-party administrators (TPAs) and employers. WorldDoc’s fully integrated product suite empowers individuals to make better healthcare decisions leading to decreased costs and improved health. WorldDoc’s solution integrates an individual’s health risk assessment (HRA), medical and pharmacy claims, laboratory testing results, medical care provider data and self-administered medical testing results to provide a comprehensive care management solution that includes personalized medical goals, care gap identification and communication with suggested treatments. WorldDoc’s complete integration of a patient’s health information provides a more personalized solution that increases member engagement. The company’s solutions contribute to effectiveness and cost savings in the areas of demand and disease management, pharmacy cost containment and disease prevention. For more information, visit www.worlddoc.com.

About D2Hawkeye

D2Hawkeye (D2) is the market leader for data service solutions for the healthcare industry. D2’s products include data mining, decision support, clinical quality analysis and risk analysis tools. The company builds and manages fully integrated medical and financial databases for its customers, applying its proprietary evidence-based medical rules, and provides an intuitive, easy-to-use, ASP-based interface for medical analytics and reporting. Industry professionals use D2’s tools to estimate cost and risk trends, to identify emerging high-risk consumers for optimal allocation of medical management resources and interventions, and to compare performance against industry benchmarks. The company also provides medical advisory, medical analytics, benchmarking and other business services on an outsourced basis. For more information, please visit www.d2hawkeye.com.

MAPK Signaling Regulates Nitric Oxide and NADPH Oxidase-Dependent Oxidative Bursts in Nicotiana Benthamiana(W)(OA)

By Asai, Shuta Ohta, Kohji; Yoshioka, Hirofumi

Nitric oxide (NO) and reactive oxygen species (ROS) act as signals in innate immunity in plants. The radical burst is induced by INF1 elicitin, produced by the oomycete pathogen Phytophthora infestans. NO ASSOCIATED1 (NOA1) and NADPH oxidase participate in the radical burst. Here, we show that mitogen-activated protein kinase (MAPK) cascades MEK2-SIPK/NTF4 and MEK1-NTF6 participate in the regulation of the radical burst. NO generation was induced by conditional activation of SIPK/NTF4, but not by NTF6, in Nicotiana benthamiana leaves. INF1- and SIPK/NTF4-mediated NO bursts were compromised by the knockdown of NOA1. However, ROS generation was induced by either SIPK/NTF4 or NTF6. INF1- and MAPK-mediated ROS generation was eliminated by silencing Respiratory Burst Oxidase Homolog B (RBOHB), an inducible form of the NADPH oxidase. INF1- induced expression of RBOHB was compromised in SIPK/NTF4/NTF6- silenced leaves. These results indicated that INF1 regulates NOA1- mediated NO and RBOHB-dependent ROS generation through MAPK cascades. NOA1 silencing induced high susceptibility to Colletotrichum orbiculare but not to P. infestans; conversely, RBOHB silencing decreased resistance to P. infestans but not to C. orbiculare. These results indicate that the effects of the radical burst on the defense response appear to be diverse in plant- pathogen interactions. INTRODUCTION

Rapid production of nitric oxide (NO) and reactive oxygen species (ROS), called the NO burst and the oxidative burst, respectively, plays a role in diverse physiological processes, such as resistance to biotic and abiotic stress, hormonal signaling, and development (Doke, 1983; Kwak et al., 2003; Bright et al., 2006; Grun et al., 2006; Takeda et al., 2008). Recently, NO has attracted attention as the radical that participates in innate immunity in plants. NO induces phytoalexin accumulation (Noritake et al., 1996), activation of the mitogen-activated protein kinase (MAPK; Clarke et al., 2000), and the expression of defense genes, such as Phe ammonia-lyase (PAL) and pathogenesisrelated proteins (Durner et al., 1998). In animals, NO is produced by NO synthase (NOS). The sources of NO synthesis in plants include reduction in nitrite by nitrate reductase (NR), oxidation of Arg to citrulline by NOS, and a nonenzymatic NO generation system (Bethke et al., 2004). Although evidence for Arg- dependent NO synthesis in plants has accumulated, no gene or protein that has a sequence similar to known mammalian-type NOShas been found in plants (Butt et al., 2003; Garcia-Mata and Lamattina, 2003). Guo et al. (2003) identified a NOS-like enzyme from Arabidopsis thaliana (At NOS1) with a sequence similar to a protein that has been implicated in NO synthesis in the snail Helix pomatia. The At NOS1 protein has no NOS activity (Zemojtel et al., 2006); therefore, At NOS1 was renamed At NOA1 for NO ASSOCIATED1 (Crawford et al., 2006). However, Arabidopsis mutant noa1 is still useful for its phenotype, which shows reduced levels of NO in plant growth, fertility, hormonal signaling, salt tolerance, and plant-pathogen responses (Guo et al., 2003; He et al., 2004; Zeidler et al., 2004; Zhao et al., 2007). Knocking out or down NOA1 expression provides a powerful tool to analyze NO function.

ROS are also important signaling molecules in plant immunity. In animals, ROS are synthesized by the phagocyte enzymatic complex of NADPH oxidase, which consists of two plasma membrane proteins, gp91^sup phox^ (phox for phagocyte oxidase) and p22^sup phox^. Cytosolic regulatory proteins, p47^sup phox^, p67^sup phox^, p40^sup phox^, and Rac2, translocate to the plasma membrane to form the active complex after stimulation (Lambeth, 2004). However, no homologs of the p22^sup phox^, p67^sup phox^, p47^sup phox^, and p40^sup phox^ regulators of the phagocyte NADPH oxidase were found in the Arabidopsis genome. However, a homolog of one component, human Rac GTPase, has been isolated from rice (Oryza sativa), and the constitutively active mutant of Rac activates ROS production (Wong et al., 2007). Plant NADPH oxidases designated as Respiratory Burst Oxidase Homolog (RBOH) have been identified as genes related to mammalian gp91^sup phox^ in various plants (Groom et al., 1996; Keller et al., 1998; Torres et al., 1998; Yoshioka et al., 2001, 2003; Sagi et al., 2004) and carry an N-terminal extension comprising two EF-hand motifs, suggesting that Ca^sup 2+^ regulates their activity. RBOHs are localized on the plasma membrane (Kobayashi et al., 2006). Arabidopsis rbohD rbohF double mutants show greatly decreased ROS production in response to infection with avirulent Pseudomonas syringae pv tomato DC3000 and Hyaloperonospora parasitica and in response to abscisic acid (Torres et al., 2002; Kwak et al., 2003). Analysis of the loss of function of Nt RBOHD in tobacco cells (Nicotiana tabacum) showed loss of ROS production by elicitor treatment (Simon-Plas et al., 2002). We also showed that silencing Nb RBOHA and Nb RBOHB in Nicotiana benthamiana plants leads to less ROS production and reduced resistance to infection by the potato pathogen Phytophthora infestans (Yoshioka et al., 2003). These reports suggest that RBOH is a key regulator of ROS production and has pleiotropic functions in plants.

The MAPK cascade is a major conserved signaling pathway used to transduce extracellular stimuli into intracellular responses in eukaryotes (MAPK Group, 2002; Nakagami et al., 2005). In the MAPK signal transduction cascade, a MAPK is activated by a MAPK kinase (MAPKK), which itself is activated by a MAPKK kinase (MAPKKK). Many studies have extensively characterized plant MAPKs, including tobacco wound-induced protein kinase (WIPK; Seo et al., 1999) and salicylic acid-induced protein kinase (SIPK; Zhang and Klessig, 1997) and their orthologs in other plant species (Lee et al., 2004; Katou et al., 2005; Pedley and Martin, 2005). WIPK and SIPK participate either in N gene-dependent resistance to tobacco mosaic virus (TMV; Zhang and Klessig, 1998; Jin et al., 2003) or in Cf9- dependent resistance to Cladosporium fulvum-derived elicitor Avr9 (Romeis et al., 1999) in a gene-for-gene specific way and in response to plant species-specific elicitors, such as elicitins (Zhang et al., 2000). MEK2, a tobacco MAPKK, is upstream of both WIPK and SIPK (Yang et al., 2001). Expression of Nt MEK2DD, a constitutively active mutant of MEK2, induces hypersensitive response (HR)-like cell death, defense gene expression, and generation of ROS, all of which are preceded by activation of endogenous WIPK and SIPK (Yang et al., 2001; Ren et al., 2002). We also cloned the potato (Solanum tuberosum) ortholog of tobacco MEK2, St MEK2, which was formerly described as St MEK1 (Katou et al., 2003). Heterologous expression of St MEK2DD in N. benthamiana induces WIPK and SIPK activities (Katou et al., 2003) and then an oxidative burst accompanied by increased RBOHB expression (Yoshioka et al., 2003). MAPKKKa was identified as an upstream activator of MEK2 and SIPK in N. benthamiana (del Pozo et al., 2004). Silencing the MAPKKKalpha gene eliminated HR-like cell death caused by interaction between the P. syringae avirulence gene AvrPto and its cognate resistant gene Pto (del Pozo et al., 2004). Interestingly, HR-like cell death induced by MAPKKKa overexpression is reduced not only by silencing MEK2 or SIPK, but also by silencing MEK1 or NTF6 (del Pozo et al., 2004). NPK1-MEK1/NQK1-NTF6/NRK1 is a pivotal MAPK cascade in the regulation of cytokinesis (Soyano et al., 2003; Sasabe et al., 2006). Like WIPK or SIPK, silencing NPK1, MEK1, or NTF6 attenuates N- and Pto-mediated resistance against TMV (Jin et al., 2002; Liu et al., 2004) and P. syringae AvrPto, respectively (Ekengren et al., 2003). These studies indicated that MAPK cascades MEK2-WIPK/SIPK and NPK1-MEK1-NTF6 participate in disease resistance in plants. In addition, recent work has shown that tobacco NTF4, which shares 93.6% identity with SIPK, is also activated by MEK2, and ectopic expression of NTF4 induces HR-like cell death (Ren et al., 2006). However, the relationship between these MAPK cascades and the radical burst in response to pathogen signals is not clear.

In this study, we investigated the roles of MEK2-WIPK/SIPK/NTF4 and MEK1-NTF6 cascades in the regulation of NO and oxidative bursts in N. benthamiana. Gain-of-function and loss-offunction analyses showed that the MEK2-SIPK/NTF4 cascade controls the NOA1-mediated NO burst and that MEK2-SIPK/NTF4 and MEK1-NTF6 cascades regulate the NADPH oxidasedependent oxidative burst. We also show that the NO burst and the oxidative burst have distinct effects on resistance to P. infestans and Colletotrichum orbiculare (syn. C. lagenarium) in N. benthamiana.

RESULTS

St MEK2^sup DD^ ActivatesMEK2-WIPK/SIPK Cascade, and Nb MEK1^sup DD^ Activates MEK1-NTF6 Cascade

To examine the function of MEK1-NTF6 cascade, we first isolated the tobacco MEK1 homolog from N. benthamiana using PCR with primers derived from a sequence of Nt MEK1 using an N. benthamiana cDNA library as a template. Analysis of the deduced amino acid sequence of the PCR product showed that the product of this gene shares >99% identity with Nt MEK1, so it was designated Nb MEK1 (N. benthamiana MEK1). In plants, MAPKKs are activated through phosphorylation of two Ser/Thr residues in a conserved S/TxxxxxS/T motif by MAPKKKs (MAPK Group, 2002). Replacement of two Ser/Thr residues with Glu or Asp results in constitutive activation of plant MAPKK (Yang et al., 2001; Ren et al., 2002). To examine the function of MEK1, we constructed Nb MEK1^sup DD^, a constitutively active mutant of Nb MEK1, in which the conserved Ser-219 and Thr-225 were converted to Asp. Nb MEK1^sup DD^ was expressed under the control of the 35S promoter of Cauliflower mosaic virus using Agrobacterium tumefaciens infiltration of N. benthamiana leaves. Immunocomplex (IC) kinase assay using anti-NTF6 antibody showed no activation of NTF6 by Nb MEK1^sup DD^, probably because the amount of endogenous NTF6 was not sufficient to detect the activity by the antibody. Therefore, NTF6- HA (hemagglutinin) was co-expressed with Nb MEK1^sup DD^-HA or with inf1, an elicitin elicitor produced by P. infestans (Kamoun et al., 2003), by Agrobacterium infiltration in N. benthamiana leaves. As shown in Figure 1A, we confirmed that NTF6 is activated by Nb MEK1^sup DD^ and INF1. Our previous results showed that Agrobacterium-mediated expression of St MEK2^sup DD^, a constitutively active mutant of St MEK2, the potato ortholog of Nt MEK2, induces HR-like cell death accompanied by oxidative burst in N. benthamiana leaves, preceded by the activation of WIPK and SIPK (Katou et al., 2003; Yoshioka et al., 2003). In this study, we also found that St MEK2^sup DD^ and INF1 activate WIPK and SIPK by IC kinase assay using anti-WIPK and SIPK antibodies (Figure 1A).

INF1 and StMEK2^sup DD^ Induce NOA1-Mediated NO Burst

We reported previously that a NO burst is induced by INF1 in tobacco cell suspension culture (Yamamoto et al., 2004). To investigate whether MAPK cascades regulate the NO burst, St MEK2^sup DD^ and Nb MEK1^sup DD^ were expressed using Agrobacterium infiltration in N. benthamiana leaves; inf1 and beta-glucuronidase (GUS) were also expressed as positive and negative controls, respectively. The NO burst was detected by 4,5-diaminofluorescein diacetate (DAF-2DA)-mediated fluorescence (Figure 1B). Sodium nitroprusside, a NO generator, produced DAF-2DA-mediated fluorescence (Figure 1B), and the inducible fluorescence was eliminated by 2-4-carboxyphenyl-4,4,5,5-tetramethylimidazoline-1- oxyl-3-oxide (cPTIO), a NO scavenger (Figure 2), indicating that DAF- 2DA detects NO. At 36 h after infiltration, the NO burst was markedly induced by the expression of St MEK2^sup DD^, but not by Nb MEK1^sup DD^ (Figure 1B), suggesting that the NO burst is regulated by MEK2-WIPK/SIPK cascade. Timecourse experiments showed that the DAF-2DA-mediated fluorescence was detected within 24 h after the infiltration and gradually increased until 36 h; thereafter, the leaf tissues showed a cell death phenotype. The timing of the NO burst was well matched with protein levels of St MEK2^sup DD^ (see Supplemental Figure 1 online). Therefore, the fluorescence intensities were measured at 36 h in the following experiments.

Next, we silenced MEK1 and MEK2 in N. benthamiana by virus- induced gene silencing (VIGS) to investigate the functions of these MAPKKs. We cloned cDNA fragments of Nb MEK1 and Nb MEK2 into tobacco rattle virus (TRV) vector and introduced these into N. benthamiana by Agrobacterium infiltration (Ratcliff et al., 2001). Three weeks after the infiltration, the efficiency of the silencing was monitored using RT-PCR. The MEK1 and MEK2 transcripts decreased markedly in the silenced plants compared with the control plants infected with TRV vector alone (see Supplemental Figure 2 online). The silenced leaves were inoculated with A. tumefaciens containing inf1, St MEK2^sup DD^, or GUS as a control. The NO generation induced by INF1 and St MEK2^sup DD^ was not compromised in MEK1- silenced plants compared with the NO generation in the TRV control- inoculated plants (Figure 1C). By contrast, MEK2-silenced plants showed a marked reduction in NO generation by INF1 (Figure 1C). NO production by St MEK2^sup DD^ decreased to the level induced by GUS as a control because VIGS of Nb MEK2 also silenced the St MEK2^sup DD^ transgene (see Supplemental Figure 2 online). These results indicate that the MEK2-WIPK/SIPK cascade, but not the MEK1-NTF6 cascade, participates in signaling pathways leading to the NO burst induced by INF1.

NOA1 participates indirectly in Arg-dependent NOS activity in plants (Guo et al., 2003; Zhao et al., 2007). To determine whether NOA1 contributes to the NO burst induced by INF1 and St MEK2^sup DD^, we isolated the NOA1 homolog from N. benthamiana (Kato at el., 2008) and silenced Nb NOA1 using the TRV-VIGS system. The transcripts in the silenced plants decreased compared with control plants infected with TRV alone (see Supplemental Figure 3A online). Silenced leaves were inoculated with A. tumefaciens harboring inf1, St MEK2^sup DD^ or GUS as a control. The NO generation induced by INF1 and St MEK2^sup DD^ significantly decreased in NOA1-silenced plants compared with TRV controlinoculated plants (Figure 2), suggesting that NOA1 participates in the NO burst induced by INF1 and St MEK2^sup DD^. Furthermore, we examined effects of some inhibitors on NO generation. L-NAME, the NOS inhibitor NG-nitro-L- Arg-methyl ester, significantly reduced NO generation induced by INF1 and St MEK2^sup DD^ in TRV control-plants but not in NOA1- silenced plants (Figure 2). By contrast, D-NAME, an inactive isomer of L-NAME, had no effect on NO burst induced by INF1 (see Supplemental Figure 4 online). The results suggested that NOA1 takes part in NO burst induced by INF1 and St MEK2^sup DD^ and are in agreement with previous reports showing the involvement of NOA1 in Arg-dependent NOS activity (Guo et al., 2003; Zhao et al., 2007). Tungstate, an NR inhibitor, also significantly decreased NO generation in both TRV control- and NOA1-silenced plants (Figure 2), suggesting that NR is also involved in NO burst induced by INF1 and St MEK2^sup DD^.

SIPK and NTF4 Are Required for NO Burst Induced by INF1 and St MEK2^sup DD^

Weevaluated whether theNOgeneration induced by INF1 and St MEK2^sup DD^ depends on WIPK, SIPK, or both. We silenced WIPK and SIPK in N. benthamiana and confirmed a marked reduction in WIPK and SIPK transcripts in the silenced plants compared with control plants infected with TRV alone (Figure 3A). The NO generation induced by INF1 and St MEK2^sup DD^ was slightly reduced in WIPK-silenced plants compared with that in TRV control plants (Figure 3B). By contrast, VIGS of SIPK and WIPK/SIPK markedly reduced the NO generation to near the control level (Figure 3B). These results indicate the involvement of SIPK in the INF1-induced NO burst.

Recently, NTF4 was shown to share the same upstream MAPKK, MEK2, with SIPK and WIPK and to participate in disease resistance. Similar to SIPK and WIPK, NTF4 can also be activated by cryptogein, an elicitin elicitor derived from oomycete pathogen Phytophthora cryptogea, like INF1 (Ren et al., 2006). It is possible that NTF4 is also silenced in SIPK-silenced leaves because NTF4 shows high sequence identity to SIPK (see Supplemental Figure 5 online). We confirmed that VIGS of SIPK also silenced NTF4 using SIPK- and NTF4- specific primers (Figure 3A). To investigate the possibility that NTF4 is involved in NO generation, gain-of-function analyses of SIPK and NTF4 were done by Agrobacterium infiltration methods. The overexpression of SIPK and NTF4 resulted in the increases in SIPK and NTF4 activities, respectively (Figure 3C) as shown by Zhang and Liu (2001) and Ren et al. (2006). NO generation was induced by NTF4 as well as SIPK and compromised in NOA1-silenced plants (Figure 3D), suggesting that SIPK and NTF4 are involved in NO burst induced by INF1 and St MEK2^sup DD^.

Silencing SIPK Compromises the Expression of RBOHB Induced by St MEK2^sup DD^ but Not by INF1

MAPK cascade participates in signaling to the oxidative burst (Yang et al., 2001; Ren et al., 2002). Our previous study showed that INF1 and St MEK2^sup DD^ induce an oxidative burst accompanied by expression of RBOHB, which is an inducible form of the NADPH oxidase of N. benthamiana (Yoshioka et al., 2003). To assess whether the expression of RBOHB induced by INF1 and St MEK2^sup DD^ depends on WIPK, SIPK, or both, we silenced the two MAPKs in N. benthamiana. Silenced leaves were inoculated with A. tumefaciens containing inf1 or St MEK2^sup DD^ (Figure 4). We confirmed a reduction in accumulation of WIPK and SIPK transcripts in the silenced plants using RNA gel blot hybridization. The expression of RBOHB induced by St MEK2^sup DD^ eliminated SIPK- and WIPK/SIPK-silenced plants (Figure 4), indicating that the MEK2-SIPK cascade regulates the expression of RBOHB. Unexpectedly, INF1-induced RBOHB expression was not compromised by the silencing of either WIPK or SIPK (Figure 4). These results suggest that INF1-induced expression of the RBOHB gene can be mediated by means of other signal pathways in addition to the MEK2-SIPK cascade.

Nb MEK1^sup DD^ Induces RBOHB-Dependent Oxidative Burst

INF1 activated NTF6 and SIPK (Figure 1A). This finding prompted us to examine the possibility that Nb MEK1^sup DD^ induces the oxidative burst accompanied by the expression of RBOHB. N. benthamiana leaves were inoculated with A. tumefaciens containing Nb MEK1^sup DD^, St MEK2^sup DD^, inf1, or GUS as control. At 24 h after inoculation with A. tumefaciens, the leaves were infiltrated with L-012 solution, a highly sensitive agent used to detect ROS (Imada et al., 1999; Kobayashi et al., 2007), and were observed using a sensitive CCD camera. We confirmed that luminol detects not only ROS but also NO, whereas L-012 is highly ROS specific (see Supplemental Figure 6 online). Time-course experiments showed that L- 012-mediated chemiluminescence peaked at 24 h after the agroinfiltration in agreement with protein levels of St MEK2^sup DD^ (see Supplemental Figure 1 online) and with the expression profile of RBOHB (Figure 4). Therefore, ROS production was determined at 24 h in the following experiments. We found that Nb MEK1^sup DD^ caused a modest oxidative burst compared with INF1 or St MEK2^sup DD^ (Figure 5A). The expression of RBOHB was assessed at the indicated times after inoculation with A. tumefaciens and Agrobacterium infiltration buffer as a control. INF1 and St MEK2^sup DD^ induced accumulation of RBOHB transcripts, and Nb MEK1^sup DD^ also significantly activated the gene compared with GUS control (Figure 5B), which agreed with the profile of oxidative burst shown in Figure 5A. VIGS of NTF6 (see Supplemental Figure 3B online) compromised the expression of RBOHB induced by Nb MEK1^sup DD^ (Figure 5C). These results suggest that the MEK1-NTF6 cascade participates in the RBOHBdependent oxidative burst. To confirm this possibility, we silenced RBOHA, which is a constitutively expressing form of the NADPH oxidase, as well as RBOHB in N. benthamiana. The effects of VIGS were monitored by RT-PCR, and both genes were well silenced (see Supplemental Figure 3B online). Silencing RBOHA slightly suppressed ROS generation induced by St MEK2^sup DD^, but knockdown of RBOHB eliminated the oxidative burst induced by INF1, St MEK2^sup DD^, and Nb MEK1^sup DD^ to the control level (Figure 5D). These results strongly suggest that in addition to the MEK2- SIPK cascade, the MEK1-NTF6 cascade also participates in the RBOHB- dependent oxidative burst.

Silencing SIPK and NTF6 Compromises the RBOHB-Dependent Oxidative Burst Induced by INF1

Both MEK2-SIPK and MEK1-NTF6 cascades might participate in the RBOHB-dependent oxidative burst (Figure 5). However, the downstream signaling pathways from INF1 to the oxidative burst are not clear. To evaluate the roles of SIPK and NTF6 in the RBOHB-dependent oxidative burst induced by INF1,wesilenced SIPK and NTF6 in N. benthamiana. The effects of VIGS were monitored by RT-PCR, and each target gene was fully silenced (see Supplemental Figure 3C online). The silenced leaves were inoculated with A. tumefaciens containing inf1. The expression of RBOHB was partially compromised in NTF6- silenced plants compared with TRV control-inoculated plants (Figure 6A). By contrast, double silencing of SIPK and NTF6 showed pronounced reduction of accumulation of RBOHB transcripts by INF1 (Figure 6A). Similarly, VIGS of SIPK and NTF6 showed a more marked reduction in ROS generation than the reduction in ROS generation in plants silenced for SIPK or NTF6 (Figure 6B). We examined the possibility that NTF4 also participates in the ROS generation as shown in NO generation because VIGS of SIPK cosilenced NTF4(Figure 3). The overexpression of SIPK and NTF4 by Agrobacterium infiltration activated RBOHB gene expression and the oxidative burst (Figures 6C and 6D). The SIPKand NTF4-induced oxidative bursts were abolished by silencing RBOHB (Figure 6D). These data indicate that both the MEK2- SIPK/NTF4 cascade and MEK1-NTF6 cascade are responsible for the RBOHB-dependent oxidative burst induced by INF1.

Silencing NOA1 and/or RBOHB Affects Susceptibility to P. infestans and C. orbiculare

We showed that NOA1 andRBOHBplay key roles in theNOburst and oxidative burst, respectively. As shown in Figure 7, we next examined the effects of silencing NOA1, RBOHB, or both on the basal defense to P. infestans, a potent pathogen of N. benthamiana (Kamoun et al., 1998), and C. orbiculare (syn. C. lagenarium), which is the causal agent of cucumber anthracnose disease and is also pathogenic to N. benthamiana (Takano et al., 2006). The effects of VIGS were monitored by RT-PCR, and each target gene was well silenced (see Supplemental Figure 3A online). INF1 derived from P. infestans induced NOA1-mediated NO and RBOHB-dependent oxidative bursts in N. benthamiana leaves, suggesting that NO and oxidative bursts were caused during P. infestans and N. benthamiana interactions. Supplemental Figure 7 online shows that C. orbiculare caused NOA1- mediated NO and RBOHB-dependent oxidative bursts in N. benthamiana leaves within 6 h after inoculation.

Zoospores of the virulent isolate of P. infestans were inoculated on the surface of the silenced leaves of N. benthamiana. NOA1- and NOA1/RBOHB-silenced plants showed yellowish leaves (Figure 7A), which were similar to the leaves of the Arabidopsis noa1 knockout mutant (Guo et al., 2003). The phenotype is distinct from disease symptoms by pathogen infection. Although TRV control leaves showed modest disease symptoms (50%) disease symptoms, respectively. Double silencing of NOA1 and RBOHB also gave a high susceptibility to P. infestans (Figures 7B and 7D). Analysis of P. infestans biomass by real-time PCR showed that the growth rate of P. infestans matches the severity of the disease symptoms in the leaves (Figure 7D). Furthermore, to rule out the possibility that the insert sequences for VIGS also silenced unknown defense-related sequences, we used 59-terminal regions of the target genes for silencing. The phenotype of the silenced plants was similar to those in Figure 7 (see Supplemental Figure 8B online). These results indicated that RBOHB rather than NOA1 plays an important role in basal defense to P. infestans.

C. orbiculare conidia were sprayed on the silenced leaves. Small dark-colored spot lesions, which reflect susceptibility, not HR cell death, appeared on the leaves 6 d after the inoculation (Figures 7C and 7E). The number and size of disease spots on NOA1- or NOA1/ RBOHB-silenced leaves increased approximately twofold compared with TRV control leaves. The number and size of spots on RBOHB-silenced leaves were similar to those of TRV control leaves. We also used 59- terminal regions of the target genes for silencing and confirmed the phenocopy in these silenced plants (see Supplemental Figure 8C online). These results indicate that NOA1, but not RBOHB, appears to participate in basal defense to C. orbiculare.

DISCUSSION

In this study, we performed Agrobacterium-mediated expression assays and VIGS as gain-of-function and loss-of-function analyses, respectively, and found that the MEK2-SIPK/NTF4 cascade controls the NOA1-mediated NO burst, and MAPK cascades MEK2-SIPK/NTF4 andMEK1- NTF6 regulate the NADPHoxidasedependent oxidative burst as summarized in Figure 8. Knockdown of NOA1 and RBOHB showed that NO and oxidative bursts participate in defense responses to pathogens.

NOA1 Is Required for NO Burst, and RBOH Is Required for Oxidative Burst in Defense Responses

Many studies have shown that NOS plays a pivotal role in NO synthesis in plants, as well as animals, and is responsible for various stress responses, development, and disease resistance (Guo et al., 2003; He et al., 2004; Zeidler et al., 2004; Zhao et al., 2007). Although arguments exist on the nature of NOA1 (Crawford et al., 2006; Zemojtel et al., 2006), the Arabidopsis knockout mutant noa1 impairs Arg-dependent NOS activity (Guo et al., 2003; Zhao et al., 2007), increases disease susceptibility to the pathogen P. syringae pv tomato DC3000 (Zeidler et al., 2004), and is highly vulnerable to salt and oxidative stress (Zhao et al., 2007). In this study, we showed that VIGS of N. benthamiana NOA1 compromised INF1- , St MEK2DD-, and pathogen-induced NO bursts. Furthermore, L-NAME, a NOS inhibitor, did not reduce the NO burst in NOA1-silenced plants (Figure 2). Together, these findings show that this gene product can participate in the process of NO production by NOS activity. NOA1 gene expression is not induced by INF1 treatment in N. benthamiana (Kato et al., 2008), suggesting that posttranscriptional control of NOA1-influenced NO production is effected through the MEK2-SIPK/ NTF4 cascade.

It has been shown that NR, a key enzyme of nitrogen assimilation, is another enzyme capable of producing NO in plants (Lamattina et al., 2003; Yamamoto et al., 2003). Here, we found that silencing NOA1 did not completely inhibit the NO burst induced by INF1 and St MEK2^sup DD^ (Figure 2). Furthermore, the NO burst was significantly suppressed by tungstate, a NR inhibitor, in both TRV control- and NOA1-silenced plants (Figure 2). These results suggest that another factor, NR, also participates in the NO burst induced by INF1 and St MEK2^sup DD^ in agreement with the previous finding that NR1 partially contributes to the INF1-induced NO burst in N. benthamiana (Yamamoto-Katou et al., 2006). However, the NOA1 silencing concomitant treatment with tungstate did not result in complete inhibition of the NO generation, suggesting that the nonenzymatic NO generation system also contributes to the NO burst, as reported by Bethke et al. (2004).

Defense-related RBOHs, which play a pivotal role in ROS production in response to pathogen signals, seem to be regulated at the transcriptional and posttranslational levels. We indicated previously that a calcium-dependent protein kinase (St CDPK5) activates potato RBOHs by direct phosphorylation of the N-terminal regions (Kobayashi et al., 2007). CDPK appears to regulate a rapid and transient accumulation of hydrogen peroxide (H^sub 2^O^sub 2^; phase I burst) and a massive oxidative burst at 6 to 9 h after elicitor treatment (phase II burst; Yoshioka et al., 2001; Kobayashi et al., 2007). Liu et al. (2007) reported that conditional gain-of- function by Nt MEK2^sup DD^ causes rapid shutdown of carbon fixation reaction in chloroplasts, which could lead to the generation of ROS in chloroplasts under illumination. They concluded that the chloroplast burst occurs earlier than the NADPH oxidase-dependent oxidative burst by MAPK (phase II burst) and that the chloroplast- generated ROS are only a facilitator that accelerates cell death because plants cells without mature chloroplasts die eventually. They suggested that mitochondriagenerated ROS might be essential in accelerating the cell death process. Communication between chloroplasts and mitochondria exists in cells undergoing HR cell death (Yao et al., 2004). Mitochondrial dysfunction can be caused by MEK2^sup DD^. MEK2^sup DD^ mediated dysfunction can be prevented by Bcl-xL, which is a mammalian anti-apoptotic factor that can prevent mitochondrial dysfunction in plants, the same as in animals (Takabatake et al., 2007). We routinely use the chemiluminescence probe L-012 to detect RBOH-generated ROS in N. benthamiana leaves. The probe has been used for the analysis of ROS generated by membrane-bound NADPH oxidase in neutrophils (Imada et al., 1999). In this study, we failed to detect rapid chloroplast- and mitochondria- generated ROS in elicited plants after treatment with INF1, St MEK2^sup DD^, Nb MEK1^sup DD^ (Figure 5D), and fungal infection (see Supplemental Figure 7 online), suggesting that our method is suitable to detect apoplastic ROS generated by membrane-bound RBOH in plant cells. We propose that early chloroplast-generated ROS caused by Nt MEK2^sup DD^ and phase I burst by elicitors might contribute to the influx of Ca2[thorn] into cytoplasm and that the increased level of Ca2[thorn] might result in activation of CDPK as an inducer of the phase II burst from NADPH oxidases localized in the plasma membrane.

Crosstalk between Two MAPK Cascades and Radical Bursts

The expression and activation of the Arabidopsis Ser/Thr kinase OXIDATIVE SIGNAL-INDUCIBLE1 (OXI1) are induced in response to H^sub 2^O^sub 2^ (Rentel et al., 2004). OXI1 is required for activation of MAPKs (MPK3 and MPK6, orthologs of WIPK and SIPK, respectively, in Arabidopsis) after treatment with H^sub 2^O^sub 2^ or an elicitor. In this study, we showed that in N. benthamiana the MEK2-SIPK cascade regulates the oxidative burst resulting from the induction ofRBOHB expression (Figures 4 to 6). Together, we can assume the existence of a positive feedback circuit between SIPK and RBOHB. However, little is known about the crosstalk between MAPK cascades and NO production. In this study, we showed that the MAPK cascade MEK2-SIPK regulates the NO burst. NO also activates potential MAPKs, as shown by an in-gel kinase assay using MBP as a substrate (Clarke et al., 2000). SIPK may give a positive feedback between NO burst signals as well as oxidative burst signals.

A novel MAPKK (MKK1) has been identified as an effective inducer of HR-like cell death in N. benthamiana. MKK1 activates SIPK, and MKK1-mediated cell death is compromised by silencing SIPK (Takahashi et al., 2007). The transient expression of SIPK is sufficient to induce HR-like cell death and the expression of 3-hydroxy-3- methylglutaryl CoA reductase, a gene encoding a key enzyme in the phytoalexin biosynthesis pathway (Zhang and Liu, 2001). This study showed that SIPK regulates the expression of RBOHB and the NO burst. These results strongly indicate that SIPK plays a central role in multiple defense responses. However, our results also showed that silencing WIPK slightly compromises the NO burst induced by INF1 and St MEK2^sup DD^ (Figure 3B). WIPK could function in accelerating SIPK-mediated cell death or in initiating a new pathway (Liu et al., 2003). WIPK might function as a factor to commit SIPK-mediated NO. NTF4 is a tobacco MAPK that reveals high sequence similarity to SIPK (93.6% identity) and a similar expression pattern and activation profile of SIPK (Ren et al., 2006). The conditional expression of NTF4 induces autophosphorylation and HR-like cell death (Ren et al., 2006). In this study, we demonstrated that NTF4 also regulates the radical bursts similarly to SIPK. NTF4 may play a similar role to SIPK in the signaling of basal defense.

The NPK1-MEK1-NTF6 cascade, a pivotal MAPK cascade in the regulation of cytokinesis (Soyano et al., 2003), participates in N- and Pto-mediated resistance to TMV and P. syringae AvrPto, respectively (Ekengren et al., 2003; Jin et al., 2003; Liu et al., 2004). In this study, we showed that the MEK1-NTF6 cascade regulates the oxidative burst accompanied by induction of RBOHB expression (Figure 5). MEK1 has been shown to be an activator of NTF6 in cytokinesis (Soyano et al., 2003), and in this study, the NTF6 activation profile by Nb MEK1^sup DD^ was obtained only when NTF6 was overexpressed in N. benthamiana leaves (Figure 1), suggesting that the amount of endogenous NTF6 was not sufficient to detect the activity by anti-NTF6 antibody. However, we cannot rule out the possibility that another efficient MAPKK activating NTF6 might exist for INF1-induced oxidative burst. How NTF6 can bifurcate two distinct cellular functions, cytokinesis and innate immunity, is unclear. These puzzles require further investigations.

NOA1 and RBOH Play Distinct Roles in Resistance to P. infestans and C. orbiculare

The Arabidopsis noa1 knockout mutant shows reduction of NO production and basal defense in response to lipopolysaccharide and an increase in the susceptibility to virulent P. syringae (Zeidler et al., 2004), indicating that NOA1 participates in NO production and defense responses. In our previous study, VIGS of RBOHA and RBOHB in N. benthamiana reduced the oxidative burst and disease resistance to P. infestans (Yoshioka et al., 2003). These studies show that NOA1 and RBOH play pivotal roles in defense responses during plant-pathogen interactions.

Plant defenses are often initiated by a gene-for gene interaction between a dominant plant resistance gene and a pathogen avirulence gene, which provides race-specific resistance. Plants also use a much less specific recognition system that identifies pathogen- associated molecular patterns, such as INF1 (Kamoun et al., 1998) and cell wall elicitor of the potato pathogen P. infestans (Katou et al., 2005). Silencing inf1 in P. infestans enhances the susceptibility of N. benthamiana (Kamoun et al., 1998), suggesting that defense responses of N. benthamiana to P. infestans are based on the basal defense by recognition of pathogen-associated molecular patterns. The same is true for C. orbiculare and N. benthamiana interactions (Takano et al., 2006). Here, we showed that NOA1 andRBOHBplay distinct roles in the resistance to P. infestans and C. orbiculare. NOA1 silencing induced high susceptibility to C. orbiculare, but not to P. infestans, whereas RBOHB silencing showed a strong effect on resistance to P. infestans, but not to C. orbiculare (Figure 7). These results indicate that the effects of the NOA1-mediated NO burst and the NADPH oxidase-dependent oxidative burst on defense response appear to be diverse in plant-pathogen interactions.

The Arabidopsis rbohD rbohF double mutant displays a marked reduction in ROS in response to infection with avirulent H. parasitica (Torres et al., 2002). However, Torres et al. (2002) found that the double mutant is not compromised in basal defense against a virulent isolate of H. parasitica, an oomycete like P. infestans. This contrast with our results might be due to the diversified effects of ROS on disease resistance dependent on each host.parasite interaction. Phytophthora species, such as Phytophthora brassicae (Roetschi et al., 2001) and several isolates of Phytophthora cinnamomi (Robinson and Cahill, 2003), can infect Arabidopsis. On the other hand, P. infestans cannot infect Arabidopsis (Huitema et al., 2003) and instead induces HR cell death accompanied by an oxidative burst in the attacked cell (Kobae et al., 2006). Transgenic potato plants expressing a H^sub 2^O^sub 2^- generating glucose oxidase are resistant to P. infestans (Wu et al., 1995). This result supports the idea that ROS play an important role in disease resistance to P. infestans. We believe that each pathogen has diverse strategies for infection. For instance, recent work has shown that Ustilago maydis, a biotrophic pathogen of maize (Zea mays), uses a redox sensor protein that controls the H^sub 2^O^sub 2^ detoxification system for coping with early plant defense responses (Molina and Kahmann, 2007). In the barley (Hordeum vulgare).Blumeria graminis interaction, silencing Hv RBOHA, a barley ortholog of Arabidopsis RBOHF, during the penetration process of B. graminis leads to increased penetration resistance (Trujillo et al., 2006), which could be due to a decrease in host cell wall softening usually induced by plant RBOH-mediated superoxide (O^sub 2^-).

ROS and NO are believed to play important roles independently or coordinately in plant innate immunity. ROS generated on the plasma membrane are released to the apoplast, inducing oxidative crosslinking of glycoproteins, strengthening the cell wall against secondary infection (Bradley et al., 1992) and simultaneously activating the Ca^sup 2+^ channel to increase the level of cytosolic Ca^sup 2+^ (Lecourieux et al., 2002). Ca^sup 2+^ may function not only as an inducer of the oxidative burst but also as a signaling molecule downstream of the oxidative burst that causes various cellular responses, including defense (Torres and Dangl, 2005). However, NO signaling includes various messenger molecules, such as cGMP, cADP ribose, and Ca^sup 2+^ (Durner et al., 1998; Wendehenne et al., 2001; Lamotte et al., 2004; Romero-Puertas et al., 2004), which both directly and indirectly modulate the expression of specific genes (Polverari et al., 2003; Parani et al., 2004). NO signaling pathways often include posttranslational modification of target proteins, such as NO-dependent Cys S-nitrosylation that can modulate the activity and function of different proteins (Sokolovski and Blatt, 2004; Feechan et al., 2005; Lindermayr et al., 2005; Romero-Puertas et al., 2007). NO can also react with O^sub 2^- to form the reactive molecule peroxynitrite (ONOO-). ONOO-can lead to formation of NO^sub 2^ and the hydroxyl radical (OHd). OH’ is a very strong oxidizing species that can rapidly attack biological membranes and all types of biomolecules, such as DNA and proteins, leading to irreparable damage, metabolic dysfunction, and cell death (del Rio et al., 2003). ONOO-is also responsible for Tyr nitration (Lamattina et al., 2003), which is the major toxic reactive nitrogen species in animal cells (Stamler et al., 1992). We reported previously that treatment of BY-2 tobacco cells with INF1 induces ONOO-generation, and we investigated Tyr nitration as a direct reaction of ONOO-(Saito et al., 2006); that study supported the idea that NO and O^sub 2^- are produced simultaneously through a convergent signaling pathway, that is, MAPK cascades in plants. ONOO- is relevant to HR and defense gene expression (Alamillo and Garcia- Olmedo, 2001). One study emphasized that the combination of NO and H^sub 2^O^sub 2^, but not ONOO-, takes part in the induction of defense responses (Delledonne et al., 2001). NO or ROS are not essential for HR in plants but induce apoptosis in adjacent cells during the defense response (Tada et al., 2004). HR cell death may require a fine balance between NO and ROS (Delledonne et al., 2001). In this study, we showed that double silencing of RBOHB and NOA1 does not confer a synergistic effect on resistance to P. infestans and C. orbiculare compared with individual silencing of these genes (Figure 7; see Supplemental Figure 8 online), suggesting that ONOO- might not be required for full defense responses to at least these two pathogens. In regulating gene expression, NO can induce the expression of PAL and chalcone synthase independently of ROS, and induction by NO of defense-related genes, such as glutathione S- transferase, depends on H^sub 2^O^sub 2^ (Grun et al., 2006). In abscisic acid signal transduction for stomatal closure, NO and H^sub 2^O^sub 2^ induced by abscisic acid individually inhibit stomatal opening specific to blue light (Bright et al., 2006; Zhang et al., 2007). However, the cooperative and individual roles of NO and ROS during disease resistance are unclear. Transgenic potato plants expressing St MEK2^sup DD^ fused to a pathogen-inducible promoter are resistant to both the biotrophic pathogen P. infestans and the necrotrophic pathogen Alternaria solani, which causes early blight of Solanaceae plants, such as potato and tomato (Solanum lycopersicum) (Yamamizo et al., 2006). However, our preliminary data indicate that transgenic potato plants carrying St CDPK5VK driven by the same pathogen-inducible promoter show high resistance to P. infestans but high susceptibility to A. solani. St CDPK5VK induces only ROS production (Kobayashi et al., 2007), and in this study, we showed that St MEK2DD induces both NO and ROS. These results support the results of this study that silencing NOA1 or RBOHB distinctly affects susceptibility to P. infestans and C. orbiculare. Plants may have obtained during evolution the signaling pathway regulating both NO and ROS production to adapt to a wide spectrum of pathogens.

METHODS

Plant Growth Conditions

Nicotiana benthamiana plants were grown at 25[degrees]C and 70% humidity under a 16-h photoperiod and an 8-h-dark period in environmentally controlled growth cabinets.

cDNA Cloning of Nb MEK1 and Site-Directed Mutagenesis

The cDNA of Nb MEK1 was amplified using PCR from an N. benthamiana cDNA library as a template (Yoshioka et al., 2003) using the following primers corresponding to the first 30 nucleotide sequences and 3′-terminal 30-nucleotide sequences of Nt MEK1, respectively: forward 5′-ATGAAGACGACGAAGCCATTGAAGGAACTT-3′ and reverse 5′-TTATCTTGGAAAATTTACAGGAGGTTCCAG-3′. The PCR products were cloned into the TOPO plasmid vector (TOYOBO) and were sequenced. The constitutively active mutant of Nb MEK1, Nb MEK1^sup DD^, with the conserved Ser-219 and Thr-225 replaced by Asp, was generated using a Mutan-Super Express Km kit (Takara). The sequences of the PCR products and Nb MEK1^sup DD^ were verified by sequencing with an ABI Prism BigDye Terminator Cycle Sequence kit (Perkin-Elmer).

Agrobacterium tumefaciens-Mediated Transient Expression in N. benthamiana

The cDNA fragment of constitutively active mutant Nb MEK1^sup DD^ was cloned into the pGreen binary vector (Hellens et al., 2000), in which a HAtag was added to the C-terminal end. Nb MEK1^sup DD^, St MEK2^sup DD^ (Katou et al., 2003), and GUS, which was used as a control for the effect of Agrobacterium infiltration, were preceded by the 35S promoter of Cauliflower mosaic virus, a 5′-untranslated region was replaced with the v sequence from the TMV, and the nopaline synthase terminator region was on the 3′-end of the gene (Jones et al., 1992).

Binary plasmids were transformed into Agrobacterium strain GV3101, which included the transformation helper plasmid pSoup (Hellens et al., 2000) by electroporation. The overnight culture was diluted 10-fold in LB/kanamycin/rifampicin/tetracycline and was cultured to OD^sub 600^ 0.6. The cells were harvested by centrifugation and were resuspended in 10 mM MES-NaOH, pH 5.6, and 10 mM MgCl^sub 2^. The suspensions were adjusted to OD^sub 600^ 0.5, and acetosyringone was added to 150 mM. The bacterial suspensions were incubated for 2 to 3 h at 22[degrees]C and then were infiltrated into leaves of 4- to 5-week-old N. benthamiana plants using a needleless syringe (Yoshioka et al., 2003). A. tumefaciens carrying inf1 was prepared as described by Kamoun et al. (2003).

VIGS

VIGS was done as described by Ratcliff et al. (2001). The following primers were used to amplify cDNA fragments from N. benthamiana using the N. benthamiana cDNAlibrary as a template (Yoshioka et al., 2003). Restriction sites were added to the 5′-end of forward or reverse primer for cloning into a TRV vector pTV00 (RNA2): Nb MEK1-F-AccI (5′-CCGGTCGACCTCAGAAACTAAGGAGATAGATCTT-3′) and Nb MEK1-R-ClaI (5′-CCATCGATAAAACCTGCTTGCAAACAACTG-3′) (restriction sites are underlined), which produced a 363-bp fragment; Nb MEK2-F-ClaI (5′-CCATCGATAGATGTGCCGTGAGATCGA-3′) and Nb MEK2-R-ClaI (5′-CCATCGATGCCTCGAGTTGATTAGTAAATTCG-3′), which produced a 261-bp fragment; NbNOA1-F-BamHI (5′- CGGGATCCCGGAGTCACAGATAGCTGACCG-3′) and Nb NOA1-R-ClaI (5′- CCATCGATGGCTGTCCTCCAGCTTTGC-3′), which produced a 478-bp fragment; Nb WIPK-F-BamHI (5′-CGGGATCCCAGATGGTACAGGGCACCAG-3′) and Nb WIPK-R- HindIII (5′-CCCAAGCTTCGACAAGATCAATAGCCAATGGG-3′), which produced a 302-bp fragment; Nb SIPK-F-ClaI (5′-CCATCGATTATGACGGAATATGTTGTGACAA- 3′) and Nb SIPK-R-ClaI (5′-CCATCGATTCTCGACAAGATCAATTGCA-3′), which produced a 323-bp fragment; Nb RBOHA-F-HindIII (5′- CCCAAGCTTCTGTGATTAACATTGACGCTC-3′) and Nb RBOHAR-BamHI (5′- CGGGATCCGCATTGTGCGAAATCGGAAC-3′), which produced a 500-bp fragment; Nb RBOHB-F-ClaI (5′-CCATCGATGTTAAACAAACGAGGCGGCA-3′) and Nb RBOHB-R- HindIII (5′-CCCAAGCTTTACATTCTCCAAATTTGGCAC-3′), which produced a 500- bp fragment; and Nb NTF6-F-AccI (5′-CCGGTCGACCGCTAGAACCACTTCAGAG- 3′) and Nb NTF6-R-ClaI (5′-CCATCGATTAGAGCCTCGTTCCATATGAGC-3′), which produced a 535-bp fragment. N. benthamiana was infected by viruses by Agrobacterium-mediated transient expression of infectious constructs. pBINTRA6 (RNA1) and the pTV00 containing the inserts (RNA2) were transformed by electroporation separately into A. tumefaciens strain GV3101, which includes the transformation helper plasmid pSoup (Hellens et al., 2000). A mixture of equal parts of Agrobacterium suspensions of RNA1 and RNA2 was inoculated into 2- to 3-week-old N. benthamiana seedlings. The inoculated plants were grown under a 16-h photoperiod and an 8-h dark period at 23’C. The upper leaves of the inoculated plants were used for assays 3 to 4 weeks after inoculation.

Immunoblotting

For immunoblotting, the protein extracts (20 mug) were separated on a 12% SDS-polyacrylamide gel and were transferred to a nitrocellulose membrane (Schleicher and Schuell). After blocking in TBS-T (50mMTris-HCl, pH 7.5, 150mMNaCl, and 0.05% Tween 20) with 5% nonfat dry milk overnight at 4[degrees]C, the membranes were incubated with monoclonal anti-HA antibody (clone HA-7; Sigma- Aldrich) diluted with TBS-T at room temperature for 1 h. After washing with TBS-T, the membranes were incubated with horseradish peroxidase-conjugated anti-mouse Ig antibody (Amersham) diluted with TBS-T for 1 h at room temperature. The antibody-antigen complex was detected using the ECL Western-Blotting detection kit (Amersham) and the Light-Capture system (ATTO) and then quantified using the CS analyzer program (ATTO).

IC Kinase Assays

IC kinase assay was done as described by Zhang and Liu (2001). In the case of using anti-NTF6 antibody, the protein extracts (400 mg) were incubated with anti-NTF6 antibody (Soyano et al., 2003) in an immunoprecipitation buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 50mMNaF, 10mM beta-glycerophosphate, 1mMNa^sub 3^VO^sub 4^, and 1% Triton X-100) at 30[degrees]C for 2 h with shaking. In the case of WIPK- or SIPK-specific antiserum, the protein extracts (50 mug) were incubated with the specific antisera in the immunoprecipitation buffer at 4[degrees]C for 2 h with shaking. Then each mixture was incubated with 40-muL aliquot of 50% (v/v) protein A-Sepharose (GE Healthcare) at 4[degrees]C overnight with shaking. In the case of using anti-HA agarose conjugate (Sigma-Aldrich), the protein extracts (200 mug) were incubated with anti-HA agarose conjugate in the immunoprecipitation buffer at 4[degrees]C overnight with shaking. Protein A-Sepharose complexes and anti-HA agarose conjugate were pelleted by brief centrifugation, washed three times with 1 mL of the immunoprecipitation buffer, and then were washed three times with 1 mL of kinase reaction buffer (20 mM HEPES-KOH, pH 7.6, 10 mM MgCl^sub 2^, and 1 mM DTT). The kinase activity in the complex was assayed at 25[degrees]C for 30 min in a final volume of 15 mL containing 0.4 mg/mL MBP, 100 muM ATP, and 8 nCi/mL of [gamma- ^sup 32^P]ATP. The reaction was stopped by adding SDS-PAGE sample loading buffer. After electrophoresis on a 15% SDS-polyacrylamide gel, the phosphorylated MBP was visualized by autoradiography.

NO Measurements

NO accumulation was monitored using NO-sensitive dye DAF-2DA (Daiichi Pure Chemicals). Leaves were infiltrated with 200 mM sodium phosphate buffer at pH 7.4, including 12.5 muM DAF-2DA using a needleless syringe and were incubated for 1 h in the dark at room temperature before observation. Fluorescence from diaminotriazolofluorescein (DAF-2T), the reaction product of DAF- 2DA with NO, was observed using a fluorescent stereomicroscope (MZ FLIII; Leica) equipped with a CCD camera. The excitation was at 470 nm, and the emission images at 525 nm were obtained at constant acquisition time. The fluorescence intensity of the digital image was determined by color histogram analysis of Photoshop version 7.0 (Adobe). ROS Measurements

ROS measurements were done as described by Kobayashi et al. (2007). The relative intensity of ROS generation was determined by counting photons from L-012-mediated chemiluminescence. The 0.5mML- 012 in 10 mM MOPS-KOH at pH 7.4 was infiltrated into N. benthamiana leaves using a needleless syringe. Chemiluminescence was monitored continuously using a photon image processor equipped with a sensitive CCD camera (Aquacosmos 2.5; Hamamatsu Photonics) and quantified using the U7501 program (http://jp.hamamatsu.com/en/ index).

RT-PCR

Total RNA from N. benthamiana leaves was prepared using TRIzol reagent according to the procedure of the manufacturer (Invitrogen). RT-PCR was conducted using a commercial kit (ReverTra Ace -a-; TOYOBO). PCR was performed by ExTaq (Takara) with denaturing, annealing, and extension temperatures of 94[degrees]C for 30 s, 55[degrees]C for 30 s, and 72[degrees]C for 1 min, respectively, for 26 cycles. Gene-specific primers of each sequence were as follows: Nb WIPK (5′-TACGGAGCTGAATGAGATGG-3′ and 5′-CGGTTTGAGATCTCTATGAAGG- 3′), Nb SIPK (5′-GGAGCAGCCACCTCCGGCGG-3′ and 5′- CATGTGGAAACTTTTCAGTG-3′), Nb NTF4 (5′-ACAGCAACCAGCTCCTCCTC-3′ and 5′- CATGTGGAAATTTTTCAACA-3′) and Nb RBOHB (5′- TTTTCTCTGAGGTTTGCCAGCCACCA-3′ and 5′-GCCTTCATGTTGTTGACAATGTCTTT- 3′). As a control for equal cDNA amounts in each reaction, PCR was done with primers for EF-1a for 26 cycles (5′- CCTCAAGAAGGTTGGATACAAC-3′ and 5′-TCTTGGGCTCATTAATCTGGTC-3′). The PCR products were separated on a 1.8% agarose gel and were visualized after ethidium bromide staining.

RNA Gel Blot Hybridization

Total RNA from N. benthamiana leaves was prepared as described for RT-PCR. RNA gel blot hybridization was done as described by Yamamizo et al. (2006). The probe for Nb WIPK was a 331-bp cDNA fragment derived from the primers used for RT-PCR. The probes for Nb SIPK and Nb RBOHB were 539-bp and 1350-bp cDNA fragments, respectively, derived from the following primers: Nb SIPK (5′- ACACGATGATGTCTGATGCG-3′ and 5′-CTTCAAGTCCCTGTGTAGAACATTTGCAG-3′) and Nb RBOHB (5′-ATGCAAAATTCTGAAAATCATCATCCGCAC-3′ and 5′- AAGGTTATCATCAAAAGGAACAGCAACACC-3′). Ethidium bromide-stained gels were used to show equal loads of RNA.

Fungal Strain, Media, and Conditions

Phytophthora infestans race 1.2.3.4 was maintained on susceptible potato (Solanum tuberosum) tubers. A suspension of P. infestans zoospores was prepared as described by Yoshioka et al. (1996). Detached leaves were inoculated with a 1-mL drop of P. infestans zoospore suspension (2 x 10^sup 5^ zoospores/mL) using a lens paper to disperse the zoospores. The inoculated leaves were kept at high humidity at 20[degrees]C.

Colletotrichum orbiculare strain 104-T was maintained on a potato dextrose agarose medium at 23[degrees]C in the dark. Suspensions of the conidia at concentration 1 x 10^sup 6^ conidia/mL were sprayed onto attached N. benthamiana leaves. The inoculated plants were kept at high humidity in the dark at 23[degrees]C for 48 h and then under a 16-h photoperiod and an 8-h dark period at 23[degrees]C.

Determination of P. infestans Biomass

Quantitative real-time PCR was applied to determine the growth of P. infestans on N. benthamiana leaves. DNA was isolated from P. infestans-inoculated leaves using the DNeasy Plant Mini Kit (Qiagen). The primers O8-3 (5′-GAAAGGCATAGAAGGTAGA-3′) and O8-4 (5′- TAACCGACCAAGTAGTAAA-3′) and EF-1a used for RT-PCR were used to amplify and detect a P. infestans-specific DNA sequence (Judelson and Tooley, 2000) and plant DNA, respectively, in the inoculated leaves. Quantitative PCR was performed using SYBR Premix Ex Taq (Takara) on a LightCycler 480 instrument (Roche Diagnostics). For each PCR, samples were prepared according to the procedure of the manufacturer. Samples were run for 40 cycles under the following thermal cycling protocol. Samples were preheated at 95[degrees]C for 10 s. Then, 40 amplification cycles were run: 5 s at 95[degrees]C and 20 s at 60[degrees]C. Fluorescence (520 nm) was detected at the end of the elongation phase for each cycle. Following the final amplification cycle, a melting curve was acquired by heating to 95[degrees]C, cooling to 65[degrees]C, and slowly heating to 95[degrees]C at 0.18C/s with continuous measurement of fluorescence at 520 nm. Relative amounts of P. infestans DNA were determined by dividing plant DNA amounts derived from EF-1a in inoculated leaves. Therefore, pathogen biomass is given as relative units.

Accession Numbers

Sequence data from this article can be found in the GenBank/EMBL/ DDBJ data libraries under accession numbers AB360634 (Nb NTF6), AB360635 (Nb MEK1), AB360636 (Nb MEK2), AB373025 (Nb SIPK), and AB373026 (Nb NTF4). The accession numbers for the other sequences mentioned in this article are as follows: St MEK2, AB091780; Nt SIPK, U94192; Nt NTF4, X83880; Nb WIPK, AB098729; Nt WIPK, D61377; Nb NOA1, AB303300; Nb RBOHA, AB079498; Nb RBOHB, AB079499; At MPK6, D21842.

Supplemental Data

The following materials are available in the online version of this article.

Supplemental Figure 1. Time Course of Changes in NO and ROS after Inoculation with A. tumefaciens.

Supplemental Figure 2. VIGS of Nb MEK2 Suppressed the Transcript Accumulation of St MEK2DD Transgene.

Supplemental Figure 3. Effects of VIGS on Nb NOA1, Nb RBOHB, Nb NTF6, Nb RBOHA, and Nb SIPK.

Supplemental Figure 4. Effects of L-NAME and D-NAME on NO Burst Induced by INF1.

Supplemental Figure 5. Sequence Alignment between Nb NTF4 and Nb SIPK, and Phylogenetic Analysis of Related MAPKs.

Supplemental Figure 6. L-012 Is a Highly Sensitive Reagent for ROS Detection.

Supplemental Figure 7. Inoculation of C. orbiculare-Induced Nb NOA1-Mediated NO Burst and Nb RBOHB-Dependent Oxidative Burst in N. benthamiana.

Supplemental Figure 8. Effects of Silencing Nb NOA1 and Nb RBOHB on Disease Resistance to P. infestans and C. orbiculare.

Supplemental Data Set 1. Text File of Alignment Corresponding to the Phylogenetic Tree in Supplemental Figure 5.

ACKNOWLEDGMENTS

We thank Jonathan D.G. Jones for pSLJ4K1 vector, Phil Mullineaux and Roger Hellens for providing pGreen binary vector, Sophien Kamoun for INF1 elicitin, David C. Baulcombe for pTV00 vector, Yuko Ohashi for anti-WIPK and SIPK antibodies, Yasunori Machida and Michiko Sasabe for anti-Nt NTF6 antibody, Yoshitaka Takano for C. orbiculare, and the Leaf Tobacco Research Center, Japan Tobacco, for N. benthamiana seeds. We also thank Greg Martin for critical reading and English correction of the manuscript, Hiroaki Kato, Daigo Takemoto, Kazuhito Kawakita, and Hitoshi Mori for valuable suggestions, and members of the Radioisotope Research Center, Nagoya University, for technical assistance. This work was supported by the Program for Promotion of Basic Research Activities for Innovative Biosciences and by a Grant-in-Aid for Scientific Research (A) from the Ministry of Education, Science, and Culture of Japan.

Received September 25, 2007; revised April 13, 2008; accepted May 7, 2008; published May 30, 2008.

This information is current as of June 30, 2008

Supplemental Data http://www.plantcell.org/cgi/content/full/ tpc.108.059014/DC1

References This article cites 33 articles, 8 of which you can access for free at:

http://www.plantcell.org/cgi/content/full/20/5/1407#BIBL

Permissions https://www.copyright.com/ccc/ openurl.do?sid=pd_hw1532298X&issn=1532298X&WT.mc_id=pd_hw1532298X

eTOCs Sign up for eTOCs for THE PLANT CELL at:

http://www.plantcell.org/subscriptions/etoc.shtml

CiteTrack Alerts Sign up for CiteTrack Alerts for Plant Cell at:

http://www.plantcell.org/cgi/alerts/ctmain

Subscription Information Subscription information for The Plant Cell and Plant Physiology is available at:

http://www.aspb.org/publications/subscriptions.cfm

W Online version contains Web-only data.

OA Open Access articles can be viewed online without a subscription.

www.plantcell.org/cgi/doi/10.1105/tpc.107.055855

REFERENCES

Alamillo, J.M., and Garci-Olmedo, F. (2001). Effects of urate, a natural scavenger of peroxynitrite-mediated toxicity, in the response of Arabidopsis thaliana to the bacterial pathogen Pseudomonas syringae. Plant J. 25: 529.540.

Bethke, P.C., Badger, M.R., and Jones, R.L. (2004). Apoplastic synthesis of nitric oxide by plant tissues. Plant Cell 16: 332.341.

Bradley, D.J., Kjellbom, P., and Lamb, C.J. (1992). Elicitor- and wound-induced oxidative cross-linking of a proline-rich plant cell wall protein: A novel, rapid defense response. Cell 70: 21.30.

Bright, J., Desikan, R., Hancock, J.T., Weir, I., and Neill, S.J. (2006). ABA-induced NO generation and stomatal closure in Arabidopsis are dependent on H^sub 2^O^sub 2^ synthesis. Plant J. 45: 113.122.

Butt, Y.K.-C., Lum, J.H.-K., and Lo, S.C.-L. (2003). Proteomic identification of plant proteins probed by mammalian nitric oxide synthase antibodies. Planta 216: 762.771.

Clarke, A., Desikan, R., Hurst, R.D., Hancock, J.T., and Neill, S.J. (2000). NO way back: Nitric oxide and programmed cell death in Arabidopsis thaliana suspension cultures. Plant J. 24: 667.677.

Crawford, N.M., Galli, M., Tischner, R., Heimer, Y.M., Okamoto, M., and Mack, A. (2006). Response to Zemojtel et al: Plant nitric oxide synthase: Back to square one. Trends Plant Sci. 11: 526.527.

Delledonne, M., Zeier, J., Marocco, A., and Lamb, C. (2001). Signal interactions between nitric oxide and reactive oxygen intermediates in the plant hypersensitive disease resistance response. Proc. Natl. Acad. Sci. USA 98: 13454.13459. del Pozo, O., Pedley, K.F., and Martin, G.B. (2004). MAPKKKalpha is a positive regulator of cell death associated with both plant immunity and disease. EMBO J. 23: 3072.3082.

del Rio, L.A., Corpas, F.J., Sandalio, L.M., Palma, J.M., and Barroso, J.B. (2003). Plant peroxisomes, reactive oxygen metabolism and nitric oxide. IUBMB Life 2: 71.81.

Doke, N. (1983). Involvement of superoxide anion generation in the hypersensitive response of potato tuber tissues to infection with an incompatible race of Phytophthora infestans and to the hyphal wall components. Physiol. Plant Pathol. 23: 345.357.

Durner, J., Wendehenne, D., and Klessig, D.F. (1998). Defense gene induction in tobacco by nitric oxide, cyclic GMP and cyclic ADPribose. Proc. Natl. Acad. Sci. USA 95: 10328.10333.

Ekengren, S.K., Liu, Y., Schiff, M., Dinesh-Kumar, S.P., and Martin, G.B. (2003). Two MAPK cascades, NPR1, and TGA transcription factors play a role in Pto-mediated disease resistance in tomato. Plant J. 36: 905.917.

Feechan, A., Kwon, E., Yun, B.W., Wang, Y., Pallas, J.A., and Loake, G.J. (2005). A central role for S-nitrosothiols in plant disease resistance. Proc. Natl. Acad. Sci. USA 22: 8054.8059.

Garcia-Mata, C., and Lamattina, L. (2003). Abscisic acid, nitric oxide and stomatal closure . Is nitrate reductase one of the missing links? Trends Plant Sci. 8: 20.26.

Groom, Q.J., Torres, M.A., Fordham-Skelton, A.P., Hammond- Kosack, K.E., Robinson, N.J., and Jones, J.D.G. (1996). rbohA, a rice homologue of the mammalian gp91phox respiratory burst oxidase gene. Plant J. 10: 515.522.

Grun, S., Lindermayr, C., and Durner, J. (2006). Nitric oxide and gene regulation in plants. J. Exp. Bot. 57: 507.516.

Guo, F.-Q., Okamoto, M., and Crawford, N.M. (2003). Identification of a plant nitric oxide synthase gene involved in hormonal signaling. Science 302: 100.103.

He, Y., et al. (2004). Nitric oxide represses the Arabidopsis floral transition. Science 305: 1968.1971.

Hellens, R.P., Edwards, E.A., Leyland, N.R., Bean, S., and Mullineaux, P.M. (2000). pGreen: A versatile and flexible binary Ti vector for Agrobacterium-mediated plant transformation. Plant Mol. Biol. 42: 819.832.

Huitema, E., Vleeshouwers, V.G.A.A., Francis, D.M., and Kamoun, S. (2003). Active defence responses associated with non-host resistance of Arabidopsis thaliana to the oomycete pathogen Phytophthora infestans. Mol. Plant Pathol. 4: 487.500.

Imada, I., Sato, E.F., Miyamoto, M., Ichimori, Y., Minamiyama, Y., Konaka, R., and Inoue, M. (1999). Analysis of reactive oxygen species generated by neutrophils using a chemiluminescence probe L- 012. Anal. Biochem. 271: 53.58.

Jin, H., Axtell, M.J., Dahlbeck, D., Ekwenna, O., Zhang, S., Staskawicz, B., and Baker, B. (2002). NPK1, an MEKK1-like mitogen- activated protein kinase kinase kinase, regulates innate immunity and development in plants. Dev. Cell 3: 291.297.

Jin, H., Liu, Y., Yang, K.-Y., Kim, C.Y., Baker, B., and Zhang, S. (2003). Function of a mitogen-activated protein kinase pathway in N gene mediated resistance in tobacco. Plant J. 33: 719.731.

Jones, J.D.G., Shlumukov, L., Carland, F., English, J., Scofield, S., Bishop, G., and Harrison, K. (1992). Effective vectors for transformation, expression of heterologous genes, and assaying transposon excision in transgenic plants. Transgenic Res. 1: 285.297.

Judelson, H.S., and Tooley, P.W. (2000). Enhanced polymerase chain reaction methods for detecting and quantifying Phytophthora infestans in plants. Phytopathology 90: 1112.1119.

Kamoun, S., Hamada, W., and Huitema, E. (2003). Agrosuppression: A bioassay for the hypersensitive response suited to high- throughput screening. Mol. Plant Microbe Interact. 16: 7.13.

Kamoun, S., van West, P., Vleeshouwers, V.G.A.A., de Groot, K.E., and Govers, F. (1998). Resistance of Nicotiana benthamiana to Phytophthora infestans is mediated by the recognition of the elicitor protein INF1. Plant Cell 10: 1413.1425.

Kato, H., Asai, S., Yamamoto-Katou, A., Yoshioka, H., Doke, N., and Kawakita, K. (2008). Involvement of NbNOA1 in NO production and defense responses in INF1-treated Nicotiana benthamiana. J. Gen. Plant Pathol. 74: 15.23.

Katou, S., Yamamoto, A., Yoshioka, H., Kawakita, K., and Doke, N. (2003). Functional analysis of potato mitogen-activated protein kinase kinase, StMEK1. J. Gen. Plant Pathol. 69: 161.168.

Katou, S., Yoshioka, H., Kawakita, K., Rowland, O., Jones, J.D.G., Mori, H., and Doke, N. (2005). Involvement of PPS3 phosphorylated by elicitor-responsive mitogen-activated protein kinases in the regulation of plant cell death. Plant Physiol. 139: 1914.1926.

Keller, T., Damude, H.G., Werner, D., Doerner, P., Dixon, R.A., and Lamb, C. (1998). A plant homolog of the neutrophil NADPH oxidase gp91phox subunit gene encodes a plasma membrane protein with Ca^sup 2+^ binding motifs. Plant Cell 10: 255.266.

Kobae, Y., Sekino, T., Yoshioka, H., Nakagawa, T., Martinoia, E., and Maeshima, M. (2006). Loss of AtPDR8, a plasma membrane ABC transporter of Arabidopsis thaliana, causes hypersensitive cell death upon pathogen infection. Plant Cell Physiol. 47: 309.318.

Kobayashi, M., Kawakita, K., Maeshima, M., Doke, N., and Yoshioka, H. (2006). Subcellular localization of Strboh proteins and NADPH-dependent O^sub 2^- -generating activity in potato tuber tissues. J. Exp. Bot. 57: 1373-1379.

Kobayashi, M., Ohura, I., Kawakita, K., Yokota, N., Fujiwara, M., Shimamoto, K., Doke, N., and Yoshioka, H. (2007). Calciumdependent protein kinases regulate the production of reactive

Populations Receiving Optimally Fluoridated Public Drinking Water – United States, 1992-2006

By Bailey, W Barker, L; Duchon, K; Maas, W

Water fluoridation has been identified by CDC as one of 10 great public health achievements of the 20th century. The decline in the prevalence and severity of dental caries (tooth decay) in the United States during the past 60 years has been attributed largely to the increased use of fluoride (I). Community water fluoridation is an equitable and cost-effective method for delivering fluoride to the community (2-4). A Healthy People 2010 objective is to increase to 75% the proportion of the U.S. population served by community water systems who receive optimally fluoridated water* (5). To update and revise previous reports on fluoridation in the United States (4) and describe progress toward the Healthy People 2010 objective, CDC analyzed fluoridation data for the period 1992-2006 from the 50 states and District of Columbia (DC). The results indicated that the percentage of the U.S. population served by community water systems who received optimally fluoridated water increased from 62.1% in 1992, to 65.0% in 2000, and 69.2% in 2006, and those percentages varied substantially by state. Public health officials and policymakers in states with lower percentages of residents receiving optimal water fluoridation should consider increasing their efforts to promote fluoridation of community water systems to prevent dental caries. Since 1945, the U.S. Public Health Service and CDC (beginning in 1975) have tracked the number of persons in the United States receiving fluoridated water.[dagger] The U.S. Environmental Protection Agency (EPA) does not regulate water fluoridation, and EPA’s Safe Drinking Water Information System (SDWIS) only tracks fluoride concentrations in water systems with naturally occurring fluoride levels above the established regulatory maximum contaminant level (4.0 ppm[section]). Water fluoridation is managed at the state level, and CDC relies on states to provide data on individual community water systems (e.g., population served, fluoride concentration, and fluoride source). During 1998-2000, CDC, in partnership with the Association of State and Territorial Dental Directors, developed the Water Fluoridation Reporting System (WFRS) to support management and tracking of state fluoridation programs. WFRS is a voluntary system designed, in part, to make additional use of community water system data that states were already required to report to EPA as part of SDWIS.

In March 2007, CDC asked state dental directors and drinking water administrators to validate their state data reported via WFRS for 2006. Estimates of the population served by community water systems were based on the number of households served (i.e., service connections) and the number of persons in each household. Some states supplemented population data in WFRS with population data from SDWIS, which can differ slightly from WFRS. The percentage of the population served by community water systems who received optimally fluoridated water was calculated by dividing the population served by community water systems with optimal fluoride levels by the total population served by community water systems.

For eight states and DC, the reported 2006 total community water system population estimates exceeded mid-year intercensal state population estimates (6), which can occur when applying a standard persons-per-household factor to the number of households served. For these eight states and DC, state community water system population estimates were set equal to the intercensal state population estimates, and estimates of the population receiving optimally fluoridated water were reduced by a factor equal to the state’s intercensal population estimate divided by the initially reported total state community water system population. National community water system population estimates were calculated by adding the state community water system population estimates after this reduction.

CDC previously published a report on fluoridation estimates for 2000 (4), using WFRS data reviewed by state oral health programs. At that time, state community water system populations that exceeded the state’s 2000 census populations (seven states and DC) were changed to match the 2000 census populations. Earlier, in calculating 1992 fluoridation estimates, state community water system populations that exceeded state census population estimates also were changed to match 1992 intercensal state population estimates (10 states and DC). Because these two reports used the reduced state community water system populations for their calculations without making any adjustments to the populations receiving fluoridated water, the percentages potentially were overstated. This report revises the 2000 fluoridation percentage estimates, applying the same methods used to produce the 2006 estimates, and reflecting improvements in the quality and accuracy of some WFRS state data. The 1992 fluoridation estimates could not be revised similarly because water system population data from 1992 were no longer available.

In 2006, 69-2% of the U.S. population served by community water systems received optimally fluoridated water (Table 1), an increase from 62.1% in 1992, and from 65-0% in 2000 (Table 2). State- specific percentages in 2006 ranged from 8.4% in Hawaii to 100% in DC (median: 77.0%). In 2006, the Healthy People 2010 target of 75% had been met by 25 states and DC (Table 1). Overall, approximately 184 million persons served by community water systems received fluoridated water; of that number, approximately 8 million persons received water with sufficient naturally occurring fluoride concentrations.

During 1992-2006, 39 states reported increases in the percentage of their populations served by community water systems who received optimally fluoridated water; percentagepoint increases ranged from 0.3 in Alabama to 69-9 in Nevada (median: 6.2). Ten states had decreases; percentagepoint decreases ranged from 0.2 in Kentucky and North Dakota to 17-0 in Idaho (median: 4.3) (Table 2). Throughout 1992-2006, 100% of the DC population served by community water systems received optimally fluoridated water.

Reported by: W Bailey, DDS, L Barker, MSPH, K Duchon, MS, W Maas, DDS, Div of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

Editorial Note: Dental caries is a complex, chronic disease with multiple protective factors (e.g., dental sealants or healthy dietary practices), including fluoride (7); teeth remain at risk for decay throughout the lifespan, with older adults experiencing rates of caries similar to rates among children (8). Community water fluoridation has been effective in preventing tooth decay (1). Commercially sold bottled waters might or might not contain fluoride, and most bottled waters do not contain fluoride in optimal concentrations (9).

WFRS data indicate that, from 1992 to 2006, the percentage of the U.S. population served by community water systems who received optimally fluoridated water increased from 62.1% to 69-2%. During that period, the percentage increased in most states; by 2006, half the states had reached the Healthy People 2010 target of 75%. However, the 2006 data also indicate substantial differences among states in progress toward that target. For example, in California, the percentage of the state population served by community water systems who received optimally fluoridated water increased by 11.4 percentage points from 1992 to 2006. However, in 2006, the percentage of the California population served by community water systems who received optimally fluoridated was only 27-1%, third lowest among states. A 1995 state law required community water systems in California to implement fluoridation if state funds were provided to the community; however, implementation has been limited by engineering and funding constraints. In Idaho, the percentage receiving optimally fluoridated water declined by 17-0 percentage points from 1992 to 2006 because of reclassification from optimal to below optimal of a large community water system in Boise. In Louisiana, the percentage declined by 15-3 points during the same period, largely because of relocation of a substantial number of residents from areas with fluoridation to areas without fluoridation after Hurricane Katrina. In Maine, several local referenda were passed during 1996-2004, authorizing community water systems to fluoridate; as a result, 29 communities gained access to fluoridated water. The Maine percentage increased by 23-8 percentage points during 1992-2006.

The findings in this report are subject to at least three limitations. First, revision of estimated percentages for 2000 using original community water system populations without similar revision of 1992 percentages resulted in a slight underestimation of percentage-point changes among certain states from 1992 to 2006. Second, changes in percentages over time for some states resulted from improvements in the quality and accuracy of WFRS data collection and not from actual increases or decreases in the state population with optimal fluoridation. Finally, not all data came from WFRS; some states provided data from other sources, which might have reduced comparability of estimates among states. Since its development during 1998-2000, WFRS has become a valuable tool for monitoring fluoridation programs, improving fluoridation data quality, and routinely reporting fluoridation status at national, state, and local levels. For 2006, 48 states and DC reported their data via WFRS. In 2002, CDC developed and launched two Internet- based systems to provide public access to water fluoridation information stored in WFRS. Oral Health Maps generates maps showing fluoridation percentages at state and county levels and provides summary data tables.[para] My Water’s Fluoride provides public access to fluoridation information for individual community water systems.** Currently, 36 states provide public access to water fluoridation information online via Oral Health Maps and My Water’s Fluoride.

Attainment of the Healthy People 2010 objective will require 1) recognition by policymakers and the public that dental caries remains an important public health problem and that fluoridation is an equitable and cost-effective method of addressing the problem, even in smaller populations where the per-capita cost of fluoridation is higher; 2) continuing science-based education of the public about the established safety of fluoridation; and 3) the political will to adopt new fluoridation systems in communities that are not served currently (10). To overcome the challenges facing fluoridation, public health professionals at the national, state, and local level will need to enhance their promotion of fluoridation and commit the necessary resources for equipment, personnel, and training.

Acknowledgments

This report is based, in part, on contributions from S Presson, D Apanian, Div of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, CDC; B Laughlin, Alabama Dept of Environmental Management; B Whistler, Alaska Dept of Health; R Tuscano, Arizona Dept of Health Svcs; L Mouden, Arkansas Dept of Health; G Hoffmann, California Dept of Drinking Water and Environmental Management; D Felzien, Colorado Dept of Public Health and Environment; P Painter, Connecticut Dept of Public Health; GB McClure, Delaware Div of Public Health; H Davis, Florida Dept of Health; E Rutti-Cain, Georgia Rural Water Assn; M Greer, Hawaii Dept of Health; L Penny, Idaho Dept of Health and Welfare; R Mutzbauer, Illinois Dept of Public Health; D Cain, Indiana State Dept of Health; R Russell, Iowa Dept of Public Health; D Waldo, Kansas Dept of Health and Environment; R Murphy, Kentucky Dept for Public Health; A Laughlin, Louisiana Office of Public Health; N Reilman, Maryland Dept of the Environment; J Feinstein, Maine Dept of Human Svcs; M Foley, Massachusetts Dept of Public Health; K Philip, Michigan Dept of Environmental Quality; D Rindal, Minnesota Dept of Health; C Seed, Montana Dental Health Program; K McFarland, Nebraska Dept of Health and Human Svcs; L Cofano, Nevada State Health Div; S Kilbreath, New Jersey Dept of Health; N Martin, New Hampshire Dept of Health and Human Svcs; R Romero, New Mexico Dept of Health; J Reuther, New York State Dept of Health; G Stewart, North Dakota Dept of Health; C Wolf, Ohio Dept of Health; M Morgan, Oklahoma State Dept of Health; D Leland, Oregon Dept of Human Svcs; K Chenosky, Pennsylvania Dept of Health; J Swallow, Rhode Island Dept of Health; D Boston, South Carolina Dept of Health and Environmental Control; J Ellingson, South Dakota Dept of Health; W Wells, Tennessee Dept of Environment and Conservation; T Napier, Texas Dept of Health; S Steed, Utah Dept of Health; S Arthur, Vermont Dept of Health Dental Svcs; L Syrop, Virginia Dept of Health; R Pedlar, Washington Dept of Health; K Cobb, West Virginia Bur for Public Health; W LeMay, Wisconsin Div of Public Health.

* Defined as a fluoride concentration of 0.7- 1.2 ppm, depending on the average maximum daily air temperature in the area; optimal concentrations are set lower in warmer climates, where the populations drink more water, and higher in cooler climates.

[dagger] Available at http://www.cdc.gov/nohss/ fsgrowth_text.htm.

[section] EPA also has set a secondary maximum contaminant level of 2.0 ppm as a precaution against possible tooth discoloration or pitting from excess fluoride exposure during the formative period for young children. Additional information is available at http:// www.epa.gov/safewater/consumer/2ndstandards.html.

[para] Available at http://apps.nccd.cdc.gov/gisdoh.

** Available at http://apps.nccd.cdc.gov/mwf/index.asp.

References

1. US Department of Health and Human Services. Oral health in America: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health; 2000. Available at http:// silk.nih.gov/public/hckl [email protected].

2. Truman BI, Gooch BF, Sulemana I, et al. Reviews of evidence on interventions to prevent dental caries, oral and pharyngeal cancers, and sports-related craniofacial injuries. Am J Prev Med 2002;23 (suppl l):21-54.

3. Griffin SO, Jones K, Tomar SL. An economic evaluation of community water fluoridation. J Publ Health Dent 2001;61:78-86.

4. CDC. Populations receiving optimally fluoridated public drinking water- United States, 2000. MMWR 2002;51:144-7.

5. US Department of Health and Human Services. Oral health; 21- 9: increase the proportion of the U.S. population served by community water systems with optimally fluoridated water. In: Healthy people 2010: understanding and improving health. 2nd ed. Washington, DC: US Department of Health and Human Services; 2000. Available at http:/ /www.healthypeople.gov/document/html/volume2/ 21oral.htm.

6. US Census Bureau. Population, population change and estimated components of population change: April 1, 2000 to July 1, 2007. Washington, DC: US Census Bureau; 2007. Available at: http:// www.census.gov/popest/datasets.html.

7. Crall JJ. Rethinking prevention. Pediatr Dent 2006;28:96- 101;192-8.

8. Griffin SO, Regnier E, Griffin PM, Huntley V. Effectiveness of fluoride in preventing caries in adults. J Dent Res 2007;86:410-5.

9. CDC Fact sheet on questions about bottled water and fluoride. Atlanta, GA: US Department of Health and Human Services, CDC; 2008. Available at http://www.cdc.gov/fluoridation/fact_sheets/ bottled_water.htm.

10. CDC. Building capacity to fluoridate: literature review. Atlanta, GA: US Department of Health and Human Services, CDC; 2003. Available at http://www.cdc.gov/fluoridation/pdf/ fluoride_campaign_lit_ review.doc.

Reported by: W Bailey, DDS, L Barker, MSPH, K Duchon, MS, W Maas, DDS, Div of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

Copyright U.S. Center for Disease Control Jul 11, 2008

(c) 2008 MMWR. Morbidity and Mortality Weekly Report. Provided by ProQuest Information and Learning. All rights Reserved.

Handmaiden to the Science?

By Ruse, Michael

Handmaiden to the Science? PHILOSOPHY OF BIOLOGY RE-ENGINEERING PHILOSOPHY FOR LIMITED BEINGS: Piecewise Approximations to Reality. William C. Wimsatt. xviii + 450 pp. Harvard University Press, 2007. $49.95. INTEGRATING EVOLUTION AND DEVELOPMENT: From Theory to Practice. Edited by Roger Sansom and Robert N. Brandon, xiv + 334 pp. The MIT Press, 2007. $34.

EVIDENCE AND EVOLUTION: The Logic Behind the Science. Elliott Sober, xx + 412 pp. Cambridge University Press, 2008. $29.99.

Half a century ago, philosophers of science paid little real attention to the nitty-gritty reality of what happens in the laboratory or field. Idealizations ran rife; the only subject considered was physics; and the only tenable philosophy was a logic- intoxicated form of positivism. But in the 1960s-thanks to people like Thomas Kuhn, who insisted in The Structure of Scientific Revolutions (1962) that philosophers must take seriously the real life of science-the field began to welcome those who took pains to study and understand the actual practice of empirical inquiry.

No area saw a greater sea change than the philosophical study of biology. The 1950s and 1960s were good to the science itself, what with the discovery of the double helix at the molecular level and the growth in confidence of evolutionary studies at the organismic level. Looking for areas to conquer, philosophers of science turned to the life sciences, with aims beyond simply showing that organisms are more than just machines or that one must invoke vitalistic modes of understanding to capture the mystery of the organism.

The first biennial conference of the (American) Philosophy of Science Association, held in Pittsburgh in 1968, marked the first real awakening of this new way of doing things. I was in attendance, one of a small group who were determined to look conceptually at the life sciences and make the philosophy of biology a genuine and worthwhile branch of the larger discipline.

Looking back now, I see that beneath the excitement was a troubling issue that remains with us today. If you are an empirical scientist, the reasons for what you do are fairly obvious: You want to understand the nature and the workings of the world of experience. But what if you are a philosopher, specifically a philosopher of science? What are you doing and why? Is your job primarily to aid science, to be a kind of high-powered theoretician? In the words of the great British empiricist John Locke, is your task that of being a “handmaiden” to the sciences? Or do you have aims of your own, and if scientists do not care for what you are doing, tant pis? Should your primary focus be on the traditional problems of philosophy-epistemology (theory of knowledge) and ethics (theory of morality)? Given the heated nature of the discussions that philosophers of science have over beers at the end of the day, probably there is no resolution to this problem; different people will simply have different aims. This diversity of goals is borne out by several recent books showing that although the seeds planted four decades ago in Pittsburgh still flourish and bloom today, there is still some confusion about what philosophers of biology should or should not be doing.

One person at that 1967 meeting in Pittsburgh was William (universally known as “Bill”) Wimsatt, then a graduate student, who outtalked us all, had more energy than the rest of the group put together and knew more biology than seemed rather decent. Wimsatt’s great abilities and enthusiasm were recognized shortly thereafter when he was awarded a postdoctoral fellowship at the University of Chicago, where he later joined the faculty. Particularly important in his intellectual development were Richard Levins and Richard Lewontin, who were both for a while at Chicago.

Wimsatt has been a strong voice arguing that the philosophy of biology exists primarily for the benefit of biology itself. For someone like myself, who is in the other camp-frankly, my dear, I don’t give a damn what the biologists think-but who finds such intellectual differences stimulating, it is rather exciting that Wimsatt, on the verge of retirement, has recently published a long- awaited book. Re-Engineering Philosophy for Limited Beings: Piecewise Approximations to Reality is a volume based on much that he has written before, but it is more than simply a collection of articles. Rather, it is a new, overview take on things, with earlier material embedded within it.

The overall theme is that we need new ways of dealing with a messy world-ways that do not guarantee immediate truths but that help us to get by and to grope our way slowly to better modes of understanding. In the volume, which is aimed at achieving these ends, Wimsatt covers many topics. For example, in a very good paper titled “False Models as a Means to Truer Theories,” he analyzes in detail an episode in the history of science-the ways in which geneticists found methods of mapping the genes on a chromosome- showing the messy but productive fashion in which the protagonists proposed limited models, ever refining their concepts until they achieved a reasonable grasp of reality.

A somewhat dated section titled “Reductionism(s) in Practice” takes up nearly half the book. Here Wimsatt goes over some of the debates about whether ideas or theories at one level can be shown to be consequences of ideas and theories at other levels. Many of the references are from the 1970s.

Finally, in an epilogue, “On the Softening of the Hard Sciences,” Wimsatt encourages us to move from strawman simplistic reductionism to messy complexity. At this point, more than anywhere, I sensed the influence of Lewontin, who as a Marxist has long decried the reductionistic tendencies of modern science and urged us to a more holistic, if more complex, view of nature.

To illustrate both the strengths and the weaknesses of Wimsatt’s thinking, let me focus on the notion of heuristics, a concept that plays a big role in his discussions and is the subject of two of the book’s four appendices. Paradoxically, it is not entirely easy to grasp the nature of the beasts, but heuristics are very much like biological adaptations-methods that help you to understand the essence of a problem and to overcome it, not necessarily perfectly but usually adequately.

Wimsatt notes that one very important thing about adaptations is that they often “serve to transform a complex computational problem about the environment into a simpler problem, the answer to which is usually a guide to the answer to the complex problem.” For instance, many plants use the shortening day as a guide to the onset of cold weather. They could be mistaken-the weather could turn unseasonably chilly early in the fall, while the days are still relatively long- but by and large the trick is good enough for this world. This tactic is likewise the way of science. Scientists in many or even all fields make reductionistic heuristic assumptions, believing that complex situations are best treated by breaking them up and looking at the parts.

Wimsatt has nothing against this approach-indeed, he admits that it is a good way to go. However, he warns that we should realize that we are using heuristics and not a God-given tool for finding the truth. Heuristics can mislead. For instance,

commonly found in simple models of systems (and even in notso- simple ones) is the assumption that the system is isolated (in effect, that it has no environment) or that its environment is constant in space and time. This asymmetry in simplifications is indicative of the kinds of biases induced by using reductionist problem-solving strategies.

By reminding us of this shortcoming, Wimsatt offers a kind of metacritique of science, showing how, in disputes, differences are often misunderstandings based on hidden assumptions, ones unseen even by the protagonists.

To illustrate his case, Wimsatt refers to work done by his former colleague Michael Wade, a population geneticist. At the end of the 1970s, Wade plunged into the dispute between those who think that natural selection always works at the individual level and those who think that it can promote the good of groups at the expense of the individual. Wade’s experiments on flour beetles suggested that group selection has a lot more power than many then thought, and Wimsatt digs into this finding-one that goes against the reductionism of making all causes work at the lowest or smallest level-arguing that the reason the individual selectionists were unprepared for the discovery was that they were making hidden assumptions that are “biologically unrealistic and incorrect,” each of which “independently has a strong negative effect on the possibility or efficacy of group selection.”

Wimsatt is making a really interesting point-despite irritating me in the process, as he does when he characterizes unfairly the supporters of individual selection. The people he names as partisans all had more nuanced views on the individual-group selection issue than he implies. The late John Maynard Smith, to take one example, openly agreed that group selection was probably responsible for the maintenance (not the origination) of sex. But I am sufficiently convinced by Wimsatt that I want to go back to the individualgroup selection debate and rethink it in the light of what he claims. Wimsatt really engages with his subject, so I am surprised at his rather gloomy assessment that “An alien power seeking to undercut our civilization could do no better than to teach most of our science and its history and philosophy as we do now.” I cannot help feeling that this is the voice of Pittsburgh still speaking.

In my view, things have changed very much for the better, as evidenced by a new collection of essays to which Wimsatt himself contributes, Integrating Evolution and Development: From Theory to Practice, edited by philosophers Roger Sansom and Robert N. Brandon. One of the most exciting new areas of study in the biological sciences is evolutionary development (“evodevo”). Once virtually ignored (by such great evolutionists as Theodosius Dobzhansky and Ernst Mayr, for example), it has now become one of the hottest subjects in the life sciences.

Philosophers have followed in the wake of the biologists’ discoveries, and this collection shows really informed and subtle work being done on uncovering assumptions and pointing to new avenues of understanding. I particularly liked Sansom’s essay on adaptability (a notion that is a great favorite of Richard Dawkins) and the essay by Paul Griffiths on the importance of evo-devo for evolutionary psychology. Griffiths shows beautifully how philosophy can take a broader view-linking development and behavior-and can point to connections that might escape the notice of the working scientist. In other words, despite Wimsatt’s gloominess, I want to congratulate those philosophers of biology who have tried to be relevant to science on their solid successes.

But I also want to note that those oriented to more traditional philosophical issues, such as epistemology and ethics, have produced some ter-, rific thinking. Elliott Sober, a philosopher of science at the University of Wisconsin-Madison, has long been a leader in this school, and his latest work, Evidence and Evolution: The Logic Behind the Science, shows why he commands our attention. He is interested in the question of evidence for theories, and he shows through a careful analysis of statistical thinking (particularly Bayesian thinking) how one can make informed decisions about claims made in biology.

Of particular interest is Sober’s critique of “intelligent design” theory. He brings new ideas to the subject, particularly through the application of probability theory, so that one reads and learns things of value quite apart from the critique as such. But I am not at all sure that I agree with his argumentation. One of the most interesting questions about evolutionary biology is whether, before Charles Darwin, Alfred Russel Wallace and the discovery of natural selection, one could get away from the God hypothesis. Many (Dawkins, for instance) argue that the design-like nature of the world-the hand and the eye-calls out for an explanation, and Dawkins maintains that before Darwin it was impossible to be an intellectually fulfilled atheist.

This is not to say that people of that early era had not criticized inferences about God made on the basis of design. To this day, there is no more withering polemic than that of David Hume, who argues in his Dialogues Concerning Natural Religion that, if there is a God, given the pains of gout, the deity must be a pretty unpleasant chap. However, against Sober and with Dawkins, I am not convinced that Hume shows that there is nothing at all-or rather, Nothing at All. (Hume himself rather admits this at the end of the dialogues.) For my money, no natural selection, then no atheism. But I agree with Sober against Dawkins that, given natural selection, one does not at once plunge into atheism.

I am a lucky person. I was excited by philosophy of science four decades ago and remain so. I congratulate those like Wimsatt who think that the philosophy of biology should be a handmaiden to the science, and also those like Sober who show that there is more to be said than this. Both ways, there is terrific work being done, and we all should celebrate this fact.

Wimsatt offers a kind of metacritique of science, showing how, in disputes, differences are often misunderstandings based on hidden assumptions, ones unseen even by the protagonists.

Michael Ruse is Lucyle T. Werkmeister Professor of Philosophy at Florida State University, and director of the program there in the history and philosophy of science. He is the author of a number of books, including Darwinism and its Discontents (Cambridge University Press, 2006), and is now uniting a book showing that it is possible for a rational person both ta be a Christian and to accept modern science.

Copyright Sigma XI-The Scientific Research Society Jul/Aug 2008

(c) 2008 American Scientist. Provided by ProQuest Information and Learning. All rights Reserved.

A Journey to Continence: A Case Study of Overactive Bladder Syndrome

By Spilde, Nancy L

Overactive bladder is a problem that many women experience and suffer with in silence for years. This is a case study about one such woman. Anna had problems with incontinence for more than five years when she sought treatment. This article presents the story of her journey and perseverance to achieve control of her bladder. Key Words: Overactive bladder syndrome, stress incontinence, urge incontinence, nocturia, urinary frequency, bladder diary.

Urinary incontinence continues to affect approximately 20% of adult women in the United States (Newman, 2002). This incontinence may be due to an overactive bladder syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia), stress incontinence, or a combination of both (Sand & Dmochowski, 2002). The Center for Women in Bismarck, ND, surveyed its population recently and derived similar information about needed continence care; there are many continence treatment options available to these women if offered. The needs of the population were acknowledged by gynecologists and health care staff at the Center for Women; subsequently, the Continence Management Center was developed, the only one of its kind in ND. It offers evaluation, behavioral therapies, medical interventions, urodynamic testing, and surgical options. Continence management referrals are accepted from a multi- state area as information about the program has grown.

Anna, a 64-year-old white female, was referred by her internist for treatment of unresolved urinary frequency, urgency, and incontinence. She stated, “When I get the urge, I need to go now; that is my problem. I know I drink a lot of water.” These urinary symptoms caused her difficulties with daily living as well as embarrassment. Her problem was familiar to the Continence Management Center. Anna’s willingness and fortitude to regain urinary control were sparked when she started seeing positive change that was a result of her treatment at the Center. This case study describes specific interdisciplinary interventions prescribed over time to return Anna to continence.

CLINICAL ASSESSMENT

Anna was currently taking trospium chloride (Sanctura(R)) 20 mg daily and had used oxybutynin chloride (Ditropan XL(R)) 10 mg, but neither medication effectively improved her urinary symptoms. She was incontinent on a daily basis (ranging from wetting her underwear to soiling her outerwear) and was using 4 to 5 thin Poise(R) pads daily. She did not experience incontinence during the night but got up 1 to 2 times to void. Stress urinary incontinence was not a problem unless her bladder was “very full.” She felt that she usually emptied her bladder, but urgency recurred shortly after emptying at times. She had no problem starting her urinary flow and denied symptoms of prolapse or straining with bowel movements. Anna had never been pregnant. She had no history of pelvic or abdominal surgeries. Menopause occurred at about 50 years of age, and she used an estrogen and progesterone supplement until 1 1/2 years ago. There was no history of urinary tract infections. She also reported hypertension that was controlled on medication, mild gastroesophageal reflux, treatment for osteoporosis, and mild depression. Her prescribed medications included amlodipine besylate (Norvasc(R)) 10 mg, esomeprazole magnesium (Nexium(R)) 40 mg, venlafaxine hydrochloride (Effexor XR(R)) 150 mg, celecoxib (Celebrex(R)) 200 mg, trospium (Sanctura(R)) 20 mg, and teriparatide (Forteo(R)) injections, and aspirin (Halfprin(R)). Herbal medications included flax seed, garlic, red rice yeast, multiple vitamin, and folic acid. Anna drank 14 glasses of water daily and an occasional cup of caffeinated coffee

Anna is retired after working 38 years in an office. She has been happily married for many years; she and her husband enjoy traveling but have had to curtail this because of her incontinence problems. She does not smoke. A workout at a local gym is performed on a daily basis.

EXAMINATION

A post-void residual (PVR) was performed to rule out the symptom of incomplete emptying. She voided 350 mls with a PVR of 20 mls. Catheterized urinalysis and culture were normal. There was no cracking or lesions on the external genitalia. Atrophic changes were noted at the vaginal introitus and urethral meatus (Kelley, 2007; Notelovitz, 1997). No protrusion into the anterior or posterior vaginal vault was observed with Valsalva. Checking for pelvic floor strength, she was graded a 2/5 (Brink, Well, Sampselle, Tallie, & Mayer, 1994) with a contraction hold time of 8 seconds initially, but decreasing contraction hold time was noted on repeated maneuvers. With pelvic floor muscle fatigue, she substituted abdominal muscles, but she corrected this with coaching. She was able to perform quick flicks of the pelvic floor muscles. The anatomy of the pelvic floor and bladder function were discussed.

TREATMENT

Anna was asked to keep a bladder diary for three days (Fantil et al., 1996). She was advised of foods and fluids that could irritate her bladder as contained in a dietary guideline (Newman, 2002). She was also advised to space her fluids evenly throughout the day and take calcium glycerophosphate (Prelief(R)) before any irritants. Instructions on pelvic floor exercises (PMEs) were given. She was to perform these three times a day, 10 in a row, starting with a three- second hold time. As endurance improved, she gradually was to increase this hold time to a 10 count. Urge control techniques to retrain the bladder were discussed in detail. She was advised to sit when an urge occurred, take slow deep breaths, perform quick flicks of the pelvic floor muscle, and use distraction techniques until the urge subsided (Newman, 2002). Information regarding a vaginal estrogen supplement was sent home with her to review. A recheck appointment was made to evaluate her bladder diary and discuss a change in her anticholinergic therapy as well as the addition of a vaginal estrogen (Suckling, Lethaby, & Kennedy, 2006).

CONTINUED CLINICAL INTERACTIONS

Two-Week Recheck

On return, Anna’s bladder diaries revealed 14 to 15 voids per day, 15 to 17 glasses (8- ounce) of fluid per day, with loss of urine a couple of times a day. She had not been performing her PMEs or using the urge control technique regularly.

She was advised to reduce her fluid intake to 10 glasses of fluid daily. The gynecologist prescribed estradiol (Vagifem(R)) tablets to use every night for two weeks, then twice per week. She was reinstructed in her PMEs and encouraged to perform them three times a day. The urge control techniques were reviewed, and she promised to use them on a regular basis.

Two-Month Recheck

Anna reports she is better. She continues to have urgency at times and is awakening 0 to 1 times at night as compared to 1 to 2 times initially. She has minimal leakage and rarely needs to change her panty liner during the day. Sanctura 20 mg daily is tolerated with no side effects. Vagifem tablets twice a week have helped her vaginal irritation, and she has noticed a decrease in vaginal dryness. Anna has reduced her fluid intake to 10 to 11 glasses of water per day. She has been using her urge control techniques and performing her PMEs. These techniques have been helping her, and she now has a 10-second contraction hold time. She feels she is seeing some positive change.

After consulting with her physician, Sanctura was increased to twice daily to decrease the urgency that she was still experiencing. The following modifications were made in her urge control techniques. If the urge was “uncontrollable” when preparing to void, she should put the lid down on the toilet, sit, and perform the quick flick technique until the urge had passed, then void. When driving into the garage, sit in the car for a minute and use the urge control to prepare the bladder before entering the house. Anna was instructed to continue her PMEs and recheck in two months to evaluate her progress.

Five-Month Recheck

At the five-month recheck, Anna was much better. Her panty liners were almost always dry. She still experienced urgency at times and awakened once at night, but this occurred “less and less often.” She was losing a small amount of urine (less than one time a week) and reported that this “was a big improvement.” She was taking Sanctura as prescribed and more faithfully performing her PMEs. The urge technique worked quite successfully most of the time, and the vaginal dryness had greatly improved on the Vagifem tablets.

After examination by her gynecologist, Anna was prescribed medroxyprogesterone acetate (Provera(R)) to use for 10 days (Nothnagle & Taylor, 2004). This was to ensure that there was not a buildup of the endometrial lining while on Vagifem (Pinkerton, 2006). Since Anna’s urgency was still present while on Sanctura, she was changed to darifenacin hydrobromide (Enablex(R)) 7.5 mg daily after consulting with her physician. She was to call in a couple of weeks to report her response to this new anticholinergic because the dose could be increased if needed. She was again encouraged to perform her PMEs and use urge control techniques. She had a good understanding of her program and was pleased with her results.

14-Month Phone Consult

Anna called the Center stating that her bladder problems had recurred. Enablex was increased to 15 mg daily. She reported having episodes of urgency and incontinence even when using the medication and her retraining techniques. She had been watching her fluid intake and had not been over hydrating. A referral to physical therapy for additional pelvic exercise instruction had been discussed during her previous visits, but she felt she could manage this on her own. Now, she was in agreement that seeing the physical therapist for instruction in Beyond Kegels was necessary (Hulme, 1997). 16-Month Phone Consult

Anna called stating she had completed her physical therapy program. She still had problems with urgency but was rarely incontinent. The urge was very strong and would occur in situations that were embarrassing to her. The conversation was relayed to her physician, and urodynamic testing was ordered to determine the exact cause of her continued symptoms. There are different types of incontinence, and treatment choices must be specific to the cause- stress versus urgency (Ostergard, Bent, & Weinberger, 1996). She had been very compliant with her continence program; however, she continued to have problems that interfered with her daily living.

CLINICAL ASSESSMENT

Anna was seen in the office; it had been 11 months since she had last been assessed. An updated history was obtained; her health status had remained unchanged. She was drinking 8 glasses of water and 1 glass of juice daily. She continued to have a “strong, sudden urge” and was incontinent of a small amount of urine daily (2 to 3 pads). On rare occasions, she had experienced complete involuntary emptying of her bladder. Sometimes, she was totally unable to delay the need to urinate and awakened once at night to void. Anna was very bothered by her continuing problem with urgency and how it affected her life.

URODYNAMICS

Testing during the filling phase showed that Anna’s bladder demonstrated large detrusor contractions, up to 70 cm/H2O, with no fluid loss when she used her urge suppression techniques. There was a small amount of fluid loss with Valsalva when her bladder was full. Uroflowmetry was normal.

TREATMENT

Following testing and consultation with her physician, Enablex 15 mg was continued, and Sanctura 20 mg at bedtime was added. It was agreed that medications and conservative therapies were not controlling her bladder contractions. She was given information about InterStim(R) neuromodulation (Medtronic) (Daneshgari, 2006; Leng & Morrisroe, 2006), and botulinum toxin (Botox(R)) injections into the bladder were discussed briefly (Smith & Chancellor, 2004).

CONTINUED CLINICAL INTERACTIONS

16.5 Month Recheck

In spite of the anticholinergic medications, urgency and incontinence continued while voiding 8 to 10 times a day and 1 to 2 times at night. Anna had been very dedicated to her PME program and performed the urge control techniques faithfully. “Using all my willpower,” she remained dry most of the time in spite of the powerful contractions. A PVR of 51 mls of urine was obtained after voiding 200 mls. Again, further treatment options were discussed, and she decided to pursue InterStim therapy.

17-Month Phone Consult

Anna and her husband jointly agreed that the InterStim procedure was the needed treatment for her bladder problem. She had met all criteria, which included completing conservative therapies and failing treatment with several anticholinergic medications.

INTERSTIM TREATMENT

Anna had the InterStim Stage I procedure followed by the implant. She reported a 50% reduction in her episodes of urgency but experienced problems with uncomfortable stimulation. Multiple attempts were made at reprogramming but appropriate stimulation did not occur. She was happy with the decreased urgency, so she opted for a revision. This was successfully performed and she achieved excellent stimulation without discomfort.

CLINICAL RESULTS

Today, Anna is a new woman. She is voiding 6 to 7 times a day and is dry. She no longer wears pads and is not bothered by urgency. She and her husband travel when and where they choose without concern for the nearest bathroom. Grateful and happy, Anna has made herself available to the public by sharing her successful continence story at a public forum, co-starring in a television interview for a local news station and being interviewed for a newspaper article.

CONCLUSION

Anna’s treatment for her overactive bladder syndrome was successful. The Continence Management Center followed the recommendations of the Managing Acute and Chronic Urinary Incontinence Clinical Practice Guideline (Fantil et al., 1996) and urology publications. Beginning with a good history and appropriate conservative therapies, many patients experience a decrease or resolution of their bladder symptoms. More invasive therapies, such as InterStim, may be needed if symptoms persist and interfere with quality of life. Continence care can be developed and implemented in any clinical setting; all that is needed is a knowledgeable, motivated nurse and supportive health care professionals.

References

Brink, C., Well, T.J., Sampselle, C.M., Tallie, E.R., & Mayer, R. (1994). A digital test for pelvic muscle strength in women with urinary incontinence. Nursing Research, 43(6), 352-356.

Daneshgari, F. (2006), Applications of neuromodulation of the lower urinary tract in female urology. International Brazilian Journal of Urology, 32(3), 262-272.

Fantil, J.A., Newman, D.K., Colling, J., DeLancey, J.O.L., Keeys, C., Loughery, R., et al. (1996). Managing acute and chronic urinary incontinence. Clinical practice guideline. Quick reference guide for clinicians (No. 2, 1996 Update). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service Agency for Health Care Policy and Research. AHCPR Pub. No. 96-0686.

Hulme, J.A. (1997). Beyond Kegels. Missoula, MT: Phoenix Publishing.

Kelley, C. (2007). Estrogen and its effect on vaginal atrophy in postmenopausal women. Urologic Nursing, 27(1), 40-45.

Leng, W.W., & Morrisroe, S.N., (2006). Sacral nerve stimulation for the overactive bladder. Urology Clinics of North America, 33(4), 491-501.

Newman, D.K. (2002). Managing and treating urinary incontinence, Baltimore, MD: Health Professions Press.

Notelovitz, M. (1997). Urogenital aging. International Journal of Gynecology and Obstetrics, 59(Suppl. 1), S35- S39.

Nothnagle, M., & Taylor, J. (2004). Vaginal estrogen preparations for relief of atrophic vaginitis. American Family Physician, 69(9), 2111-2112.

Ostergard, D.R., Bent, A.E., & Weinberger, M.W. (1996). Differential diagnosis of urinary incontinence. Urogynecology and urodynamics (4th ed.), Baltimore, MD: Williams & Wilkins.

Pinkerton, J. (2006). Vaginal estrogen therapy: The question of systemic absorption. The Female Patient: Signature Series. Retrieved April 7, 2008, from http://www.femalepatient. com/html/arc/sig/meno/ articles/ 031_02_024.asp

Sand, P., & Dmochowski, R, (2002). Analysis of the standardization of terminology of lower urinary tract dysfunction: Report from the standarisation sub-committee of the International Continence Society. Neurology Urodynamics, 21, 167- 178.

Smith, C., & Chancellor, Ml. (2004). Emerging role of botulinum toxin in the management of voiding dysfunction. The Journal of Urology, 171, 2128-2137.

Suckling, J., Lethaby, A., & Kennedy, R. (2006). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Systemic Review, 4, CD001500.

Nancy L. Spilde, RN, CURN, is Director of Continence Management, the Center for Women, Mid Dakota Clinic, Bismarck, ND.

Copyright Anthony J. Jannetti, Inc. Jun 2008

(c) 2008 Urologic Nursing. Provided by ProQuest Information and Learning. All rights Reserved.

Pharmacologic Management of Multiple Sclerosis

By Blasier, Mary Gail

Key Words: Multiple sclerosis, central nervous system, disease modifying therapies, quality of life. Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), which is composed of the brain, optic nerves, and spinal cord (Graham, 2009). It is thought to be an autoimmune disorder that afflicts approximately 400,000 Americans in early to middle adulthood (ages 20 to 40) (National Multiple Sclerosis Society [NMSS], 2008). About 200 people are newly diagnosed each week. Worldwide, MS is believed to affect about 2.5 million (NMSS, 2008). Women are affected twice as often as men, and Caucasians are affected more often than Hispanics, Blacks, or Asians (Graham, 2009). The disease is more prevalent in the colder climates of North America and Europe. If someone is born in a high-risk area for MS and moves to a low-risk area after age 15, that person still carries the risk of the area of origin (Graham, 2009).

ETIOLOGY AND PATHOPHYSIOLOGY

Susceptibility may be determined by genetic and environmental factors, as well as triggers, such as the Epstein-Barr virus. MS is characterized by chronic inflammation and destruction of the myelin sheath of neurons in the CNS. The myelin sheath is essential for the normal conduction of nerve impulses. Patches of myelin deteriorate at irregular intervals along the nerve axon, causing slowing of nerve conduction. Axonal destruction also occurs in MS (Graham, 2009).

CLINICAL MANIFESTATIONS

Precipitating factors can precede the onset of an exacerbation of MS, such as infection, physical injury, emotional stress, pregnancy, and fatigue (Graham, 2009). Signs and symptoms of MS most commonly include weakness and/or sensory symptoms involving a limb, visual difficulties, and gait and coordination abnormalities. Sensory symptoms may include “pins and needles” in a limb. Optic neuritis can result in blurring or misting of vision. Initial symptoms present as follows:

* Sensory loss – 37%.

* Optic neuritis – 36%.

* Weakness – 35%.

* Paresthesias – 24%.

* Diplopia – 15%.

* Ataxia – 11%.

* Bladder dysfunction – 4%.

Physical examination may be difficult in terms of diagnosis due to the widespread nature of the symptoms; delayed diagnosis is common. MRI is abnormal in over 95% of patients (NMSS, 2008).

MS has four clinical patterns of presentation, making the onset insidious or dramatic (Graham, 2009). The pattern of presentation determines the treatment. The four presentation patterns are:

* Relapsing-remitting MS is characterized by recurrent attacks of neurologic dysfunction with or without recovery.

* Secondary progressive MS presents with a relapsing-remitting pattern but evolves to be progressive.

* Primary progressive – Gradual progression of disability from onset.

* Progressive-relapsing – Rare; begins with progressive but relapses can occur.

PROGNOSIS

The chronic nature of this disease creates serious quality-of- life issues over a lifetime. Fifteen years after diagnosis, 20% of patients have no functional limitation, 70% are limited or unable to perform major activities of daily living, and 75% are not employed (Hauser & Goode, 2004). Bladder and bowel dysfunction, vision loss, weakness, loss of coordination, fatigue, and/or depression are the primary problems experienced by most patients (Graham, 2009). Detrusor hyperreflexia is seen in 60% of patients, and about one- third of patients with detrusor hyperreflexia have vesicosphincter dyssynergia (Hauser & Goode, 2004; Siroky, Oates, & Babayan, 2004). About 20% of patients have detrusor areflexia.

TREATMENT

Treatment generally falls into one of three categories: 1) treatment of acute relapses, 2) treatment aimed at disease management, and 3) treatment of symptoms (Graham, 2009).

Acute Relapses

Acute relapses that produce functional impairment may be treated with a short course of intravenous or oral corticosteroids to decrease inflammation and suppress the immune system. This regimen speeds recovery and may modestly improve the degree of recovery. The most common drug for acute relapses is methylprednisolone. Other immunosuppressive agents may be used for more severe exacerbations (Graham, 2009).

Disease Management

The FDA has approved several disease modifying therapies (DMT) to treat MS (see Table 1). Unfortunately, these drugs do not cure MS or make the patient feel better while taking them. However, DMTs slow the progression of the disease to provide long-term benefits for patients. People who start treatment early and continue with treatment have better outcomes. The actions of DMTs include:

* Decrease the frequency and severity of clinical attacks.

* Decrease the accumulation of lesions found in the brain and spinal cord.

* Slow the onset of disabilities (Graham, 2008; NMSS, 2008).

Three of the DMTs are classified as interferons: interferon beta- 1b (Betaseron(R)) and interferon beta-1a (Avonex(R) or Rebif(R)) (Graham, 2009; NMSS, 2008). Interferons are antiviral proteins produced by cells infected by a virus. These proteins are designed to inhibit the replication of virus cells. The interferon medications are injected subcutaneously (SQ) or intramuscularly (IM), with time frames that vary from every other day for Betaseron (SQ), once a week for Avonex (IM), and 3 times a week for Rebif (SQ). Side effects include fatigue, fever, allergic reactions, flu- like symptoms, injection site reactions, depression, and elevated liver enzymes (Graham, 2009).

Glatiramer acetate (Copaxone(R)) is an artificial protein that resembles the natural myelin protein that protects nerve fibers. It mimics the myelin basic protein and interrupts the inflammatory cascade to prevent damage to myelin (Graham, 2009; NMSS, 2008). Copaxone is given daily by subcutaneous injection. Because it is not an interferon, it does not produce side effects associated with interferons; however, vasodilation, anxiety, face flushing, chest tightness, and shortness of breath lasting less than 15 minutes have been reported.

Mitoxantrone HCI (Novantrone(R)) is an immune suppressing drug designed to slow down or turn off inflammatory cells that can cause damage to nerve cells (NMSS, 2008). Novantrone is given 4 times a year via intravenous (IV) infusion. The lifetime cumulative dose is limited to 140 mg/m2 (approximately 8 to 12 doses over 2 to 3 years) because of possible cardiac toxicity. The patient will show blue green urine 24 hours after dose, and he or she may be susceptible to infections, bone marrow decrease, nausea, fatigue, and liver or cardiac damage.

Natalizumab (Tysabri(R)) was approved by the FDA in 2006 and has been shown to be helpful in patients who have not had success with interferon drugs. This DMT drug is a recombinant monoclonal antibody that binds to alpha 4-integrin (NMSS, 2008). It is indicated as monotherapy for relapsing forms of MS to delay the accumulation of physical disability and reduce relapses. Before the patient can begin Tysabri, there must be a 2-week wash-out period if the patient has been treated with interferon drugs or Copaxone. Patients treated with Novantrone or other immunosuppressant medications should wait three months prior to starting Tysabri.

Tysabri is known to predispose patients to infection. Serious hypersensitivity (anaphylactic) reactions have occurred in less than 1% of patients. More common side effects may include dizziness, fever, rash, urticaria, rigors, nausea, flushing, hypotension, dyspnea, and chest pain. Nine percent of patients who experienced hypersensitivity reactions to Tysabri had detectable neutralizing antibodies to the drug. Administered by intravenous infusion monthly, it has been shown to be useful in patients who have not responded other interferon-type drugs (NMSS, 2008).

Symptom Management

DMTs lessen the frequency of relapses, but other treatment forms are necessary to deal with symptom management. Additional symptomatic treatment may include clonazepam (Klonopin(R)) and propranolol (Inderal(R)) for ataxia and tremors; baclofen (Lioresal(R)), diazepam (Valium(R)), or tizanidine (Zanaflex(R)) for spasms; and anticonvulsants, such as gabapentin (Neurontin(R)), carbamazepine (Tegretol(R)), and phenytoin (Dilantin(R)), for pain (Graham, 2009). Bladder dysfunction can be managed with anticholinergics, such as oxybutynin (Ditropan(R)) and propantheline (Pro-Banthine(R)), initially (Graham, 2009).

CONCLUSION

Disease modifying treatments have meant improved quality of life for MS patients. As the disease progresses, the use of different drug classes to combat symptom flares and exacerbations varies. These drugs have side effects as well as benefits, complicating the lives of patients stricken with this chronic progressive disease.

References

Graham, P. (2009). Management of clients with degenerative neurologic disorders. In J. Black & J. Hawks (Eds.), Medical- surgical nursing: Clinical management for positive outcomes (8th ed., pp. 1909-1914). Philadelphia: Elsevier Saunders.

Hauser, S., & Goode, D. (2004). Multiple sclerosis and other demyelinating diseases. In D.L. Kasper, E. Braunwald, S. Hauser, D. Longo, J.L. Jameson, & A.S. Fauci (Eds). Harrison’s principles of internal medicine (16th ed., pp. 2461-2465). New York: McGraw-Hill.

National Multiple Sclerosis Society (NMSS). About MS. (2008). Retrieved March 24, 2008, from http://www.nationalmssociety.org/ about-multiple-sclerosis/index.aspx

Siroky, M., Oates, R., & Babayan, R. (2004). Handbook of urology (3rd ed.). Philadelphia: Lippincott, Williams & Wilkins. Mary Gail Blasier, MSN, BSN, ANP, CUNP, is a Urologic Nurse Practitioner, Urology Department, Veterans’ Administration Hospital, Ann Arbor, MI.

Copyright Anthony J. Jannetti, Inc. Jun 2008

(c) 2008 Urologic Nursing. Provided by ProQuest Information and Learning. All rights Reserved.

Urinary Incontinence in the Childbearing Woman

By Herbruck, Lianne F

Urinary Incontinence (UI) is an often under-reported and untreated medical condition that affects the lives of women of all ages and backgrounds. Although there are six major types of UI, stress urinary incontinence (SUI) is the type most often associated with women of childbearing age. Development of SUI has also been linked to the childbirth process itself.This article will discuss the types, characteristics, and diagnosis of UI, with a focus on SUI. Precipitating factors for SUI, including the influence of pregnancy, childbirth, and aging on its development, will be reviewed. Key Words: Urinary incontinence, pelvic floor disorder, stress urinary incontinence, pelvic organ prolapse, pregnancy, aging, childbirth.

Urinary incontinence (UI) is an undiagnosed, under-reported, and often untreated medical condition that highly impacts quality of life for women of all ages (Bernier & Sims, 2009; Kelleher, 2003; Morkved, Bo, Schei, & Salvesen, 2003; Peeker & Peeker, 2003; Subak et al, 2006; Trowbridge, Wei, Fenner, Ashton- Miller, & DeLancey, 2007). Though study estimates vary widely, the estimated prevalence of UI is between 25% to 55% (Altman et al., 2006; Brolmann, 2004; Buchsbaum, Chin, Glantz, & Guzick, 2002; Culligan & Heit, 2000; Lowdermilk, 2004). As many as one-third of woman 40 years of age or older, and up to 50% of women aged 60 and older, report symptoms of UI at least once per week (Danforth et al., 2006; Huang, Brown, Thom, Fink, & Yaffe, 2007; Pantazis & Freeman, 2006; Trowbridge et al., 2007; Waetjen et al., 2003).

The number of elderly women is predicted to more than double in the United States between 2000 and 2050. Because incidence of UI increases with each decade, it is easy to predict that there will be an increased demand for services pertaining to female pelvic floor disorders (PFD) and UI (Brolmann, 2004; Trowbridge et al., 2007). However, only 20% to 25% of women with UI symptoms solicit medical advice, and many of those who do wait years before seeking care (Culligan & Heit, 2000; Kelleher, 2003; Pantazis & Freeman, 2006; Trowbridge et al., 2007; Viktrup, Rortviet, & Lose, 2006).

BACKGROUND

A woman’s biology, as well as environmental influences, contribute to and encourage the development of PFD and UI. Obesity, vaginal delivery, and multiparity are some factors that increase risk (Nygaard, 2005, 2006; Peeker & Peeker, 2003; Wesnes, Rortveit, Kari, & Hunskaar, 2007; Wilson, Herbison, & Herbison, 1996). Although primary risk factors for incontinence may differ over the course of a woman’s lifetime, damage to muscles, nerves, and connective tissue of the pelvic floor (PF) resulting from pregnancy and childbirth are believed to be major contributors to the development of disorders, such as UI, pelvic organ prolapse (POP), and fecal incontinence (Culligan, Blackwell, Murphy, Ziegler, & Heit, 2005; Danforth et al., 2006). These three conditions, either alone or in combination, make up the very definition of pelvic floor disorders (Brolmann, 2004).

The association between UI and pregnancy and childbirth is one that has been widely accepted for the last several decades. It is thought that trauma to the supportive tissue, ligaments, and pelvic floor muscles, as well as denervation of the PF during obstetric events, increases the likelihood of UI development (Altman et al., 2006; Morkved et al., 2003; Nygaard, 2005; Pantazis & Freeman, 2006; Wesnes et al., 2007). Damage to the pudendal nerve, such as that which can occur during childbirth, is associated with PFD (Peeker & Peeker, 2003; Viktrup et al., 2006). Childbirth injuries to the PF and their potential long-term sequelae are major public health concerns because the economic and psychological costs of managing UI and POP are significant (Heit, Mudd, & Culligan, 2001).

The causal association of UI with pregnancy and childbirth, particularly antenatal and prepregnancy UI, has become widely accepted over the last several decades. It is thought that childbirth-related UI results from trauma to the supportive tissue, ligaments, and pelvic floor muscles, as well as from denervation of the PF during obstetric events (Altman et al., 2006; Morkved et al., 2003; Pantazis & Freeman, 2006; Wesnes et al., 2007; Woldringh, van den Wijngaart, Albers-Heitner, Lycklama a Nijeholt, & Lagro- Janssen, 2007). Vaginal delivery may increase the risk of PFD by two to three fold, and first delivery has a greater association with longlasting SUI over first pregnancy (Viktrup et al., 2006; Wesnes et al., 2007; Nygaard, 2005; Sand et al., 1995). High parity and forceps deliveries are associated with an increased incidence of postnatal UI, which is a risk factor for long-term UI (Pantazis & Freeman, 2006; Peeker & Peeker, 2003).

Much of the literature that focuses on vaginal deliveries and their relation to PFD and UI are based on all types of vaginal deliveries. This includes instrumental deliveries as well as common second-stage interventions, including episiotomy and forced pushing. These types of interventions may increase the risk of PFD by compromising the integrity of the intact pelvic floor during birth (Leslie, 2004).

Recently, there has been a trend in primary, elective cesarean sections (CS) without medical indications. Instead of undergoing a trial of labor and subsequent vaginal delivery, women are opting for a surgical resolution to their pregnancies. Protection of the PF is one of the main arguments for this procedure (Bettes et al., 2007; Nygaard, 2006; Visco et al., 2006). However, most women who deliver vaginally do not have severe PFD (Nygaard, 2005). In addition, it is important to note that some women who never become pregnant or bear children develop PFD or UI (Buchsbaum et al., 2002).

TYPES OF URINARY INCONTINENCE

The six types of UI classifications are stress (SUI), urge (UUI), mixed (MUI), overflow, functional, and reflex (see Figure 1). The three most common types of UI are SUI, UUI, and MUI. SUI is the most common type of UI in women under age 60 and accounts for almost half of incontinence in all women (McCool & Durain, 2004; Waetjen et al., 2003).

SUI results from ineffective closure of the bladder neck and the urethral sphincter, often due to loss of integrity of the vaginal musculofascial attachments (including the pubo-urethral ligaments and endopelvic fascia) that normally support the bladder neck and urethra in a retropubic position. This loss leads to hypermobility and descent of structures, which ultimately results in impaired intra-abdominal pressure transmission to the urethra (Bernier & Sims, 2009; Culligan & Heit, 2000; Lingam, 2001; Lowdermilk, 2004; McCool & Durain, 2004; Pantazis & Freeman, 2006).

This loss of bladder neck support is often attributed to nerve, muscle, and connective tissue damage during vaginal delivery. Changes in the urethrovesical junction due to weakness of the periurethral muscles from childbirth or menopause cause general loosening of the PF, which can create a funneling effect of the bladder neck during exertion (Bernier & Sims, 2009; Culligan & Heit, 2000; McCool & Durain, 2004; Pantazis & Freeman, 2006).

Up to one-third of women experience SUI precipitated by physical activity and exertion (including laughing, coughing, and exercising) in the absence of bladder (detrusor) contraction (Culligan & Heit, 2000; Moore, 2001; Rousseau, 2004). Deficient PF support, obesity, urinary tract infection (UTI), chronic cough, or sphincter weakness (intrinsic sphincter deficiency) are contributory factors (Bernier & Sims, 2009; Culligan & Heit, 2000; McCool & Durain, 2004; Pantazis & Freeman, 2006;). Intrinsic sphincter deficiency is usually a more severe form of SUI that is associated with advanced age, estrogen loss, previous vaginal surgery, obstetric trauma, urogenital prolapse, and certain neurological conditions (Culligan & Heit, 2000). There is no urge component with SUI (Peeker & Peeker, 2003).

UUI is an involuntary loss of urine associated with a strong desire to void without delay, whether or not the bladder is full. This is accompanied by the inability to tighten the urethral sphincter to inhibit voiding. It is sometimes referred to as overactive bladder (OAB) (Bernier & Sims, 2009; Culligan & Heit, 2000; McCool & Durain, 2004; Peeker & Peeker, 2003; Pantazis & Freeman, 2006).

MUI is identified when symptoms of both SUI and UUI are present. It is diagnosed by a combination of urodynamic conditions, such as urodynamic SUI and detrusor overactivity (Bump, Norton, Zinner, & Yalcin, 2003; Culligan & Heit, 2000). Treatment of MUI is based on the predominate, or most bothersome, symptoms (Culligan & Heit, 2000; McCool & Durain, 2004; Pantazis & Freeman, 2006; Peeker & Peeker, 2003). In the clinical setting, MUI symptoms are actually more common than mixed conditions, and women whose UI is more bothersome or is perceived to be more severe tend to be diagnosed with MUI. However, upon urodynamic testing, many of these women often show conclusive results for either SUI or UUI, not both (Bump et al, 2003). In a randomized, double-blind, placebo-controlled study, Bump and coauthors (2003) found that with treatment and as the severity of UI improved, mixed symptoms resolved. This suggests that SUI that is more severe may produce mixed symptoms (Bump et al., 2003), which may indicate that UI symptoms often imprecisely predict the true pathophysiologic mechanism responsible for UI in individual patients (Bump et al., 2003; Lingam, 2001). Generally, pregnancy and childbirth are more likely to precipitate symptoms of SUI. For these reasons, this article will focus on SUI. RISK FACTORS FOR STRESS URINARY INCONTINENCE

General

Common causes of SUI include pregnancy, vaginal delivery, menopause, and surgical procedures that damage nerves leading to pelvic floor muscles (Bernier & Sims, 2009). Trauma to the supportive tissue and denervation of the PF, particularly the pudendal nerve, during obstetric events increase the likelihood of longterm UI (Altman et al., 2006; Pantazis & Freeman, 2006). The pudendal nerve innervates the anal and urethral sphincters as it travels along the pelvic sidewall, where it is particularly vulnerable to injury from the compressive forces of labor and delivery (Heit et al., 2001). High parity, operative vaginal deliveries (forceps and vacuum extraction), episiotomy, birth weight greater than 4,000 g, and second stage of labor lasting longer than 60 minutes significantly increase the risk of SUI after first delivery. This potential increase in the incidence of postnatal UI is a risk factor for long-term UI (Pantazis & Freeman, 2006; Viktrup et al., 2006). First delivery has a greater association with long- lasting SUI over first pregnancy, and women with two live births have as much as a 67% increased odds of UI compared to nulliparous women (Danforth et al.,2006; Sand et al, 1995; Viktrup et al., 2006; Wesnes et al., 2007).

Other risk factors for SUI include advanced age, ethnicity, body mass index (BMI) > 30, diabetes mellitus, smoking, hysterectomy, PF injury, spinal cord trauma, neurological disease, chronic cough, and constipation (see Figure 2) (Danforth et al., 2006; Heit et al., 2001; McFarlin, 2004; Minassian, Lovatsis, Pascali, Alarab, & Drutz, 2006; Moore, 2001; Pantazis & Freeman, 2006; Rovner & Wein, 2004; Wesnes et al., 2007).

Both former and current cigarette smoking is positively associated with frequent and severe incontinence (Danforth et al., 2006). Chronic coughing exerts significant force on the bladder; the pressure from frequent and forceful coughing may ultimately cause damage to the urethral sphincter, vaginal supports, and perineal nerves, thereby worsening symptoms of SUI (Moore, 2001; Walters, 2005). Decreases in collagen synthesis associated with smoking may weaken pelvic support structures, and smokingrelated diseases (such as chronic obstructive pulmonary disease or asthma) may have direct or indirect effects on bladder and urethral function (Danforth et al., 2006).

A study by Minassian et al. (2006) found an association between childhood nocturnal enuresis and adult detrusor overactivity. Patients with previous history of nocturnal enuresis also had a greater risk for developing bladder dysfunction as adults (Minassian et al., 2006). Further investigation of this finding would be useful to help fully assess the impact of childhood UI on UI in adulthood because it could make providers aware of women who are likely to develop UI whether or not they give birth.

Connective tissue disorders have a clear association with UI and POP (Heit et al., 2001). Although abnormalities of collagen have been implicated in pathogenesis of UI and POP, the cause or effect remains to be established (Sultan & Fernando, 2001). Vaginal deliveries do not cause, nor does CS prevent, connective tissue abnormalities. These abnormalities may occur after years of decreased pelvic support, progressive pudendal neuropathy, and hypoestrogenism (Heit et al., 2001). Primary connective tissue abnormalities occur with pregnancy, and women who present with POP may have a genetically weaker endogenous collagen type and composition (Sasso, 2006). Identifying antenatal markers of collagen weakness that can predict women who may develop UI requires further study (Sultan & Fernando, 2001).

High BMI (>30) is a significant risk factor for long-term SUI symptoms, especially during the antenatal period (Buchsbaum et al., 2002; Danforth et al., 2006; Minassian et al., 2006; Moore, 2001; Peeker & Peeker, 2003; Viktrup et al., 2006; Wesnes et al., 2007). Certain medications, including opioids, sedatives, alcohol, antihistamines, hypotensive agents, beta-adrenergic blockers, and diuretics, can contribute to SUI, as can chronic disease and caffeine intake (Carroll, 2009; Kincade et al., 2007; Moore, 2001). Family history of SUI in the mother or any UI in multiple first- degree relatives are also predictors of SUI in individual women (Heit et al., 2001). Caucasian race is associated with an increase in UI risk, and structural and functional differences in the urethra and its support systems have been demonstrated between African- American and Caucasian women. African-American women have greater levator ani (LA) strength and greater urethral sphincter closure pressure (Danforth et al., 2006; Graham & Mallett, 2001; McIntosh, 2005; Moore, 2001, Pantazis & Freeman, 2006; Waetjen et al., 2003).

Influence of Pregnancy

Physical changes during pregnancy may play a contributory role in the process of fecal and urinary incontinence, and even the most non- traumatic birth can result in loss of pelvic muscle tone from pregnancy alone (Borello-France et al., 2006; Martindale & Paisley, 2004; McCool & Durain, 2004). Pregnancy as a risk factor for UI development suggests that factors other than the delivery of a child can contribute to SUI (Nygaard, 2006; Peeker & Peeker, 2003; Wesnes et al., 2007; Wilson et al., 1996). Although UI has been reported in 34% of women at 3 months postpartum, peak incidence is during pregnancy (Sultan & Fernando, 2001).

In the first trimester, the increased weight of the uterine fundus presses directly on the bladder and can compress the ureters. The ureters, renal pelvis, and calices dilate, and increasing levels of progesterone may lead to smooth muscle relaxation. Renal blood flow increases 50% with accompanying increases in the glomerular filtration rate (Martindale & Paisley, 2004). In the second trimester, the uterus rises up and out of the pelvis to become an abdominal organ, and pressure on the bladder lessens. In the third trimester, after the presenting part of the fetus descends into the pelvis, direct pressure on the bladder, coupled with decreased room for bladder distension, increases UI symptoms again (Varney, Kriebs, & Gregor, 2004a).

Hormonal influences may also precipitate urinary changes in pregnancy leading to UI development (Viktrup et al., 2006; Woldringh et al., 2007). Though urinary frequency is often a non-pathological discomfort of pregnancy, onset of SUI during first pregnancy or the puerperal period carries the risk of long-term symptoms at 5 and 15 years post-first delivery (Dolan, Hosker, Mallett, Allen, & Smith, 2003; Varney et al., 2004a; Viktrup et al., 2006; Woldringh et al., 2007). Five years post-delivery, the risk of SUI is four times as high (Viktrup et al., 2006), and at 15 years post-delivery, it is twice as high (Dolan et al., 2003). Obesity before first pregnancy and delivery increases the risk of SUI; in this case, there is a risk that SUI will become chronic and continue up to 12 years postpartum (Viktrup et al., 2006; Wesnes et al., 2007).

Using data from the Norwegian Mother and Child Cohort Study, Wesnes et al. (2007) investigated the incidence and prevalence of UI during pregnancy and its associated risk factors. Of the 43,279 data sets examined, 26.2% of all women reported UI before pregnancy (15.4% of nulliparous women, 33% of primiparous women, and 40% of multiparous women). SUI was the most commonly reported (Wesnes et al., 2007). During pregnancy, 58.1% (25,121) of women reported UI, again with SUI the most common. Among women who were continent prior to pregnancy, incidence of any incontinence by week 30 of pregnancy was 45.6%. During pregnancy, 48% of nulliparous women and 66.6% of parous women experienced incontinence. In this study, prevalence of any UI was doubled compared with prevalence before pregnancy, with the increase most notable in the SUI component. UI both prior to and during pregnancy was found to be associated with parity, age, and BMI (Wesnes et al., 2007).

Bony Pelvis

The bony structure of the pelvis itself may indicate women at a higher risk for developing UI after pregnancy and childbirth, and may also provide further explanation for the racial differences in UI symptoms. Handa and coauthors (2003) performed a retrospective, record review, casecontrol study of women who had undergone pelvic MRI to examine differences between the bony pelvis structures of women with and without PFD. Fifty-nine subjects were in the case group (women with PFD) and 39 were in the control group (women without PFD). Of the 59 women with PFD, the most common complaints were SUI and POP. According to the demographics of the study cohort, women presenting with PFD were more likely to be white, older, and of higher parity.

Typical obstetric pelvic measurements that are adequate for vaginal delivery include a transverse inlet of 12 cm or more, an obstetrical conjugate of 10 cm or more, and an interspinous diameter of 10 cm or more (Lowdermilk, 2004; Varney, Kriebs, & Gregor, 2004b). The four common pelvic shapes are gynecoid, android, anthropoid, and platypelloid (see Table 1). Handa et al. (2003) found that women who had a wide transverse inlet (>13.9 cm) (odds ratio 3.425) and narrow obstetric conjugate (odds ratio 0.233) were more likely to have PFD. Using logistic regression to control for age and parity, PFDs were 7.2 times more likely in women with transverse inlets greater than 13.9 cm (p

Advancing Age

Before menopause, estrogen receptors are present in female urethral and bladder tissues, as well as in the PF musculature (Herbruck, 2009; Chancellor, 2000; Moore, 2001; Rovner & Wein, 2004). Depletion of estrogen at menopause is associated with diminished urethral mucosa, vascularity, and thickness, all of which can cause the urethra to loose its ability to maintain a tight seal, especially when intra-abdominal pressure increases, such as with the Valsalva maneuver, coughing, or exercise (Bernier & Sims, 2009; Moore, 2001). Reduction of estrogen with aging also leads to vaginal dryness, loss of tissue elasticity affecting support in the perineal region, devascularization and thinning of mucosal and support tissues, urogenital changes (including decreases in collagen content), and atrophic changes in tissues of the pelvic floor (McIntosh, 2005; Rousseau, 2004; Sasso, 2006). Loss of estrogen also contributes to an increased tendency for PFD development in women with pelvises damaged by the childbirth process (McIntosh, 2005).

Independent predictors of UI in older women include Caucasian race, estrogen cream use, vaginal dryness, vaginal discharge, lifetime number of UTIs (> 6), and diabetic peripheral nephropathy. History of hysterectomy is predictive of severe incontinence (Jackson, Scholes, Boyko, Abraham, & Fihn, 2006). In some women, shrinking of the uterus, vulva, and distal portion of the urethra that accompanies aging can lead to urinary frequency, dysuria, uterine prolapse, and SUI (Lowdermilk, 2004).

Pelvic Organ Prolapse

Pelvic organ prolapse (POP), a commonly occurring and distressing condition, is defined as protrusion or projection of pelvic organs into the vagina or outside the vagina that progresses over time (McIntosh, 2005; Sasso, 2006; Farkas & Radley, 2002). Vaginal anatomical models from DeLancey (1993) depict the support of pelvic structures to show that vaginal prolapse is a phenomenon of the failure of vaginal, not uterine, support (Delancey, 1999; Farkas & Radley, 2002). It is commonly thought that POP is caused by denervation of PF muscles and/or disruption of endopelvic fascia (Sasso, 2006). POP is associated with a distortion of the urethra and may cause voiding difficulties (Fernando, Thakar, Sultan, Shah, & Jones, 2006). Annual costs in the U.S. have been estimated to be around $10 billion annually for POP treatment and care (Romanzi, 2002). POP is often thought of as a silent disease because many women who suffer with the associated symptoms, including UI, rectal pressure, pain, and discomfort, often find it embarrassing to discuss it with their providers (Fernando et al., 2006; Sasso, 2006).

Risk factors for POP include age, parity, forceps delivery, neruomusclar damage of the PF, family history of prolapse, obesity, HRT use, menopause, hysterectomy, and connective tissue disorders (Bradley, Zimmerman & Nyggard, 2007; DeLancey et al., 2007; Farkas & Radley, 2002; Heit & Culligan, 2001; Sasso, 2006). Other contributing factors to POP include smoking, individual anatomy, constipation, neurological disease, long labor, instrument-assisted delivery, large birthweight babies, chronic respiratory disease, and Caucasian race (Buchsbaum et al., 2006; McIntosh, 2005; Vimplis & Hooper, 2005).

Vaginal birth confers a 4 to11-fold increase in risk for developing POP among parous women and is the single most important modifiable factor for this condition (Delancey, et al., 2007). Fiftypercent of parous women over age 50 are affected by POP (Fernando, et al, 2006); however, many parous women never develop symptoms of POP. POP can also occur in women who have never given birth because uterine prolapse occurs in 2% of nulliparous women (Buchsbaum, et al., 2006; McIntosh, 2005). Lukacz, Lawrence, Contreras, Nager, and Luber (2006) found that incidence of POP is the same in women who have had a CS after labor had begun and women who had vaginal delivery, but incidence was lower in women who had a CS without labor. This may indicate that it is the event of labor, rather than the pregnancy, that contributes more to POP development. Their study also found that women who had been pregnant but who had never delivered an infant had an increased risk in POP over nulliparous women.

Bradley et al. (2007) performed a 4-year prospective observational study on 259 postmenopausal women to examine the natural history of POP and risk factors for changes in vaginal descent. They found that prolapse progresses and regresses in older women, with rates of vaginal descent progression slightly greater than regression. DeLancey et al. (2007) studied 286 women (151 with POP and 135 without POP) using MRI to determine and compare LA defects between the groups. LA muscles are unique striated muscles that play a critical role in pelvic organ support because they provide postural and upward support to the pelvic viscera. They found that there are strong associations between POP and major LA defects (p

Although POP is a common disorder, the true incidence is not known. Some women who present with what would be considered “severe” POP have no symptoms, while some women with “mild” POP have debilitating symptoms (Sasso, 2006; Vimplis & Hooper, 2005). Patients with a major degree of POP rarely have SUI (Vimplis & Hooper, 2005; Ward, 2003).

Treatment and assessment of POP is based as much on symptomology as it is the extent of the prolapse. Symptom assessment must include the prolapse itself, as well as related PFDs, including urinary, bowel, and sexual functioning. The patient’s view of her symptoms, needs, and expectations are paramount to her treatment (Farkas & Radley, 2002). Symptoms generally relate to type and location of POP, but location and extent may not correlate well with symptom severity (Sasso, 2006). Treatment of POP strives to maintain urinary and bowel function, preserve sexual function, and decrease irritating symptoms (Farkas & Radley, 2002; Vimplis & Hooper, 2005). Symptoms generally relate to type and location of POP, but location and extent may not correlate well with symptom severity (Sasso, 2006).

Treatment of POP strives to maintain urinary and bowel function, preserve sexual function, and decrease irritating symptoms (Farkas & Radley, 2002; Vimplis & Hooper, 2005). Pessary use improves POP and associated pelvic organ dysfunction, including bladder, bowel, and sexual function. Pessaries may be an appropriate conservative treatment, and is a first-line treatment in women who are not good surgical candidates (Bernier & Sims, 2009, Fernando et al., 2006; Herbruck, 2009; Vimplis & Hooper, 2005). Sometimes pessary placement can unmask incontinence by straightening out urethral kinks that may have been causing some level of urinary retention (Walters, 2005). However, pessary placement, particularly when fitted with an incontinence ring, can help reduce symptoms of known SUI and UUI (Culligan & Heit, 2000; Fernando et al., 2006; McIntosh, 2005; Rovner & Wein, 2004).

Alternative treatment of POP may also include lifestyle changes, such as weight loss or resolution of constipation, to prevent worsening of POP (Vimplis & Hooper, 2005). Surgical treatment includes colposuspension of the anterior or posterior compartments. Newer techniques exist, including tension-free vaginal tape and other procedures that employ the use of synthetic materials. Ongoing studies aim to determine their effectiveness when compared to colposuspension (Farkas & Radley, 2002).

SUI in the Nulliparous Woman

With aging populations on the rise, greater numbers of nulliparous women are being identified with urogential prolapse and SUI (Sultan & Fernando, 2001). It is important to remember that nulliparous women experience SUI and that UI itself is not entirely related to childbirth (Lowdermilk, 2004). Additional factors other than childbirth that might contribute to UI development include heredity, menopause and the subsequent loss of estrogen, and pelvic surgeries (Altman et al., 2006; Buchsbaum et al., 2002; Nygaard, 2005).

Buschbaum and colleagues (2002) performed a study examining the prevalence of UI among a group of 149 nulliparous nuns. Individual medical history, demographic data, and symptoms of UI were examined. This study concluded that prevalence of UI among nulliparous, postmenopausal nuns was similar to UI rates reported by parous, postmenopausal women. After multivariate logistic regression, BMI (p = 0.001), multiple UTIs (p = 0.033), and depression (p = 0.022) were significant statistics that correlated with UI in the study group (Buchsbaum et al., 2002).

Since parity and pelvic trauma are considered major risk factors for SUI, one might expect the occurrence of UUI to be higher than occurrence of SUI in nulliparous postmenopausal women. However, in the Buchsbaum et al. (2002) study, they found that UI in elderly, postmenopausal, nulliparous women was associated with SUI more often than UUI, even in the absence of trauma of the pelvic floor due to pregnancy or childbirth. These results directly contradict the theories that nulliparity protects against SUI. Trowbridge and colleagues (2007) performed a cross-sectional study involving a cohort of 82 nulliparous women to evaluate the effects of aging, independent of parity, on POP, urethral support and function, and levator function. Women 20 to 71 years of age underwent a pelvic examination. Additional tests performed were POP quantification (POP- Q measured at maximal Valsalva strain), urethral angles by cotton- tipped swab, and multichannel urodynamics and uroflow. Vaginal closure was also quantified. In this study, increasing age was associated with decreasing maximal urethralclosure pressure (r = – 0.758, p

SUMMARY

The effects of UI on women are wide-reaching and life altering. Costs in both financial and emotional/social realms burden women of all ages throughout their life cycle. Though studies continue to find associations between incontinence and childbearing, it is prudent to remember that there are other genetic and environmental factors that can play a roll in the establishment of UI and PFDs in any individual woman’s health history.

Future studies may investigate which exact biological and environmental factors play roles that may place certain women at higher risk for severe PFD and UI (Nygaard, 2005). Additional studies regarding relationships between the maternal bony pelvis and obstetrical injuries may also provide further insight into PF issues. Studies that examine modifications and improvements in labor and birth procedures (including management of the second stage of labor, positional changes and perineal management during delivery, use of episiotomy, instrumental/operative vaginal deliveries, and cesarean section) to impart the least damage to the PF have the potential to benefit all childbearing women. Studies designed to evaluate the natural history of incontinence over a woman’s lifetime have the potential to provide strong scientific evidence for a cause- and-effect relationship of an etiology, as well as a better understanding of the natural occurrence and progression of UI and PF issues (Handa et al., 2003; McFarlin, 2004).

Urologic Nursing Editorial Board Statements of Disclosure

Christine Bradway, PhD, RN, disclosed that she is on the Consulting Board for Boehringer Ingelheim Pharmaceuticals, Inc.

Kaye K. Gaines, MS, ARNP, CUNP, disclosed that she is on the Speakers’ Bureau for Pfizer, Inc., and Novartis Oncology.

Susanne A. Quallich, ANP,BC, NP-C, CUNP, disclosed that she is on the Consultants’ Bureau for Coloplast.

All other Urologic Nursing Editorial Board members reported no actual or potential conflict of interest in relation to this continuing nursing education article.

Figure 1.

Major Classifications of Urinary Incontinence

Stress Urinary Incontinence

Involuntary leakage upon effort or exertion, or on sneezing or coughing; loss of urine upon increased abdomen pressure.

Causes:Urethral hypermobility due to weakened pelvic floor muscles, pregnancy, intrinsic sphincter deficiency, or aging.

Urge Urinary Incontinence (Overactive Bladder in Between Overactivity)

Involuntary leakage of urine immediately preceded or accompanied by urgency; sudden sensation of a need to urinate with inability to get to a toilet before involuntary leakage.

Causes:Overactive bladder; detrusor overactivity +/- spontaneous contraction, bladder infections, nerve damage from stroke, dementia, or multiple sclerosis.

Mixed Urinary Incontinence

Involuntary leakage associated with urgency as well as with exertion, effort, or increased abdominal pressure, causing symptoms of both conditions.

Causes:See above; usually the type causing the most bothersome symptoms will be treated first.

Overflow Incontinence

Condition where the bladder is full but not able to empty properly. This causes leaks, dribbles, and hesitancy. More common in men.

Causes:Urethral blockage hindering passage of urine from the bladder; weakened bladder contractions due to diabetes mellitus or neurologic disorder.

Functional Incontinence

Condition where the urinary system is normal, but sufferers have mental or physical conditions that preclude adequate or appropriate toileting.

Causes:Parkinson’s disease, Alzheimer’s disease, severe depression, severe arthritic conditions.

Reflex Incontinence

Involuntary loss of bladder control without warning; the bladder empties due to reflex activity with no control of urination.

Causes:Neurological impairment, such as quadriplegia or spinal cord lesions.

Figure 2.

Risk Factors for Stress Urinary Incontinence

Female gender

Pregnancy

Vaginal delivery

Advanced age

BMI > 30

Diabetes mellitus

Smoking

Hysterectomy

Spinal cord trauma

Neurological disease

Chronic cough

Constipation

Pelvic floor injury

High impact exercise

Ethnicity (Caucasian race)

Pelvic surgery

Certain medications

Pelvic prolapse

References

Altman, D., Ekstrom, A., Gustafsson, C., Lopez, A., Falconer, C., & Zetterstrom, J. (2006). Risk of urinary incontinence after childbirth: A 10-year prospective cohort study. Obstetrics and Gynecology, 108(4), 873-878.

Bernier, F., & Sims, T.W. (2009). Management of clients with urinary disorders. In J.M. Black & J.H. Hawks (Eds.), Medical- surgical nursing: Clinical management for positive outcomes (8th ed., pp. 727-778). St Louis, MO: Elsevier Saunders.

Bettes, B.A., Coleman, V.H., Zinberg, S., Spong, C.Y., Portnoy, B., DeVoto, E., et al. (2007). Cesarean delivery on maternal request: Obstetrcian-gynecologists’ knowledge, perception and practice patterns. Obstetrics and Gynecology, 109(1), 57-66.

Borello-France, D., Burgio, K.L., Richter, H.E., Zyczynski, H., FitzGerald, M.P., Whitehead, W., et al. (2006). Fecal and urinary incontinence in primiparous women. Obstetrics and Gynecology, 108(4), 863-872.

Bradley, C.S., Zimmerman, M.B., & Nygaard, I.E. (2007). Natural history of organ prolapse in postmenopausal women. Obstetrics and Gynecology, 109(4), 848-854.

Brolmann, H.A.M. (2004). Pelvic floor disorders: Diagnosis, management and new developments. Gyneacology Forum, 9(1), 1-5.

Buchsbaum, G.M., Chin, M., Glantz, C., & Guzick, D. (2002). Prevalence of urinary incontinence and associated risk factors in a cohort of nuns. Obstetrics and Gynecology, 100(2), 226-229.

Buchsbaum, G.M., Duecy, E.E., Kerr, L.A., Huang, L.S., Perevich, M., & Guzick, D.S. (2006). Pelvic organ prolapse in nulliparous women and their parous sisters. Obstetrics and Gynecology, 108(6), 1388-1393.

Bump, R.C., Norton, P.A., Zinner, N.R., & Yalcin, I. (2003). Mixed urinary incontinence symptoms: Urodynamic findings, incontinence severity and treatment response. Obstetrics and Gynecology, 102(1), 76-83.

Carroll, R.G. (2009). Anatomy and physiology review: The elimination systems. In J.M. Black & J.H. Hawks (Eds.), Medical- surgical nursing: Clinical management for positive outcomes (8th ed., pp. 644-652). St Louis, MO: Elsevier Saunders.

Chancellor, M.B. (2000). First-line therapy for stress incontinence. Reviews in Urology, 2(4), 229-230.

Culligan, P.J., & Heit, M. (2000). Urinary Incontinence in women: evaluation and management. American Family Physician, 62(11), 2433- 2444, 2447, 2452.

Culligan, P.J., Blackwell, L., Murphy, M., Ziegler, C., & Heit, M.H. (2005). A randomized, double-blinded, sham-controlled trial of postpartum extracorporeal magnetic innervation to restore pelvic muscle strength in primiparous patients. American Journal of Obstetrics and Gynecology, 192, 1578-1582.

Danforth, K.N., Townsend, M.K., Lifford, K., Curhan, G.C., Resnick, N.M., & Grodstein, F. (2006). Risk factors for urinary incontinence among middleage women. American Journal of Obstetrics and Gynecology, 194(2), 339-345.

DeLancey, J.O. (1993). Anatomy and biomechanics of genital prolapse. Clinical Obstetrics and Gynecology, 36, 897-909.

DeLancey, J.O. (1999). Structural anatomy of the posterior pelvic compartment as it relates to rectocele. American Journal of Obstetrics and Gynecology, 180, 815-823.

DeLancey, J.O, Morgan, D.M., Fenner, D.E., Kearney, R., Guire, K, Miller, J.M., et al. (2007). Comparison of levator ani muscle defects and function in women with and without pelvic organ prolapse. Obstetrics and Gynecology, 109(2, part 1), 295-302.

Dolan, L.M., Hosker, G.L., Mallett, V.T., Allen, R.E. ,& Smith, A.R. (2003). Stress incontinence and pelvic floor neurophysiology 15 years after the first delivery. British Journal of Obstetrics and Gynaecology, 110, 1107-1114.

Farkas, A.G., & Radley, S.C. (2002). Clinical management of urogential prolapse: New approaches. Current Obstetrics and Gynaecology, 12, 207-211.

Fernando, R.J., Thakar, R., Sultan, A.H., Shah, S.M., & Jones, P.W. (2006). Effect of vaginal pessaries on symptoms associated with pelvic organ prolapse. Obstetrics and Gynecology, 108(1), 93-99.

Graham, C.A., & Mallett, V.T. (2001). Race as a predictor of urinary incontinence and pelvic organ prolapse. American Journal of Obstetrics and Gynecology, 185, 116-120.

Handa, V.L, Pannu, H.K., Siddique, S., Gutman, R., VanRooyen, J., & Cundiff, G. (2003). Architectural differences in the bony pelvis of women with and without pelvic floor disorders. Obstetrics and Gynecology, 102(6), 1283-1290. Heit, M., Mudd, K., & Culligan, P. (2001). Prevention of childbirth injuries to the pelvic floor. Current Women’s Health Reports, 1, 72-80.

Herbruck, L. (2009). Management of women with reproductive disorders. In J.M. Black & J.H. Hawks (Eds.), Medicalsurgical nursing: Clinical management for positive outcomes (8th ed., pp. 912- 939). St Louis, MO: Elsevier Saunders.

Huang, A.J., Brown, J.S., Thom, D.H., Fink, H.A., & Yaffe, K. (2007). Urinary incontinence in older community- dwelling women: The role of cognitive and physical function decline. Obstetrics and Gynecology, 109(4), 909-916.

Jackson, S.L., Scholes, D., Boyko, E.J., Abraham, L., & Fihn, S.D. (2006). Predictors of urinary incontinence in a prospective cohort of postmenopausal women. Obstetrics and Gynecology, 108(4), 855-862.

Kelleher, C. (2003). Investigation and treatment of lower urinary tract dysfunction. Current Obstetrics and Gynaecology, 13, 342-349.

Kincade, J.E., Dougherty, M.C., Carlson, J.R., Wells, E.C., Hunter, G.S., & Busby-Whitehead, J. (2007). Factors related to urinary incontinence in communitydwelling women. Urologic Nursing, 27(4), 307-317.

Leslie, M.S. (2004). Counseling women about elective cesarean section. Journal of Midwifery and Women’s Health, 49(2), 155-159.

Lingam, K. (2001). Genuine stress incontinence. Current Obstetrics and Gynaecology, 11, 353-358.

Lowdermilk, D.L. (2004). Structural disorders and neoplasms of the reproductive system. In D.L. Lowdermilk & S.E. Perry (Eds.), Maternity and women’s health care (8th ed., pp. 289-326). St. Louis, MO. Mosby.

Lukacz, E.S., Lawrence, J.M., Contreras, R., Nager, C.W., & Luber, K.M. (2006). Parity, mode of delivery, and pelvic floor disorders. Obstetrics and Gynecology, 107(6),1253-1260.

Martindale, A.D., & Paisley, A.M. (2004). Surgical and urological problems in pregnancy. Current Obstetrics and Gynaecology, 14, 350- 355.

McCool, W.F., & Durain, D. (2004). Common diagnoses in women’s gynelogical health. In H. Varney, J.M. Kriebs, & C.L. Gregor (Eds.), Varney’s midwifery (4th ed., pp. 379-437). Sudbury, MA: Jones and Bartlett Publishers, Inc.

McFarlin, B.L. (2004). Elective cesarean birth: Issues and ethics of an informed decision. Journal of Midwifery and Women’s Health, 49(5), 421-429.

McIntosh, L. (2005). The role of the nurse in the use of vaginal pessaries to treat pelvic organ prolapse and/or urinary incontinence: A literature review. Urologic Nursing, 25(1), 41-48.

Minassian, V.A., Lovatsis, D., Pascali, D., Alarab, M., & Drutz, H.P. (2006). Effect of childhood dysfunctional voiding on urinary incontinence in adult women. Obstetrics and Gynecology, 107(6), 1247- 1251.

Moore, D. (2001). The impact of incontinence. Retrieved March 19, 2008, from http://www.drdonnica.com/articles/00003198.htm

Morkved, S., Bo, K., Schei, B., & Salvesen, K.A. (2003). Pelvic floor muscle training during pregnancy: A singleblind randomized controlled trial. Obstetrics and Gynecology, 101(2), 313-319.

Nygaard, I. (2005). Should women be offered elective cesarean section in the hope of preserving pelvic floor function? International Urogynecology Journal, 16, 253-254.

Nygaard, I. (2006). Urogynecology: The importance of long-term follow up. Obstetrics and Gynecology, 108(2), 244-245.

Pantazis, K., & Freeman, R.M. (2006). Investigation and treatment of urinary incontinence. Current Obstetrics and Gynaecology, 16, 344- 352.

Peeker, I., & Peeker, R. (2003). Early diagnosis and treatment of genuine stress urinary incontinence in women after pregnancy: Midwives as detectives. Journal of Midwifery and Women’s Health, 48(1), 60-66.

Romanzi, L.J. (2002). Management of the urethral outlet in patients with severe prolapse. Current Opinions in Urology, 12(4), 339-344.

Rousseau, M.E. (2004). Health care of midlife and again women. In H. Varney, J.M. Kriebs, & C.L. Gregor (Eds.) Varney’s midwifery (4th ed., pp. 335-377). Sudbury, MA: Jones and Bartlett Publishers, Inc.

Rovner, E.S., & Wein, A.J. (2004). Treatment options for stress urinary incontinence. Reviews in Urology, 6(Supp 3), S29-S47.

Sand, P.K., Richardson, D.A., Staskin, D.R, Swift, S.E., Appel, T.A., Whitmore, K.E., et al. (1995). Pelvic floor electrical stimulation in the treatment of genuine stress incontinence: A multicenter, placebo-controlled trial. American Journal of Obstetrics and Gynecology, 173, 72-79.

Sasso, K.M. (2006). The Colpexin(TM) Sphere: A new conservative management option for pelvic organ prolapse. Urologic Nursing, 26(6), 433-440.

Subak, L.L., Brown, J.S., Kraus, S.R., Brubaker, L, Lin, F., Richter, H.E., et al. (2006) The “costs” of urinary incontinence for women. Obstetrics and Gynecology, 107(4), 908-916.

Sultan, A.H., & Fernando, R. (2001). Maternal obstetric injury. Current Obstetrics and Gynaecology, 11, 279-284.

Trowbridge, E.R., Wei, J.T., Fenner, D.E., Ashton-Miller, J.A., & DeLancey, J.O.L. (2007). Effects of aging on lower urinary tract and pelvic floor function in nulliparous women. Obstetrics and Gynecology, 109(3), 715-720.

Varney, H., Kriebs, J.M., & Gregor, C.L. (2004a). Normal pregnancy database: Adaptation of the mother, development and growth of the embryo and the fetus an the placenta. In H. Varney, J.M. Kriebs, & C.L. Gregor (Eds.), Varney’s midwifery (4th ed., pp. 543- 593). Sudbury, MA: Jones and Bartlett Publishers, Inc.

Varney, H., Kriebs, J.M. & Gregor, C.L. (2004b). Anatomy of the pelvis, pelvic types, evaluation of the bony pelvis and clinical pelvimetry. In H. Varney, J.M. Kriebs, & C.L. Gregor (Eds.), Varney’s midwifery (4th ed., pp. 1205- 1215). Sudbury, MA: Jones and Bartlett Publishers, Inc.

Viktrup, L., Rortveit, G., & Lose, G. (2006). Risk of stress urinary incontinence twelve years after the first pregnancy and delivery. Obstetrics and Gynecology, 108(2), 248-254.

Vimplis, S., & Hooper, P. (2005). Assessment and management of pelvic organ prolapse. Current Obstetrics and Gynaecology, 15, 387- 393.

Visco, A.G., Viswanathan, M., Lohr, K.N., Wechter, M.E., Gartlehner, G., Wu, J.M., et al. (2006). Cesarean delivery on maternal request: Maternal and neonatal outcomes. Obstetrics and Gynecology, 108(6), 1517-1529.

Waetjen, L., Subak, L.L., Shen, H., Lin, F., Wang, T.H., Vittinghoff, E., et al. (2003). Stress urinary incontinence surgery in the United States. Obstetrics and Gynecology, 101(4), 671-676.

Walters, M.D. (2005). Urinary incontinence in women. ACOG Practice Bulletin No. 63. American College of Obstetricians and Gynecologists. Obstetrics and Gynecology, 105, 1533-1545.

Ward, S.J. (2003). Gynaecological urology. Current Obstetrics and Gynaecology, 13, 52-56.

Wesnes, S.L, Rortveit, G., Kari, B., & Hunskaar, S. (2007). Urinary incontinence during pregnancy. Obstetrics and Gynecology, 109(4), 922-928.

Wilson, P.D., Herbison, R.M., & Herbison, G.P. (1996). Obstetric practice and the prevalence of urinary incontinence three months after delivery. British Journal of Obstetrics and Gynaecology, 103, 154-161.

Woldringh, C., van den Wijngaart, M., Albers-Heitner, P., Lycklama a Nijeholt, A.A.B., & Lagro-Janssen, T. (2007). Pelvic floor muscle training in not effective in women with UI in pregnancy: A randomized controlled trial. International Urogynecology Journal, 18(4), 383-390.

Lianne F. Herbruck, MSN, RN, CNM, is a Certified Nurse Midwife, Cleveland, OH.

Note: Objectives and CNE Evaluation Form appear on page 172.

Note: The author reported no actual or potential conflict of interest in relation to this continuing nursing education article.

Copyright Anthony J. Jannetti, Inc. Jun 2008

(c) 2008 Urologic Nursing. Provided by ProQuest Information and Learning. All rights Reserved.

The First Discovery of DNA

By Dahm, Ralf

Few remember the man who discovered the “molecule of life” three- quarters of a century before Watson and Crick revealed its structure On February 26, 1869, in the old university town of Tubingen in southwest Germany, the young Swiss doctor Friedrich Miescher, who had settled there only a few months earlier, completed a letter to his uncle in which he described a momentous discovery. He had found a substance that he was certain resided in the cell nucleus and which differed in chemical composition from proteins or any other compound known at the time. Without grasping the reach of his work, Miescher had started one of the greatest scientific revolutions. Years later, it would completely change the fundamental understanding of life and lead to medical breakthroughs unimaginable in Miescher’s time.

Johann Friedrich Miescher was born into a family of scientists in 1844 (he was always known as Friedrich, even in his publications later in life). Miescher’s father and his maternal uncle, Wilhelm His, were distinguished medical doctors and professors of anatomy and physiology at the University of Basel in Switzerland. A range of scientists frequently visited the home, and their lively discussions exposed the young Miescher to a variety of scientific ideas and concepts. In such surroundings, Miescher developed a keen interest in the natural sciences. At the age of 17 he started his studies of medicine in Basel and graduated in 1867 when he was only 23 years old.

At first he considered practicing medicine, like his father. However, poor hearing from an illness he had contracted in childhood would have made some parts of that job difficult for him. His fascination with the sciences suggested research as an avenue for him to pursue. Inspired by his uncle’s conviction that the “last remaining questions concerning the development of tissues could only be solved on the basis of chemistry,” Miescher decided to study biochemistry.

In the spring of 1868 he moved to Tubingen to work under the guidance of two of the most renowned scientists of the time: the organic chemist Adolf Strecker, in whose laboratory Miescher worked for one semester, and the biochemist Felix Hoppe-Seyler, one of the pioneers in a nascent branch of science referred to as “physiological chemistry.” Between 1860 and 1871, Hoppe-Seyler headed one of the first biochemical laboratories worldwide. It was located in Tubingen’s medieval castle, high above the old town and the surrounding river valleys (Hoppe-Seyler’s laboratory was in a converted laundry room, whereas Miescher’s was put in the former kitchen). Hoppe-Seyler had previously accomplished, among other things, groundbreaking experiments concerning the properties of hemoglobin-seminal work that was to influence countless subsequent studies on the structure and function of this and other proteins. In a very short span of time, his laboratory had attained a reputation that reached far beyond the boundaries of the city.

Elementary Analyses

Under Hoppe-Seyler’s guidance, Miescher set out to determine the chemical composition of cells. Lymphocytes were to serve as the source material for these studies. By studying this “most simple and independent cell type,” he hoped to understand the secrets of cellular life. But lymphocytes proved difficult to purify from lymph glands in the large quantities needed for chemical analyses. Hoppe- Seyler, who had a long-standing interest in the nature of blood, likely suggested that Miescher turn to closely related leukocytes instead. Thus the discovery of DNA made a rather unappetizing start: Miescher isolated the cells he needed from the pus on wound dressings he obtained from the surgical hospital in Tubingen. At the time, a plentiful production of pus from wounds was still widely held to be a requirement to purge the body of harmful substances. Antiseptics were not yet commonly used and purulent bandages were available in large quantities.

First of all, Miescher had to develop methods to wash the leukocytes from the surgical cloth. He tested a variety of salt solutions, always checking the outcome of his trials under a microscope. Once he had established the conditions, he set out to characterize and categorize the different proteins and lipids he isolated from the cells. Like many of his contemporaries, he hoped to discover how cells work by analyzing their proteins, so Miescher described their properties and attempted to classify them. But his work was plagued with setbacks. The diversity of proteins within a cell was too much for the relatively primitive methods and equipment of his time. During his experiments, however, Miescher detected a substance with unexpected properties. It could be precipitated by acidifying the solution and redissolved by making the solution more alkaline. Unknowingly, Miescher had, for the first time, obtained a crude precipitate of DNA.

But where did this enigmatic substance come from? When Miescher had extracted leukocytes with acids, he had noticed that prolonged exposure of the cells to diluted hydrochloric acid resulted in a cellular residue consisting of what looked like isolated nuclei. He also noticed that these nuclei could no longer be stained yellow with iodine, an indication that the proteins had been largely extracted. Very weak alkaline solutions led to a strong swelling of the nuclei, without, however, dissolving them. Based on these observations Miescher speculated that his mysterious precipitate could only belong to the nuclei.

At that time, very little was known about this organelle. Although the nucleus had been discovered as early as 1802, its function in the cell remained a matter of intense controversy and speculation. However, in 1866, three years prior to Miescher’s discovery, the influential German biologist Ernst Haeckel had proposed that, the nucleus contained the factors responsible for the transmission of hereditary traits. This suggestion led to a renewed interest in the role of the nucleus. Miescher’s serendipitous finding opened a door to gleaning more information on the nature of this mysterious organelle.

Before being able to further characterize the nuclear precipitate, however, Miescher had to develop protocols to isolate nuclei with higher purity. After many trials, he finally hit on a method. He rinsed the cells several times with fresh solutions of a diluted hydrochloric acid over a period of several weeks at “wintry temperatures,” which were important to minimize degradation of his material. This treatment broke apart the cells’ membranes and stripped most of the cytoplasm off the nuclei. He next removed the lipids by vigorously shaking the material in a combination of water and ether. When the mixture settled, Miescher observed mat the extracted nuclei sank to the bottom of the vessel as fine granules. When he added alkaline solutions to these nuclei, he found that they swelled and faded, just as he had seen with his earlier preparations. When he added acid, on the other hand, the swelling was reversed and again a white, woolly precipitate appeared. With these experiments Miescher showed that the precipitate he had previously observed had indeed come from the nuclei. As a consequence, Miescher later named it nuclein, a term still preserved in today’s name deoxyribonucleic acid.

Despite nuclein’s unusual behavior, Miescher was not yet entirely convinced that it was distinct from protein. He thus devised further experiments to learn more about the nature of this strange molecule. Chiefly, he intended to determine its elementary composition, but to do so he needed still purer nuclein. In particular, he had to remove as much of the contaminating cytoplasm as possible. Miescher decided to try a method that Wilhelm Kuhne had described only one year earlier in his textbook on physiological chemistry. Kuhne had observed that cells can be broken apart with solutions containing the digestive enzyme pepsin, which dissolves cytoplasm without attacking nuclei.

This approach was precisely what Miescher needed. Unfortunately, at the time, pepsin could not be ordered from a chemical supplier. Instead Miescher had to isolate it for himself. Thus he embarked on the second unsavory part of his scientific journey: He rinsed out pig stomachs with diluted hydrochloric acid and filtered the washed- out contents to obtain a crude solution of protein-digesting enzymes. Treating cells with this solution not only chewed apart the proteins, it also showed that nuclein was indeed not a protein.

Now Miescher finally had an optimized protocol to isolate DNA. He began by washing the leukocytes several times with warm alcohol. This broke the cells up and removed most of the cytoplasm. Moreover, it dissolved most lipids. Subsequently, he digested the extract with his pepsin solution. This treatment resulted in a fine, gray sediment. To remove residual lipids, Miescher shook the sediment in ether and again in warm alcohol. He noted that the “nuclear mass” purified in this way showed the same chemical behavior as the nuclear extracts isolated with his previous protocols. Next, Miescher washed the preparation with alkaline solutions, such as highly diluted sodium carbonate. When subsequently adding an excess of acetic or hydrochloric acid, he got a flocculent precipitate, which he could redissolve by adding alkaline solutions. This precipitate was the first comparatively dean preparation of DNA, pure enough for Miescher to finally embark on an analysis he had been planning for some time: to determine which elements make up nuclein. Elementary analyses were one of the few methods available to characterize novel molecules at the time. The procedures involved heating the substance in the presence of various chemicals that selectively reacted with the different constituent elements. The resulting reaction products were weighed to determine the amount of each element present in the substance under test. The process was laborious and time consuming, so much so that Miescher called it “factory work,” but he kept at it. So far, Miescher had established that nuclein behaved differently from proteins and lipids in his isolation procedure: Enzymes capable of breaking down proteins were unable to degrade it, and it could not be extracted by strong organic solvents. The analysis of its elementary composition held another surprise for Miescher. Besides containing the elements carbon, oxygen, hydrogen and nitrogen, which are known to be very abundant in proteins, the molecule did not contain sulfur and it did harbor large quantities of phosphorus. The latter was a very unusual finding because virtually no other organic molecules containing phosphorous were known at the time. This result finally convinced Miescher that he had discovered a fundamentally new type of cellular substance.

Publishing Woes

In the autumn of 1869 Miescher finished his initial analyses of nuclein and returned to Basel for a short holiday. During this time he began writing his first scientific publication on his analysis of the biochemical composition of leukocytes, including his discovery of nuclein. In his manuscript, Miescher was confident about the importance of his findings and stated that the new substance he had discovered would prove to be of equal stature to proteins. Following his holiday, Miescher returned to the laboratory. However, he did not go back to Tubingen but rather to the University of Leipzig. To broaden his scientific education, he had decided to turn to other topics and thus joined the laboratory of the noted physiologist Carl Ludwig to investigate, for instance, the nerve tracts in the spinal cord that transmit pain. Although Miescher tackled the new tasks with his characteristic conscientiousness, he did not develop the same enthusiasm he had felt for his project in Tubingen.

During his first months in Leipzig, Miescher also finalized the draft of his first publication. Shortly before Christmas of 1869, he was done, and he prepared to send the manuscript to HoppeSeyler for his approval. On December 23, he wrote in a letter to his parents: “On my table lies a sealed and addressed packet. It is my manuscript, for the shipment of which I have already made all necessary arrangements. I will now send it to Hoppe-Seyler in Tubingen. So, the first step into the public is done, given that Hoppe-Seyler does not refuse it.”

Hoppe-Seyler didn’t reject Miescher’s paper. But his former mentor was suspicious of the unusual results and wanted to verify them for himself before publication. This attitude was none too surprising given that not long before HoppeSeyler’s laboratory had been the site of a protracted argument over whether a putative phosphate-containing molecule from brain tissue actually existed. In this context, Hoppe-Seyler would of course view skeptically a junior scientist’s claim of having discovered a fundamentally new molecule. Moreover, Miescher’s manuscript was to be included in the Medicinisch-chemische Untersuchungen (Medical-chemical Investigations), a journal Hoppe-Seyler himself published. Hoppe- Seyler would have been especially stringent about which papers he accepted for publication there.

Thus, Miescher had to resign himself to months of anxious waiting for Hoppe-Seyler to validate his findings. Although overall Hoppe- Seyler was positive about Miescher’s work, his initial analyses of nudein’s elemental composition differed from Miescher’s. He cautioned that these differences might not be meaningful, but it was dear that this would delay things further. Hoppe-Seyler offered to submit the manuscript to another journal if Miescher wanted, but the younger scientist preferred to wait for the verification of his results and to see his work appear in his former mentor’s journal.

Matters were made worse by the outbreak of the Franco-Prussian war. Starting in July 1870, a federation of German states was embroiled in a bitter conflict with France, which diverted both resources and attention away from academic science. Over time, Miescher grew increasingly worried about the delay in publishing his manuscript. He wanted to submit his habilitation (a kind of postdoctoral thesis) at the University of Basel so he would be able to be appointed professor there. Moreover, he feared that other scientists might discover nuclein also and publish on it before him.

He repeatedly wrote to Hoppe-Seyler, gently trying to speed things up. Despairing over the long delay, he even contemplated sending his work to another journal and asked Hoppe-Seyler to return his manuscript. But after a year of suspense, in October 1870, Miescher received Hoppe-Seyler’s reply to his letters. Hoppe-Seyler reported that he had been able to corroborate Miescher’s results on nuclein and that he intended to publish Miescher’s manuscript in the next issue of his journal. The letter also included Hoppe-Seyler’s findings on the topic for Miescher’s comments.

Miescher was overjoyed by the prospect of his paper finally seeing me light of day and promptly sent his comments back to Hoppe- Seyler. A few weeks later he received the proofs of his first publication. In the accompanying letter, Hoppe-Seyler pointed out that they were full of typographical errors because the printers found it difficult to decipher Miescher’s handwriting.

At long last, in early 1871, Miescher’s manuscript was published as the first paper in an issue of Hoppe-Seyler’s journal, which contained two additional articles on nuclein: one by another student of Hoppe-Seyler’s demonstrating the presence of the molecule in the nucleated erythrocytes of birds and snakes, and Hoppe-Seyler’s own article in which he reported that he had confirmed Miescher’s findings on nuclein.

Return to Basel

After his stay in Leipzig, Miescher had been offered the prospect of a professorship at the University of Basel, and so in 1870 he returned to his hometown. His scientific achievements abroad had established his reputation as a dedicated and resourceful researcher. In 1871 he submitted his habilitation, and in the following year, at the age of only 28, he was offered the Chair of Physiology at the university, the same post both his father and his uncle had once held. Miescher worked exceptionally hard in his new position, often to the point of exhaustion. In addition to his passion for science, he was driven not least by the desire to dispel any suggestions that he might have been appointed because of his family ties rather than his accomplishments.

In Basel, Miescher also resumed his work on nuclein, which had all but ceased during his stay in Leipzig. He was spurred on in some part because Hoppe-Seyler wished to continue research on nuclein but agreed to limit his work, as long as Miescher’s own efforts picked up again. Miescher’s aim was to characterize nuclein in greater detail than he had done in Tubingen. But his working conditions were poor and his progress accordingly slow.

In a letter to a friend he lamented: “During the last two years, I have feverishly yearned to be back at the meat pots of the Tubingen castle laboratory. I do not really have a laboratory to speak of here, I am just tolerated in a small corner of the chemistry lab where I can hardy twitch, as it is already overly stuffed with students and on top of that, the professor of chemistry does his research here too.” He continues, “You can surely imagine what it is like to be hindered by appalling external circumstances from energetically pursuing things that may never again be placed so conveniently beneath my fingertips….”

But Miescher did not give up. Inspired by his uncle’s interest in developmental biology, he turned to studying nuclein in eggs and sperm cells. He quickly realized that sperm cells, consisting largely of nuclei, were an ideal source to isolate nuclein in large quantities and purity. Basel proved to be the perfect place for these experiments. As it was situated on the Rhine River, which at the time had a large annual upstream migration of salmon to their spawning grounds, Basel had a thriving salmon fishing industry. This gave Miescher access to an abundance of freshly caught fish. Thus, in the autumn of 1871, he converted to using salmon sperm as his source material for nuclein and developed successive, increasingly sophisticated protocols.

As during his experiments in Tubingen, Miescher used only fresh material and worked rapidly during the isolation of nuclein. Moreover, he had to handle the material in the cold to prevent degradation of the molecule. Because cold rooms were not available in those days, he could only carry out the isolation during the winter months.

Often he would get up in the middle of the night to catch salmon from the Rhine River, bring them to his laboratory and work away during the early hours of the day with the windows of his laboratory wide open to the freezing cold outside. Arduous as it was, this procedure enabled Miescher to isolate copious amounts of the purest nuclein that he had ever had at his disposal, allowing him to carry out the comprehensive, quantitative analyses that he had planned to do in Tubingen. With these new observations, he confirmed his earlier results and determined the phosphorous content of nuclein with amazing accuracy. In 1874 he published his results on the occurrence of nuclein in the sperm of various vertebrates. At the time, scientists were seeking to find out how embryonic development works and how hereditary traits are passed on. Miescher came within arm’s reach of the answer. In his article he wrote: “If one wants to hypothesize that a single substance specifically is the cause of fertilization in any way, then-without a doubt-one would have to think primarily about nuclein.” However, Miescher did not believe that a single molecule could be responsible for inheritance and scrapped the idea, mainly because he could not envisage how the same substance could lead to the diversity of different animal species whose sperm he had examined. He wrote: “There will be differences in the chemical structure of the molecule,” but continued, “though only in a limited diversity.” Too few, according to Miescher, to be responsible even for the differences observed between individuals of the same species, let alone the sometimes vast variation between different species. Instead he favored the idea that mechanical stimuli caused by the movement of the sperm and processes-as observed during the excitation of nerves and muscle fibers-are responsible for the development of the fertilized egg.

Aside from this notion, however, Miescher also developed a hypothesis to explain the transmission of hereditary information that, although incorrect in its details, came remarkably close to describing the way information is actually stored in DNA. He speculated that information might be encoded in the stereochemical state of carbon atoms, or in other words, their arrangement within molecules. Much as an alphabet of 26 letters is sufficient to express all words and concepts in a variety of different languages, molecules could be made up of different stereoisomers, or specific geometric arrangements of the constituent atoms. The vast numbers of asymmetric carbon atoms in large organic molecules, such as proteins, would allow an enormous number of stereoisomers. A molecule containing, for example, as few as 40 asymmetric carbon atoms could have 2(40), or more than one trillion, stereoisomers. This number, Miescher reasoned, would be large enough to encode the hereditary information for all the diverse forms of life. Miescher further proposed that errors in individual molecules might be prevented from manifesting themselves in the developing embryo by the fusion of information from two germ cells during fertilization. These views seem to anticipate what is now considered common knowledge: that intact alleles from one parent can compensate for defects in the allele inherited from the other.

Broadening Interests

Over time, Miescher increasingly turned to other areas of research and no longer published on nuclein. From the mid187Os onward, for instance, he studied the changes in the anatomy of salmon during their annual migrations from the ocean to their fresh- water spawning grounds in the Rhine, a trip during which the fish cease eating entirely.

Miescher spent entire winters getting up in the middle of the night to spend the early hours of the day catching salmon on the banks of the river. He carried thousands of them to his lab, measured and weighed them, examined their muscles, internal organs and blood. He was fascinated by the fact that the sexual organs of these fish undergo an immense growth, until they make nearly a quarter of the fish’s mass, at the expense of the animal’s muscles.

Based on these studies of the metabolism of salmon, in the autumn of 1876 the Swiss government requested him to prepare a report on the diet of inmates at Basel prison. Miescher was none too happy about this task, which took months to complete, but the authorities were impressed with his work and he received similar inquiries from other prisons. His uncle later wrote about this period that “Every jail wanted to have its very own menu.” But it did not end there: Educational institutions, associations for the nutrition of the people and other institutions concerned with nutrition-all sought Miescher’s advice. Finally, he had enough of this work and became disgruntled. He asserted: “I have made myself too green and now the goats are eating me. Inquiry on the diet of the Swiss people, cookbook for workers, nutrient tables for the national exhibition, controversies with the Chamer Milk Company-in brief, I’m on the best way to becoming the guardian for the stomachs of all three million Swiss.”

Eventually, Miescher turned to a new challenge. In 1885 he founded the first anatomical-physiological institute of Basel. As its first director, Miescher took his position very seriously. He encouraged an active scientific life and recruited renowned master technicians who designed and developed new machines and instruments for physiological measurements, which functioned with unrivalled precision. He investigated how blood composition varies at different altitudes and discovered that blood’s concentration of carbon dioxide, not oxygen, regulates breathing.

Yet, over time, Miescher’s increasing commitments exhausted him. His obsession with his work and his need for perfection afforded him everdiminishing rest. He slept less and less, hardly attended social functions and continued working through his holidays. Totally worn out, his body became weaker by the day and in the early 1890s he contracted tuberculosis. He had to retire from work and moved to a sanatorium in Davos in the Swiss Alps.

One last time he tried to pull together his previous work, including his research on nuclein. But his strength failed him and, in 1895, Friedrich Miescher died, at the age of just 51. After Miescher’s death, his uncle Wilhelm His published his nephew’s collected papers. In the introduction he wrote: “The appreciation of Miescher and his works will not diminish with time, instead it will grow, and the facts he has found and the ideas he has postulated are seeds which will bear fruit in the future.” Despite his favorable appraisal, even Wilhelm His could not imagine how true his words would become.

DNA Research after Miescher

Why is Miescher’s name not widely associated with DNA today? For one, unlike many diseases, species or anatomical structures, molecules are not usually named after their discoverer. Moreover, Miescher was not good at promoting his work. He was introverted and interacted with only a limited number of his colleagues. He lacked students, many of whom were put off by his reclusive nature. In addition, despite his passionate drive for scientific research, he was insecure and a perfectionist, leading him to repeat experiments and delay publication. Even during his lifetime, Miescher felt that research on nuclein was increasingly being associated with other researchers. For example, in 1889 Richard Altmann renamed the molecule “nucleic acid,” a fact that greatly annoyed Miescher because he had always been very specific about the acidic nature of nuclein. Perhaps most critically, the gap of 75 years between Miescher’s discovery of DNA and the realization of its importance may have just been too long.

For almost 50 years following Miescher’s death, most scientists believed that DNA, composed of only four types of building blocks, was too simple a molecule to encode the information required to produce the diversity of life. Proteins, with their more complicated composition and structures, were considered far more likely candidates to bear and transmit hereditary information. Widespread interest in DNA was revived only in the 1940s, when Oswald T. Avery and his colleagues Colin MacLeod and Maclyn McCarty proved that DNA does indeed cany the genetic information. In 1952 Alfred Hershey and Martha Chase confirmed DNA as the genetic material and one year later, building on x-ray analyses by Rosalind Franklin and Maurice Wilkins, Francis Crick and James Watson famously solved its structure.

At that point, the individual pieces of the puzzle fell into place. DNA not only had a structure, but this structure could also explain how it functioned, how it can be faithfully replicated prior to each cell division and how the information contained in it can be read to produce proteins. Finally, by the mid-1960s-almost 100 years after Miescher’s experiments-the genetic code was cracked and scientists could finally read the language in which genetic information is written. These breakthroughs were the foundation for the emergence of an entirely new kind of biological research, molecular genetics. Since then, DNA has become more than just a molecule. It has been transformed into the icon of the modern life sciences. But nearly 150 years after Miescher’s first experiments, there still remains a lot to discover about DNA.

For relevant Web links, consult this issue of American Scientist Online:

http://www.americanscientist.org/ IssueTOC/issue/1101

Bibliography

Dahm, R. 2008. Discovering DNA: Friedrich Miescher and the early years of nucleic acid research. Human Genetics 122:565-581.

Dahm, R. 2005: Friedrich Miescher and the discovery of DNA. Developmental Biology 278:274-288.

Lagerkvist, U. 1998. DNA Pioneers and Their Legacy. New Haven: Yale University Press.

Miescher, F. 1871. Ueber die chemische Zusammensetzung der Eiterzellen. [On the Chemical Composition of Pus Cells.] Medicinischchemische Untersuchungen 4:441-460.

Portugal, F. H., and J. S. Cohen. 1977. A Century of DNA. Cambridge: MIT Press.

Wolf, G. 2003. Friedrich Miescher, the man who discovered DNA. Chemical Heritage 21(10-11):37-41.

Ralf Dahm is group leader at the Center for Brain Research, Medical University of Vienna. His research focuses on the genetics behind the development and diseases of the eye and brain. From 1999 to 2005 he worked at the Max Planck Institute for Developmental Biology in Tubingen, Germany, where he became interested in the early history of DNA research. Address: Center for Brain Research, Division of Neuronal Cell Biology, Medical University of Vienna, Spitalglasse 4, A-1090 Vienna, Austria. Internet: [email protected]

Copyright Sigma XI-The Scientific Research Society Jul/Aug 2008

(c) 2008 American Scientist. Provided by ProQuest Information and Learning. All rights Reserved.

Health Rivals Are Partners in New Unit Opening Soon

By Cheryl Powell, The Akron Beacon Journal, Ohio

Jul. 23–A new hospital in Akron for critically ill patients who require long stays could jump-start more cooperation between the city’s rival health-care systems.

In mid-August, national hospital chain Select Medical Corp. will open a long-term acute-care hospital on East Market Street in partnership with cross-town rivals Akron General Health System and Summa Health System.

Select is overseeing the hospital’s day-to-day operations and holds the majority stake in the venture; Akron General and Summa have equal minority shares. Specifics of the joint ownership deal are not being released.

Officials from the three partners and the city will be at a ribbon-cutting ceremony at 10:30 this morning for the 53,000-square-foot, two-story facility known as Select Specialty Hospital-Akron.

The $20 million project is among the first major initiatives in a biomedical corridor designated by the city to promote medical-related development.

Project developer Mike Wojno, president and chief executive of Wojno Development, calls the new hospital an excellent example of “co-op-etition.” Wojno’s business oversaw the project and owns the building, which is being leased to Select under a long-term deal.

“It’s the cooperation of competitors,” Wojno said. “I really think that’s something that’s going to be key, not only to the biomedical corridor but to all of Northeast Ohio.”

Collaboration model

Summa President and Chief Executive Thomas J. Strauss said that “any chance for Akron General and Summa Health System to collaborate, especially without duplicating an asset in the community, makes all the sense in the world.

“Our goal is that this is a model for further collaboration at a time when this city needs further collaboration.”

Strauss said said rehabilitation is another area that could benefit from collaboration between Summa and Akron General.

In addition, Akron General and Summa continue talks with Akron Children’s Hospital, the University of Akron and the Northeastern Ohio Universities Colleges of Medicine and Pharmacy about a partnership for research, said Alan Bleyer, Akron General’s president and chief executive.

The hospitals also could be partners to care for medically underserved residents, Bleyer said.

“Where it makes sense from the standpoint of community service, access and cost, then there certainly are many other opportunities that the local health-care providers can entertain discussions,” he said.

Acute care is combined

Select already ran separate long-term acute-care units known as “hospitals within hospitals” at Akron General and Summa’s Akron City Hospital.

Long-term acute-care hospitals (LTACHS) are described as a middle ground between nursing homes and hospital intensive-care units, with patients staying an average of 25 days or longer.

Most patients have multiple health problems, which require a team approach to getting them well and helping them return to their home or a skilled nursing facility, said Kimberly Thomas, chief executive of Select Specialty Hospital-Akron.

Conditions often treated at LTACHs include respiratory problems, heart failure, renal failure and diabetes, she said.

To account for the increased level of care needed by the patients, Select and similar specialty hospitals get higher payments than general hospitals do from Medicare, the federal health insurance program for people 65 and older and some younger disabled Americans.

But possible changes to Medicare payment rules for hospitals-within-hospitals prompted Select and the two Akron hospitals to talk in 2006 about building a stand-alone facility, Bleyer said.

“Rather than having a free-standing, 28-bed hospital on West Market and another 28-bed unit on East Market, it just made a great deal of sense for us to come together and collaborate,” he said.

The 34-bed Select unit inside Akron General closed in the spring. The space has been converted into Akron General’s neuroscience unit for patients with brain-spinal cord trauma, seizures, strokes, Parkinson’s and Alzheimer’s diseases and other neurological problems.

Select will continue to run a unit inside City Hospital until the new facility opens Aug. 15, Thomas said.

Summa still is determining how the space will be used after the LTACH moves, spokesman Mike Bernstein said.

Unit at old Taylor site

The new hospital is at the site of the former Taylor Pontiac dealership, across from the Haven of Rest and adjacent to the former post office, which is being leased by Summa for information technology and finance employees.

The new hospital will employ about 210, including 55 new positions, Thomas said.

The facility has 60 private rooms, including six high-observation beds similar to intensive-care units. The building is designed to provide services such as CT scans and other tests, lab work, dialysis and rehabilitation in-house.

“This is truly a state-of-the-art facility,” Thomas said.

Cheryl Powell can be reached at 330-996-3902 or [email protected].

—–

To see more of the Akron Beacon Journal, or to subscribe to the newspaper, go to http://www.ohio.com.

Copyright (c) 2008, The Akron Beacon Journal, Ohio

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Coroner Calls for Perjury Probe into Forged Hospital Signature

A CORONER has asked police to launch a perjury investigation after rejecting evidence given by two hospital workers at an inquest into the death of an elderly patient.

Roger Whittaker had heard evidence over three days regarding the death last year at Dewsbury & District Hospital of retired debt collector Wanda ‘Jenny’ Murphy, who’s signature was apparently forged on a self-discharge form.

The 78-year-old from Brunswick Street, Westborough, Dewsbury, was taken to hospital. On August 13 last year, a worried neighbour telephoned for an ambulance, but she was later discharged from hospital. She had returned from a holiday in Malta in May after collapsing.

Mrs Murphy was admitted again later in the month but then fell at home and eventually died in the hospital on September 1 last year after contracting bronchial pneumonia.

The inquest into her death was originally resumed at the end of May when James Counsell, representing Dr Rohit Sinha, a junior doctor involved in her care, said Mrs Murphy “‘had indicated that she wanted to stay in the hospital” but only shortly afterwards became determined to leave.

She left the hospital in the middle of the night by taxi.

An investigation was started by the authorities after Mrs Murphy’s daughter, Fran Simpson, 47, claimed her mother’s signature on the August 13 self-discharge note did not correspond with her mother’s usual handwriting.

The inquest previously heard that Dr Sinha was asked by police if he had ‘panicked’ after they began investigating offences involving forgery and misconduct following her death. He denied any wrongdoing.

Staff nurse Nichola Royal, 33, was interviewed by a police officer who told her Mrs Murphy’s signature had been forged and explained that handwriting samples had been taken.

She denied any knowledge of who had signed the discharge document in the patient’s name.

Yesterday at Bradford Coroner’s Court, Mr Whittaker recorded a verdict of “accidental death to which neglect contributed.”

He said: “I want to refer this case back to West Yorkshire Police. I think it is appropriate that they should look at it for perjury during this inquest.”

He said he was satisfied after hearing evidence from a forensic science specialist that the “signature purporting to be that of Wanda Murphy was not. That the signature is countersigned by Dr Sinha is incontrovertible.”

He added: “I don’t accept evidence of Nichola Royal and Dr Sinha that she discharged herself. Wanda Murphy’s signature was a cynical attempt to show the contrary.

“Self-discharge or not there should have been a follow-up which clearly didn’t happen.”

Mr Whittaker also called for the professional bodies governing Dr Sinha and Nichola Royal to give “professional consideration of their roles in this case.”

Tracey McErlain-Burns, chief nurse and director of patient experience, at The Mid Yorkshire Hospitals NHS Trust, said: “I have offered my genuine apologies to Mrs Murphy’s family for the additional distress they have been through.

“We will now carefully consider the findings of the inquest and I give Mrs Murphy’s family my personal commitment that we will take any action that needs to be taken.”

(c) 2008 Yorkshire Post. Provided by ProQuest Information and Learning. All rights Reserved.

The First Years – Keep Baby’s Delicate Skin Out of Sun — A Single Bad Burn Can Increase Melanoma Risk

By Barbara Holden

We all know a severe automobile accident, malnutrition, infectious disease, trauma and neglect can threaten the life of your child. But did you know that one single sunburn can put your child at risk for melanoma, the most serious type of skin cancer?

“Skin cancers are typically considered to be caused by repeated sunlight exposure over time, but research clearly shows that just one severe sunburn as a child can create a melanoma in later life,” said senior vice president of the Skin Cancer Foundation and former American Academy of Dermatology president, Dr. Rex A. Amonette .

“No other skin cancer, only melanoma, can be attributed to one particular severe sunburn incident,” he adds. “That’s highly significant, and parents and care takers need to understand the risk.”

This is the trick melanoma plays on us. It only takes one sunburn – just one – to lay the foundation for a life-threatening cancer. As parents and grandparents, we must protect our children from the sun from day one and monitor their skin, keeping close watch on any freckles and moles the child may have.

Other risk factors include fair skin, light eyes, many freckles, a family history of melanoma or a weak immune system.

Those with dark skin have less of a risk but are more likely to get it under the nails or on their palms and soles.

If you need a few reminders of how to keep your little one safe in the sun, the Skin Cancer Foundation offers these tips:

Make sure that your baby’s stroller or carriage provides adequate shade, with a hood or other shade-providing structure.

Sunscreen should not be used on babies under 6 months old. Babies under 6 months should be exposed to the sun as little as possible.

Your baby should have fresh air and light – but ideally, not at the peak times of the day between 10 a.m. and 4 p.m. Schedule your baby’s stroll around the neighborhood in the early morning or late afternoon, when the sun’s rays are less powerful.

Your baby (and you) should wear a sun hat or bonnet with a wide brim whenever she is outside because melanoma can occur on the scalp, too.

Make sure your baby’s arms and legs are covered by tightly woven (but loose-fitting) clothing.

For toddlers, use a sunscreen with an SPF (sun protection factor) of at least 15. The higher the SPF, the more UVB protection the sunscreen has.

The melanoma resource Web site Melanoma.com says that children get 80 percent of their lifetime sun exposure before the age of 18 and that protecting the skin during the first 18 years of life can reduce the risk of some types of skin cancer by up to 78 percent.

Your baby’s skin is the largest organ in her body, and it’s up to you to take good care of it. Sure, you’ll have to chase her up, down and around the house to slather that sunscreen on; then you’ll have to do it all over again a few hours later. But she’ll thank you later when she’s a healthy, happy and wrinkle-free adult.

Speaking of adults – be sure mom, dad and grandma are setting a good example. It’s important for you to wear sunscreen and hats when you go out and play, too.

The great news about all of this is that there are so many things you can do to protect your family from sunburns now and from skin cancer later. And if your little one learns these sun-safe habits as a toddler, chances are pretty good she’ll practice them as an adult and even pass them down to your grandchildren.

Learn more about sun safety and melanoma at skincancer.org,

Barbara Holden is a director at the Urban Child Institute, a Greater Memphis organization dedicated to promoting early childhood development. The Commercial Appeal is a partner with the Urban Child Institute in this effort to help parents and other caregivers learn skills that nurture and educate the minds of infants and children. For more information, go to theurbanchildinstitute.org or dial 211 for the Public Library and Information Center.

Originally published by Barbara Holden Special to My Life .

(c) 2008 Commercial Appeal, The. Provided by ProQuest Information and Learning. All rights Reserved.

Palm Beach County, Fla., Commission to Vote on Donation for Research Group

By Stephen Pounds, The Palm Beach Post, Fla.

Jul. 22–The Palm Beach County Commission will vote today on a plan to give almost $87 million to the Max Planck Society in return for 135 high-wage jobs and a giant research partner for Scripps Florida.

The Munich, Germany-based research institution plans to build its first U.S. center, a 100,000-square-foot “bio-imaging” facility, just west of Scripps in Jupiter.

Max Planck operates 80 research centers employing 12,600 people in Europe, mostly in Germany, on a budget of $2.2 billion. It boasts 17 Nobel laureates since its founding in 1948.

While Scripps got its $190 million within two years of signing its contract with the county, Max Planck will have to wait a while longer for its money. It will get $39.4 million from the county in 2008, $15.6 million in 2011, $13.1 million in 2013, $13.4 million in 2015 and $5.3 million in 2017. All of the grant money is being financed through revenue bonds.

As much as $60 million will be spent on building construction; the rest is for operations, including $4.1 million for equipment alone.

“The $4.1 million, they’ll get upfront, for the temporary facility,” said Assistant County Administrator Shannon LaRocque.

For its part, the state came to an agreement in March with Max Planck for $94 million, and has disbursed $10 million from Florida’s Innovation Incentive Fund.

Max Planck is still negotiating with Florida Atlantic University to obtain a 50-year lease for 6 acres of land on its Jupiter campus.

Under the deal, it must operate the research center for 15 years in Palm Beach County, with 70 percent of its employees remaining in the county for at least 10 years.

“The negotiations went very satisfactorily. It was very smooth,” Max Planck President Peter Gruss said Monday. “There was a hurdle here and there, but it worked out well, and we look forward to getting the votes (today).” LaRocque said the county’s negotiations were less bumpy than with Scripps two years ago because Max Planck’s proposal didn’t carry the political and environmental baggage that the Scripps deal did. Environmentalists successfully stared down Scripps on its first site selection, Mecca Farms, and a new site had to be found.

“By the time we got to Scripps (negotiations), everybody had had enough. It was so controversial. Scripps was very emotional,” she said. “There was no emotion with Max Planck. It was very professional, a two-way discussion.” Also in contrast to Scripps is Max Planck’s commitment of royalties. Scripps made no royalties pledge at all, but Max Planck has agreed to spend 3 percent of its royalties on education programs in Palm Beach County for 10 years, and reinvest the rest in the local Max Planck institute for 20 years.

“All of Max Planck’s royalties will remain in Palm Beach County,” LaRocque said, unlike its normal procedure of giving a third each to the local institute, the scientists and the Max Planck parent organization.

Gruss said it was no easy decision to keep Max Planck’s royalties in Florida and to commit part of them to school programs here. But it may serve as a carrot for commission approval.

“We had to think very hard. We were forgoing our organizational one-third,” Gruss said. “The money will stay with the institute here to generate more stipends. Then, there’s the 3 percent of royalties. We hope that will allow them to vote for it.” In other provisions, Max Planck will be required to establish mentoring programs for students in grades K-12; start an internship program for high-school and community-college teachers; and hold a career day for middle- and high-school students.

It also must put in place hiring practices that strive to give preference to low-income county residents for jobs and implement a policy of spending up to 15 percent of its operating budget on equipment and supplies from local businesses.

Perhaps most important for economic-development officials, Max Planck must help recruit other biotechnology institutes and companies to move or expand here.

Scripps helped lure the Torrey Pines Institute for Molecular Studies and the Burnham Institute for Medical Research to Florida, but neither landed in Palm Beach County, preferring Port St. Lucie and Orlando, respectively.

“Palm Beach County will gain international exposure,” said Kelly Smallridge, president of the Business Development Board of Palm Beach County. “Max Planck has agreed to be part of our marketing outreach. This is a role that they want to play, and it strengthens the economic return on this investment. Their name will open doors.” In the meantime, Scripps has grown to 271 scientists and technicians at its temporary quarters at FAU, where Max Planck will house its scientists until its buildings are constructed. Scripps’ permanent campus of three laboratory buildings is three to four months away from completion.

“We’ll actually start moving in October, and it will take the better part of three months to complete the move,” Scripps spokesman Keith McKeown said. “We should finish in early January.” After the initial announcement almost five years ago that Scripps was expanding to Florida from its headquarters in La Jolla, Calif., the life-science business cluster is finally showing signs of growth, LaRocque said.

Scripps has spun off its first company, Xcovery Inc. A new biotech incubator owned by Alexandria Real Estate Equities has opened in Jupiter and found its first occupant, Cytonics Inc. And economic development officials are negotiating with an unidentified Melbourne agriculture-bioscience firm to relocate here.

“Max Planck wouldn’t even have talked to us if not for Scripps,” LaRocque said.

—–

To see more of The Palm Beach Post — including its homes, jobs, cars and other classified listings — or to subscribe to the newspaper, go to http://www.palmbeachpost.com.

Copyright (c) 2008, The Palm Beach Post, Fla.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

SSP,

Charity Ball Helps Raise Funds for Medical Aid in Third World

A SPECTACULAR ball sponsored by a Wirral law firm raised thousands of pounds for a local charity.

Around 170 people attended the New Hope Charity Ball, at Hillbark Hotel, Frankby, raising almost pounds 9,000 for New Hope Ministries Charitable Trust.

The glittering black tie event, sponsored by Heswall-based DGB Solicitors, included a four-course meal and charity auction conducted by Radio Merseyside’s antiques expert John Crane.

Singers from London’s Opera Interludes and bands Cross Purposes and Citizen provided the live entertainment.

The money raised will help New Hope Ministries Charitable Trust’s overseas missions that take medical aid to the Third World.

The charity, which was formed by Heswall couple John and Myra Sloan in 1997, has already provided tens of thousands of people in Guyana, Uganda and the Philippines with medical care.

Debbie Black, Principal of DGB Solicitors, said: “It was a truly wonderful evening. New Hope Ministries Charitable Trust works tirelessly to improve the lives of those less fortunate than ourselves.

“John and Myra’s dedication to helping others is infectious, and DGB Solicitors is very proud to have supported the event.”

The money raised from the event, which was held on Friday, July 11, will go towards funding health workers based in rural Uganda.

John Sloan, a hospital consultant, said: “I was bowled over by the quality of the evening and by the level of support. Not only did we raise around pounds 9,000, but we all had a great time.”

Myra Sloan, a GP, added: “We have been in touch with our Ugandan partners and they are so excited by the fact we can employ two health workers.

“The evening will have a significant impact in the lives of many for at least two years.”

(c) 2008 Daily Post; Liverpool. Provided by ProQuest Information and Learning. All rights Reserved.

NexMed Receives FDA Response for ED Product

NexMed, Inc. (Nasdaq: NEXM), today announced the receipt of a non approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for its topical treatment for erectile dysfunction (ED). The major regulatory issues raised by the FDA were related to the results of the transgenic mouse carcinogenicity study which NexMed completed in 2002.

Commenting on today’s announcement, Vivian Liu, President and Chief Executive Officer of NexMed said, “The transgenic mouse concern raised by the FDA is product specific, and does not affect the dermatological products in our pipeline. While we are disappointed by the FDA’s decision, the deficiencies cited in their letter were not unexpected. One positive outcome is the fact that the FDA did not cite the lack of completion of our long term open label safety study as a deficiency. We are encouraged that we do not need to redo this study, which would have taken up to 18 months to complete and at a substantial cost.”

Hem Pandya, Vice President and Chief Operating Officer of NexMed added, “We remain committed to bringing our ED product to market, where there is a real demand from both patients and the urology community at large. As such, we plan to meet with the FDA and come to agreement on the necessary actions required in order to resubmit our NDA and resolve the deficiencies cited.” Mr. Pandya further added, “We will also submit to the Agency final reports for two new, two-year carcinogenicity studies in both mice and rats, which were identified in the FDA’s letter as part of the information package needed to resolve the major deficiencies cited.”

Conference Call

NexMed will host a conference call to discuss the non-approvable letter on Wednesday, July 23, 2008, at 8:30 am EST. The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 292154 are both required for playback. The conference call will also be Webcast live at URL http://www.investorcalendar.com/IC/CEPage.asp?ID=132337. The Webcast replay will be available for three months.

About NexMed

NexMed, Inc. is leveraging its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. Novartis is completing pivotal Phase 3 trials for NexMed’s NM100060, a novel onychomycosis treatment exclusively licensed to Novartis. In November 2007, the Company signed a U.S. licensing agreement for the ED Product with Warner Chilcott. NexMed’s pipeline also includes a Phase 2 treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.

Warning: Unauthorized Wild Vineyard Products Pose a Risk to Health

Further to an advisory posted in December 2007 (http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2007/2007_179-eng.php), Health Canada is informing Canadians of additional information on Wild Vineyard products that pose a risk to health. These products, listed below, have been found to contain unacceptable levels of bacterial contamination and/or heavy metal contamination, such as lead. In addition, some of these products are inappropriately labelled.

 Will's Rain Forest Clear Lung Wild Vineyard Female Wild Vineyard Red Clover Plus Wild Vineyard Bowel Plus Haven Basket Natural 292 Heavenly Orchard Herbal Concentrate Heavenly Orchard Cal Mag Organic Haven Red Raspberry Plus Organic Haven Waist a Way Natures Valley Dulse Plus Herbal Valley Bentonite & More Herbal Valley Royal Silver 

Symptoms of exposure to heavy metals include nausea, abdominal pain, vomiting, muscle cramps, diarrhoea, heart abnormalities, anaemia, as well as bone, liver, kidney and nervous system problems. Bacterial contamination of health products can pose a risk to human health and may cause a variety of adverse effects, such as gastrointestinal upset and bacterial infection.

The products listed above have been available over the Internet and at retail stores in Canada. The products have also been distributed by Health Trek and by Sho-Tai practitioners. The products are not authorized for sale in Canada.

As of March 6, 2008, there have been five cases of adverse reactions reported in Canada that are linked to the use of Wild Vineyard products.

Wild Vineyard is not authorized to manufacture, package, label or import natural health products in Canada.

Health Canada reminds consumers not to use the products listed above, or any products previously identified in the December 28, 2007 advisory (http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2007/2007_179-eng.php). Health Canada advises consumers who have used these products and who are concerned about their health to contact a health practitioner for advice. The Department also advises retailers to remove these products from their shelves.

Natural Health Products that are authorized for sale in Canada have a Natural Product Number (NPN), a Drug Identification Number for Homeopathic Medicine (DIN-HM), or an eight-digit Drug Identification Number (DIN) on the label. These numbers indicate that the products have been assessed by Health Canada for safety, effectiveness and quality.

Consumers requiring more information about this advisory can contact Health Canada’s public enquiries line at (613) 957-2991, or toll free at 1-866-225-0709.

To report a suspected adverse reaction to this product, please contact the Canada Vigilance Program of Health Canada by one of the following methods:

 Telephone: 1-866-234-2345 Facsimile: 1-866-678-6789 Canada Vigilance Program Marketed Health Products Directorate Ottawa, Ontario, AL 0701C K1A 0K9 E-mail: [email protected] 

The Canada Vigilance adverse reaction reporting form, including a version that can be completed and submitted online, is located in the MedEffect Canada (www.healthcanada.gc.ca/medeffect) area of the Health Canada Web site.

Egalement disponible en francais

 Contacts: Media Inquiries: Health Canada 613-957-2983  Public Inquiries: 613-957-2991 1-866-225-0709  

SOURCE: Health Canada

Premier’s Newest SpendAdvisor Release Features Reports That Help Explain Changes in Supply Costs

The newest version of the Premier healthcare alliance’s widely adopted SpendAdvisor spend management decision support tool can identify and measure the drivers of supply cost, and a new tier analyzer report will measure performance of all contracts against tier requirements.

“It has been said that some things continue to get better with age. This has definitely proven to be true with Premier’s newest MySpend release,” said Norton Healthcare Contract Administrator Rebecca L. Williams. Norton Healthcare is the Louisville area’s leading hospital and healthcare system including four large hospitals, 10 immediate care centers, and some 50 other service locations.

“With a few clicks of my mouse, I can now produce reports that get to the heart of what is driving changes in Norton Healthcare’s supply chain,” Williams continued. “What used to be a very tedious process to determine if increased costs were being driven by purchasing volume, product mix, or pricing can now be produced in a few minutes.

“The ability to, at a quick glance, look into a category of products, down to the transaction level, is nothing short of amazing. In my opinion,” Williams said, “My Spend is the most user friendly software available in the market today. The ability to run accurate reports, with ease, has provided Norton with quick results. The savings we achieved during the first month paid for the program and continue to strengthen Norton’s bottom line with each passing month. MySpend is a must have for materials management.”

Premier Group Vice President Marla Weigert said, “This release represents a powerful mix of new functionality as well as improvements to existing reports.” Changes are based on member feedback as well as advancements in Premier’s data and technology supporting the SpendAdvisor platform.

A new series of “Change in Supply Cost” reports provide a broad view of major drivers of changes in total spend in a single facility or across a group of facilities. The new version is already available to users of SpendAdvisor.

Weigert said the version identifies root causes of supply chain expenses by leading member users through an analysis that focuses on changes that have the greatest bottom line impact. “With it, members can analyze whether changes are the result of pricing, volume or product mix, helping them not only understand recent and historical changes and patterns but also target key adjustments that will result in optimal savings.”

The new release also includes improvements that strengthen the SpendAdvisor tier qualification logic released in November. The reports now provide additional information making them even more actionable. A new view assesses contract performance measured against tier requirements on any contract in the portfolio.

Additional improvements include UNSPSC classification codes and descriptions added to the custom report builder module and new benchmarking reports for products that haven’t yet been purchased but are being considered, as well as other report and usability improvements.

More than 110 integrated delivery networks representing more than 630 facilities and approximately $8 billion in spend have installed or committed to the MySpend module of SpendAdvisor. Hospitals and healthcare systems using SpendAdvisor are experiencing better contracts with savings of between 4 percent and 8 percent on average.

“One of Premier’s primary roles is to bring cutting-edge technology solutions to systemic problems that inhibit the efficient and cost-effective delivery of healthcare to the communities our members serve,” Weigert said. “We will continue to enhance SpendAdvisor and deliver on our promise to unlock the improvement potential of our spend analytics tools for our members.”

About Premier Inc., 2006 Malcolm Baldrige National Quality Award recipient

Serving more than 2,000 U.S. hospitals and 53,000-plus other healthcare sites, the Premier healthcare alliance and its members are transforming healthcare together. Owned by not-for-profit hospitals, Premier operates one of the leading healthcare purchasing networks and the nation’s most comprehensive repository of hospital clinical and financial information. A subsidiary operates one of the nation’s largest policy-holder owned, hospital professional liability risk-retention groups. A world leader in helping healthcare providers deliver dramatic improvements in care, Premier is working with the United Kingdom’s National Health Service North West and the Centers for Medicare & Medicaid Services to improve hospital performance. Headquartered in San Diego, Premier has offices in Charlotte, N.C., Philadelphia and Washington. For more information, visit www.premierinc.com.

Dr. Linnell Joins Practice

LEWISTON – Community Clinical Services Women’s Health Associates announces the arrival of Elizabeth Linnell, MD, who specializes in obstetrics and gynecology.

Dr. Linnell graduated cum laude from Albany Medical College in Albany, N.Y. She completed her residency in obstetrics and gynecology at Maine Medical Center in Portland. She also held the positions of OB-GYN administrative chief resident and instructor for the University of Vermont College of Medicine at Maine Medical Center.

Last year, Dr. Linnell was part of a 40-member team that provided free surgical services to the poor in Chulucanas, Peru.

Women’s Health Associates is located at the St. Mary’s Corinne Croteau Lepage Women’s Health Pavilion, 330 Sabattus St. For more information or to schedule an appointment with Dr. Linnell, call 777- 4300.

(c) 2008 Sun-Journal Lewiston, Me.. Provided by ProQuest Information and Learning. All rights Reserved.

NCMC Hospitality House Gets Facelift

By Greeley Tribune, Colo.

Jul. 22–The North Colorado Medical Center’s Hospitality House has been renovated.

NCMC officials said furniture valued at more than $46,000 will round out renovations just in time for National Hospitality House Week, July 20 — 26.

The house, on 15th Street on the north side of NCMC’s campus, serves as a home-away-from-home for NCMC patients and their families. In 2007, 1,057 families stayed at the house.

In its 16th year, the facility provides lodging at a reduced cost — as low as $15 per night — which can be a relief for patients and families who travel from out of town for care, said Leslie Gann Exner, director of volunteer services and the house.

In a press release, she said furniture from Designers Loft will go into 16 rooms and will complete a remodeling project that started a few years ago. The older furniture will be donated to the Weld Furniture Bank.

“Communities outside of Greeley know about the Hospitality House because people travel for care and stay here,” Exner said in the press release. “We also have volunteers, nurses, physicians and other departments that refer patients and their families here when they need lodging.”

The cost at the facility is $15 for a standard room that has a bed, small refrigerator, microwave and bathroom. The apartment, for $25, has two single beds, a sofa, loveseat, private bathroom and efficiency kitchen. Guests also have the use of on-site laundry and the common kitchen and living area.

For meals, guests may visit the NCMC Banner Bistro or the NCMC 16th Street Terrace within the hospital and receive discounts.

The Hospitality House program was started by employees who saw the hardship people faced when they traveled from out of town for health care and paid $80 to $140 or more to stay in a hotel.

Once the Ella Mead Hall of Nursing in honor of the former Greeley physician, the building was a family resource center before being converted for guest housing. Hospital funds cover the cost of the salaries, building maintenance and facilities. Other financial support comes from the NCMC Foundation.

Fundraiser set

The NCMC Foundation will host its annual Thissen Construction Corporation Hospitality Bowl-A-Thon, Aug. 1 at Highland Park Lanes in Greeley.

Teams of four bowlers compete in various bowling games. Major, corporate and team sponsorships support the event. Bowlers dress in costume according to the event theme — which is Indy Adventure Bowl this year — and have a chance to win prizes through the evening.

For more information about the event, call Diana Wood at the NCMC Foundation at (970) 395-2687.

—–

To see more of the Greeley Tribune, or to subscribe to the newspaper, go to http://www.greeleytribune.com.

Copyright (c) 2008, Greeley Tribune, Colo.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

The Post-Crescent, Appleton, Wis., Business Innovator Column

By Maureen Wallenfang, The Post-Crescent, Appleton, Wis.

Jul. 21–Meet Inc. Innovator: Lisa Benson

–Title: President and co-owner of Ledgeview Partners

–Type of service: Consulting, implementation and support services for Microsoft Dynamics CRM. The firm is a Microsoft certified partner.

–Address: 911 N. Lynndale Drive, Grand Chute

–Benson’s background: Age 39, originally from Sheboygan, now living in Fond du Lac. BBA from University of Wisconsin-Eau Claire, MBA from UW-Oshkosh. Additional Web-based and classroom training from Microsoft.

–Prior work experience: Worked as an IT consultant and CIO for a Menasha Corp. subsidiary.

–Her duties: Business management, sales and marketing

–Opened firm: In November with partner Doug Fissell, who handles sales and operations

–Web site: www.ledgeviewpartners.com

–Staff: Besides the two partners, there is one full-time employee

QUESTION: Your consulting firm works exclusively with Microsoft Dynamics CRM. How do you describe a customer relationship management (CRM) system in simple language?

ANSWER: It is a software package that’s integrated with Outlook, first of all. People use Outlook day-in and day-out for e-mail. What it does is gives a 360-degree view of all of your interactions with the customer. So it’s everything your sales team is doing, everything your marketing team is doing and everything your customer support is doing with that particular customer or with the prospective customer. They’re tracking correspondence, e-mails, sales opportunities, open customer service requests. It’s meant to go to one spot and see everything that’s going on with that particular customer.

Q: What’s its advantage?

A: The power of having all that information consolidated and at their fingertips. Many of our customers have this information, but it’s on a sales person’s laptop or in a mainframe computer system or its in spreadsheets and e-mail messages. It’s scattered all about. To have all that information at their fingertips allows them to better serve their customers and retain their customers. They appear very well organized and that they know their customers well.

Q: What’s your firm’s relationship with Microsoft?

A: Microsoft sells its business products through certified partners, such as ourselves. We resell the software and provide all the services associated with implementing that and supporting the software.

Q: Are people in this area required to buy through you?

A: No. There are a number of choices of where they can purchase the software. But generally, they hire a certified partner such as ourselves to help implement it. We’ve been trained, tested and had to achieve some successful projects where customers gave positive references to Microsoft before Microsoft gave us this certification.

Q: How many clients do you have?

A: We have seven currently. We’re probably reaching our max right now with the three of us. We are looking to hire a fourth person.

Q: Does Microsoft send you customers?

A: Rarely. They’ll send us leads occasionally of people who have called Microsoft directly.

Q: Are you the only certified partner in this area?

A: We’re not the only one, but we are the only one that focuses exclusively on Microsoft CRM. There are at least two other companies that we know of that install Microsoft Dynamics CRM. But they do lots of other things. One’s in Madison, one’s in Green Bay. We’ve asked Microsoft nationwide how many partners they have that focus just on this product and they tell us there’s just a handful.

Q: You must believe in this if you’re devoting yourselves solely to this one program?

A: We believe heavily in the power of focus and being excellent in a few things. It’s a differentiator for us. We’re very familiar with Microsoft technologies and when we saw this product, and the fact that Microsoft geared this to work with any size business, made it cost affordable for any size business, and made it so flexible that it could work for any industry or type of business, we felt that in itself was a huge opportunity. It’s also technically very sound.

Q: What’s the cost?

A: It will depend on how much Microsoft software you buy over the years. It’s very variable. For the smallest user, Microsoft just launched an offering called Microsoft CRM Online. You sign up on the Internet and pay $39 per user per month.

Q: For a big company, like Appleton [Papers], it’s obviously more complex. You probably spend a lot of time with them?

A: We do. When it comes to a company like Appleton Papers, they have many other systems already in place that they want to integrate with the software. So there’s more custom work that’s part of our services.

Q: Albert Selker of Appleton Papers said he was pleased with your company’s customer focus. He said you were on time and on budget. Did the paper present unique needs?

A: Microsoft tried to not build in every single possible feature that they could think of because through their research they found that was why other CRM tools were failing. Rather what they did was spent their money developing customization tools that come with the product. We, as certified partners, know how to use the tools to customize it to the industry, to the exact business.

Q: What about the future?

A: Our goal is to open our second location in Wisconsin in the first quarter of next year. We want to open a third location out of state within a year after that.

INNOVATOR INSIGHTS:

–Encouraging user adoption: “The worst thing that could happen would be for us to implement the software and six months down the road it becomes shelfware, meaning the customer stopped using it. We try to encourage slow adoption which helps the users become acclimated to the tool and helps it become part of how they work everyday.”

–Economy’s effect: “Our business is growing because our business is helping customers better manage and retain their existing customers, which is so important these days. Our customers are still willing to invest in solutions that help them retain their customer base.”

–Getting started: “We sit down with [clients] and talk through their CRM strategy, if they even know what that is. If they don’t, we help them figure it out. Though that process of discovery, we learn a fair amount about their businesses, their challenges and their customer base.”

Know a young entrepreneur? Send Inc. Innovator nominations to [email protected].

—–

To see more of The Post-Crescent, or to subscribe to the newspaper, go to http://www.postcrescent.com.

Copyright (c) 2008, The Post-Crescent, Appleton, Wis.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

MSFT,

Arnot Ogden Medical Center Selects SIS Perioperative Solution

ATLANTA, July 22 /PRNewswire/ — Arnot Health has selected Surgical Information Systems (SIS) to be the perioperative systems provider for Arnot Ogden Medical Center, a not-for-profit, 256-bed medical facility serving southern New York and northern Pennsylvania.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080722/SISLOGO )

The SIS Essentials perioperative solution, featuring the AHA-endorsed SIS Surgical Scheduling and HFMA Peer Reviewed SIS Rules-Based Charging, was chosen to replace Arnot Ogden’s current system provided by Mediware Information Systems. Due to Mediware’s recent announcement that it would no longer invest in its operating room software products, Arnot Ogden was in search of a long-term, financially stable surgical partner as well as a proven and powerful system that would allow physicians to uphold a high quality of care for years to come.

“As a community hospital offering highly specialized services, Arnot Ogden Medical Center was pleased to find a surgical systems partner that is focused so intently on the surgical space,” said AOMC Executive Director of Product Line Services, Richard N. Hoffman, MHA, FACHE. “We chose SIS because of the company’s successful track record and forward-thinking approach to surgery.”

Surgical Information Systems’ Chief Executive Officer Ed Daihl said that a best-of-breed approach is most beneficial to the perioperative department because of its significant impact on patient safety, operational efficiencies and revenue management.

“The OR impacts patient outcomes more than any other department, and typically represents up to 70% of a hospital’s total revenue,” said Daihl. “That’s why it is so important for medical centers like Arnot Ogden to select a surgical system that will provide critical clinical financial data, and enable physicians to provide the highest level of care.”

About SIS

SIS provides software solutions that are uniquely designed to add value at every point of the perioperative process. Developed specifically for the complex surgical environment, all SIS solutions — including anesthesia — are architected on a single database and integrate easily with other hospital systems. SIS offers the only surgical scheduling system endorsed by the American Hospital Association (AHA), and a rules-based charging system that has been granted Peer Reviewed status by the Healthcare Financial Management Association (HFMA).

   For more information visit our website, http://www.sisfirst.com/ .    About Arnot Health  

Arnot Health, celebrating 120 years as a regional healthcare provider in 2008, provides diagnostic, ambulatory, secondary and tertiary acute care, as well as rehabilitative and wellness services to the Southern Tier of New York and the Northern Tier of Pennsylvania. Arnot Ogden Medical Center is an independent, not-for-profit, 256-bed tertiary medical facility with more than 300 physicians from over 50 specialties.

Photo: http://www.newscom.com/cgi-bin/prnh/20080722/SISLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]

Surgical Information Systems

CONTACT: Brent Harrison of Surgical Information Systems, +1-800-866-0656,[email protected]

Web site: http://www.sisfirst.com/

AIG Employee Benefit Solutions(R) Announces LIVESTRONG(TM) SurvivorPlan

AIG Employee Benefit Solutions(R) announced today the launch of the LIVESTRONG(TM) SurvivorPlan, a distinctive supplemental insurance policy developed in partnership with the Lance Armstrong Foundation. The new policy provides participants the opportunity to connect with a broad array of resources designed to help them stay healthy and, should a cancer diagnosis arise, take control of their treatment. The policy is being offered to the employer market through AIG Employee Benefit Solutions and is underwritten by AIG Life Insurance Company, Wilmington, DE, and American International Life Assurance Company of New York, N.Y.

“In addition to giving employees educational and financial resources to help them live a healthy lifestyle today, the LIVESTRONG SurvivorPlan also provides them with emotional and financial benefits in the event of a diagnosis,” said John Penko, senior vice president of sales, AIG Employee Benefit Solutions. “This is a plan any employer can get behind to protect their employees.”

In terms of keeping employees healthy, early detection is one of the keys. As such, the LIVESTRONG SurvivorPlan provides an annual $100 screening benefit to cover a wide variety of early detection tests such as mammograms, colonoscopies, electrocardiograms and others.

For those employees or members of their family covered under the plan who receive a cancer diagnosis, the LIVESTRONG SurvivorPlan provides them with immediate access to the outstanding support system of the Lance Armstrong Foundation and also delivers the financial support needed to stay focused on recovery.

“While most health insurance can cover the direct costs of a cancer diagnosis, out-of-pocket costs and other expenses place a tremendous financial burden on cancer survivors and their families,” said Penko.

Loss of wages and salary, deductibles, coinsurance, travel expenses to and from treatment centers, lodging, meals and child care comprise about 63 percent of the total cost of cancer treatment.(1)

The LIVESTRONG SurvivorPlan helps offset these costs, which are not often considered when dealing with cancer. Plus, all benefits are payable directly to the insured to use as they see fit. For some, this may mean a practical application of the funds to offset related medical expenses, while others may opt to use the funds to spend quality time with family. No one experiences cancer the same way, and the LIVESTRONG SurvivorPlan enables policy owners the flexibility to use the financial benefit however they want.

“When most people think of insurance, they think of it as a benefit to families of a loved one who has died,” said Doug Ulman, Lance Armstrong Foundation president. “The LIVESTRONG SurvivorPlan is a living benefit, paid to the policyholder upon diagnosis to help them pay for the costs associated with their disease and hopeful recovery. It is intended for people living with cancer; people who are planning for survival and fighting the disease every day. We believe in helping survivors every step of the way, and that includes making smart financial decisions.”

Other coverages provided by the LIVESTRONG SurvivorPlan include, but are not limited to prolonged hospital stays, radiation/chemotherapy treatments, intensive care unit treatment, nursing services and hospice care, bone marrow transplants, second surgical opinions and National Cancer Institute evaluation/consultation.

For more information on AIG Employee Benefit Solutions’ LIVESTRONG SurvivorPlan, visit www.aiglivestrong.com.

(1) Cancer Facts & Figures, American Cancer Society, 2005

About the Lance Armstrong Foundation

The Lance Armstrong Foundation (LAF) unites people through programs and experiences to empower cancer survivors to live life on their own terms and to raise awareness and funds for the fight against cancer. The LAF focuses on cancer prevention, access to screening and care, research and quality of life for cancer survivors. Founded in 1997 by cancer survivor and champion cyclist Lance Armstrong, the LAF has raised more than $250 million for the fight against cancer. Join 60 million LIVESTRONG wristband wearers and help make cancer a national priority. Unite and fight cancer at LIVESTRONG.org.

AIG Employee Benefit Solutions(R), www.aigebs.com, is the marketing brand under which group employee benefit insurance products and individual worksite products (including life, accidental death & dismemberment, disability, dental vision, cancer insurance and critical illness products) are offered by the insurance companies that comprise AIG American General, including AIG Life Insurance Company, American General Assurance Company, American International Life Assurance Company of New York, The United States Life Insurance Company in the City of New York and American General Life Insurance Company.

AIG American General, www.aigag.com, is the marketing name for the insurance companies and affiliates comprising the domestic life operations of American International Group, Inc. (AIG). AIG American General-branded companies offer a broad spectrum of fixed and variable life insurance, annuities and accident and health products to serve the financial and estate planning needs of its customers throughout the United States.

AIG American General pays a license fee to a third party to use the trademarks LIVESTRONG(TM) and the Lance Armstrong Foundation(TM). The Lance Armstrong Foundation’s mission is to provide practical tools and information that people with cancer need to live strong.

 AIG Employee Benefit Solutions insurance products underwritten by: AIG Life Insurance Company Wilmington, Delaware (AIG Life) American International Life Assurance Company of New York New York, New York (AI Life) Subsidiaries of American International Group, Inc. (AIG) 

LIVESTRONG(TM) SurvivorPlan is the marketing name for the Group Critical Illness Insurance Policy/Cancer Indemnity Expense Certificate Rider. Policy form series number: GCI50001, a limited benefit plan. The policy form number for the AILife Policy is GCI50001-NY-0605.

The underwriting risks, financial and contractual obligations and support functions associated with products issued by AIG Life and AI Life are its responsibility. AIG does not underwrite any insurance policy referenced herein.

AIG Life Insurance Company does not solicit business in the state of New York. Policies and riders not available in all states.

American International Group, Inc. (AIG), a world leader in insurance and financial services, is the leading international insurance organization with operations in more than 130 countries and jurisdictions. AIG companies serve commercial, institutional and individual customers through the most extensive worldwide property-casualty and life insurance networks of any insurer. In addition, AIG companies are leading providers of retirement services, financial services and asset management around the world. AIG’s common stock is listed on the New York Stock Exchange, as well as the stock exchanges in Ireland and Tokyo.

Big Plans for Rideout Expansion

By Nancy Pasternack, Appeal-Democrat, Marysville, Calif.

Jul. 22–Plans for a 250,000-square-foot expansion, an eight-floor main tower, and a helicopter landing pad at Rideout Memorial Hospital in Marysville are underway, pending the results of an environmental impact report.

Officials of Fremont Rideout Health Group hope to break ground in late 2009 and complete the project by the end of 2012.

The City of Marysville approved a contract last week for Planning Partners, an environmental consulting group, to produce the $198,000 report, which will include ground and air traffic study results.

Fremont Rideout Health Group, owner of the hospital and of Fremont Medical Center in Yuba City, has agreed to fund the study and reimburse the city for related administrative costs.

The project has been budgeted at $140 million.

“It’ll be quite a building, and will serve the citizens of this region for quite a long time,” said Tony Moddesette, vice president of facilities and projects for Fremont Rideout.

The helicopter landing pad, according to the most recent revision of expansion plans, will be constructed atop an eight-floor tower above the main entrance.

Fremont Rideout’s plans are part of a move to streamline operations in its two locations, and to move all acute and inpatient care to the hospital in Marysville.

Changes in earthquake compliance codes for hospitals require updated construction with a deadline to move out of noncompliant buildings by the end of 2013.

Most of the health group’s buildings in Yuba City will be unusable for inpatient care, according to Moddesette.

Expansion of the Marysville hospital will include connecting hallways from the main tower to the emergency room, which will have its own entrance and parking lot off of Third Street.

According to Moddesette, the weekend of July 12-13 brought 140 patients to the Rideout Emergency Room, a volume that is not out of the ordinary.

“ERs across the state are overwhelmed,” he said. On average, two or three patients are transported each month by medical transport helicopter to Sacramento-area hospitals.

“It can be really terrible,” Moddesette said. “We get gunshot patients — all kinds of things come through there.”

Currently, part of the hospital’s parking lot has to be cleared out in order for a helicopter to land, which, “can cause a little bit of delay,” in treatment, he said.

In addition to the helicopter landing pad and ER access, the expansion plans also include room for 132 additional inpatient beds and an option to convert additional space for 36 more.

City Services Director Dave Lamon said changes to the hospital will likely have a positive impact both on health care in the Yuba-Sutter area, and on Marysville’s flagging economy.

“We’ll have more doctors and related medical development around the hospital,” he said. “Any increased activity like that is good for the city.”

But, he said, “the process is really just getting started.”

Contact Appeal reporter Nancy Pasternack at 749-4712 or [email protected]

—–

To see more of the Appeal-Democrat, or to subscribe to the newspaper, go to http://www.appeal-democrat.com.

Copyright (c) 2008, Appeal-Democrat, Marysville, Calif.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Colleagues at Canyon View Praise Departing Southwick

By Cassidy Friedman, The Times-News, Twin Falls, Idaho

Jul. 22–Directing the psychiatric branch of a Twin Falls’ hospital was just like running any business, said Bill Southwick.

That might seem odd given that Southwick’s 11 years were consumed by victims from averted suicide jumps on the Perrine Bridge, delusional schizophrenics, and resistant police in-custodies lashing out in violence.

It was also not uncommon to spot the director of Canyon View Psychiatric and Addiction Services at midnight, back at the facility, working with a patient after his staff, shorthanded and unable to cope on its own, called him up at his home.

Despite what he says about running his department like a business, Southwick’s reasons for returning to the facility those late nights were personal. He’d made a promise to his staff.

“My promise to the staff was that I would not leave them short,” Southwick said. “They would always have the resources necessary.”

When Southwick, now 41, took a job earlier this month as chief nursing officer at Salt Lake Regional Medical Center after the Utah hospital scouted him out, he received the farewell of a friend who will be missed — perhaps even more than a goodbye fit for a top-dog administrator.

“Bill was very involved,” said Dr. Cory Alexander, a local psychiatrist since the mid-’90s. “I remember being on call — it’s been years — I remember coming in there to see the patient in the middle of the night and Bill was there. He was very accessible and available.”

Southwick’s associates say he was a nurse first, an administrator second, which separated him from the typical administrator.

The great challenge he faced is that in rural Idaho — as with other rural areas in the U.S. — mental illness is still mired in stigma. More metropolitan areas seem more aware of the seriousness and treatment options for mental illnesses, he said.

Suppressed under the surface, mental illness can lead to suicide as naturally as cancer can lead to death, he said. He made it the goal of his tenure to “get the word out” to the community.

He gave speeches to community groups on subjects including stress management and improving communication. He launched a project with Idaho Department of Health and Welfare.

He hoped to convey his message to the “rough and tough” farmer who fears asking for help. Suicide is much more commonly attributed to mental illnesses than the public realizes, he said, noting one in five women and one-eighth of men at some point in their life will suffer from a mental illness.

Because of Southwick’s commitment to his job, working for him felt more like joining a partnership than working in subordination to an employer, said Billie Henry, Canyon View’s office manager.

“Working for him was wonderful,” Henry said. “He is the most patient, compassionate man I have ever met in my whole life.”

Those virtues made him seem more nurse than administrator, and it was his nursing training that taught him how to work so well with people, Alexander said.

“He’s very laid back, very personable,” she said. “He was the kind of person you would feel like opening up to. He was a good listener. You felt like you were talking to a nurse.”

The hospital has appointed a co-management team to succeed Southwick, which pairs Janie Humphrey with Dr. Rick Yavruian, a medical director, Southwick said.

Cassidy Friedman may be reached at 208-735-3241 or [email protected].

—–

To see more of The Times-News, or to subscribe to the newspaper, go to http://www.magicvalley.com

Copyright (c) 2008, The Times-News, Twin Falls, Idaho

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia

DUBLIN, Ireland, July 22 /PRNewswire-FirstCall/ — Amarin Corporation plc today announced that the Company recently met with officials at the U.S. Food and Drug Administration (FDA) to discuss the Company’s plans to develop AMR101 for the treatment of hypertriglyceridemia. Following these discussions, the Company is proceeding to Phase 3 with AMR101 in hypertriglyceridemia.

Dr. Declan Doogan, Head of Research and Development of Amarin, commented: “The meeting with the FDA was very successful as it gives us a clear path forward for the program. We are particularly pleased that we can proceed to Phase 3.”

Thomas Lynch, Chairman and Chief Executive Officer of Amarin, added: “Over the past year we have assembled a highly experienced team of cardiovascular experts to develop AMR101 for this significant indication. Our initial objective of designing the Phase 3 program and obtaining FDA feedback has been achieved. Having completed our recent financing, we now look forward to conducting the Phase 3 program.”

AMR101 is an ultra-pure ethyl ester of eicosapentaenoic acid (Ethyl-EPA). Amarin has collected a substantial body of data on AMR101 to date. Amarin has previously investigated AMR101 in central nervous system (CNS) disorders in several double-blind, placebo controlled studies, including Phase 3 trials in Huntington’s disease. Over 900 patients have received AMR101 in these studies, with over 100 receiving continuous treatment for a year or more. In all studies performed to date, AMR101 has shown a very good safety profile.

Hypertriglyceridemia refers to a condition in which patients have high blood levels of triglycerides and is associated with increased levels of heart disease. It is one component of a range of lipid disorders collectively referred to as dyslipidemia. The overall dyslipidemia population in the U.S. is believed to be in excess of 100 million, with over 10 million of those diagnosed with hypertriglyceridemia.

Numerous studies have demonstrated the safety, tolerability and efficacy of Ethyl-EPA in lowering plasma triglycerides in patients with high triglyceride levels of varying degrees of severity. In Japan, an Ethyl-EPA prescription product has been approved for the treatment of high triglycerides and has been on the market for seventeen years. Data from Amarin’s Huntington’s disease trials indicate that AMR101 lowers triglycerides in patients with elevated baseline levels.

About Amarin

Amarin is a biopharmaceutical company focused on improving the lives of patients suffering from cardiovascular and central nervous system (CNS) diseases. Amarin’s cardiovascular programs, including AMR101 for hypertriglyceridemia, capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin’s CNS development pipeline includes programs in myasthenia gravis, Huntington’s disease, Parkinson’s disease, epilepsy and memory. Amarin is listed in the U.S. on the NASDAQ Capital Market (“AMRN”).

Disclosure Notice

The information contained in this document is as of July 22, 2008. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking statements about Amarin’s financial condition, results of operations, business prospects and products in research that involve substantial risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “forecast”, “intend”, “plan”, “believe” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: Amarin’s ability to maintain sufficient cash and other liquid resources to meet its operating and debt service requirements; the success of Amarin’s research and development activities; decisions by regulatory authorities regarding whether and when to approve Amarin’s drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin’s products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affecting Amarin’s products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin’s ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin’s product candidates; governmental laws and regulations affecting Amarin’s operations, including those affecting taxation; risks relating to the Company’s ability to maintain its Nasdaq listing; general changes in International Financial Reporting Standards; and growth in costs and expenses. A further list and description of these risks, uncertainties and other matters can be found in Amarin’s Form 20-F for the fiscal year ended December 31, 2007, filed with the SEC on May 19, 2008.

Amarin Corporation Plc

CONTACT: Contacts: Amarin: +353-(0)1-669-9020, Thomas Lynch, Chairmanand Chief Executive Officer, Alan Cooke, President and Chief OperatingOfficer or Darren Cunningham, EVP Strategic Development and InvestorRelations, [email protected]

St. Mary Medical Center Is First in the Nation to Offer Patients State-of-the-Art Open MRI Technology

LANGHORNE, Pa., July 22 /PRNewswire/ — St. Mary Medical Center today announced that it has invested more than $3 million to add a new, high-field truly open magnetic resonance imaging (MRI) system. St. Mary Imaging/Langhorne will be the first clinical site in the nation to offer this exciting new technology. The Hitachi OASIS is a state-of-the-art scanner that delivers outstanding image quality in an open system environment preferred by patients for its comfort and convenience.

The OASIS is unique, because it is an open MRI system that incorporates the capabilities of high-field strength imaging. Although open MRI systems have been in use since the early 1990s, most physicians prefer the higher resolution of diagnostic images obtained in high-field strength MRIs. High-field strength MRIs typically have an enclosed circle design within which a magnet rotates, and for many patients, this tunnel-like experience can be source of anxiety and discomfort. Open MRI systems were designed to alleviate feelings of claustrophobia and increase patient comfort, yet until now, could not quite match the level of image quality offered by a high-field system.

The high-field open MRI is a breakthrough in advanced technology that successfully accommodates patient comfort and produces high-quality diagnostic information for every region of the body. The wide-table design also better accommodates obese, pediatric and limited-mobility patients, including the elderly or infirm. In addition, the high-field open unit offers fast scan times and motion-compensation technology for clearer imaging. A variety of specialized coils are used for advanced detailed studies of the brain, spine, shoulders, legs, breast, neurovascular and abdomen.

This new high-field open MRI technology offers patients and physicians the best of both worlds, notes Dr. Daniel Cohen, St. Mary Medical Director of MRI. “As technology has continued to progress, the differences in image quality and patient comfort have been minimized. We can now offer patients the security of a spacious design for added comfort during scans while simultaneously providing the most accurate scan results to aid physicians in their diagnoses,” Cohen says.

Magnetic resonance imaging is an advanced diagnostic imaging procedure that uses a powerful magnet and radio waves to produce detailed three-dimensional images of body organs and structures without the use of x-ray or other radiation. Detailed images of the brain, spine, joints, pelvis, abdomen and chest are useful for soft-tissue injuries and conditions often associated with cancer, stroke, heart and vascular disease, or sports trauma.

MRI is just one hallmark of the significant growth in advanced imaging technologies provided through St. Mary Imaging. Digital radiology and mammography, PET-CT, 64-slice Cardiac CT, ultrasound and bone density Dexa Scans also are used for diagnosis. In addition, all imaging studies at St. Mary are conveniently accessible to physicians and medical staff through a computerized Picture Archival and Communications System (PACS). In 2006, St. Mary expanded access to diagnostic imaging in opening an offsite imaging center to better serve the needs of the community. St. Mary Imaging/Richboro, in the Richboro Shopping Center, provides diagnostic MRI and CT scanning services for outpatients requiring imaging studies.

St. Mary Imaging is a full-service department that performs more than 250,000 procedures each year. St. Mary Imaging is accredited by the American College of Radiology, a national quality indicator. In addition, all technologists are nationally certified and all studies are read by board-certified radiologists. “St. Mary offers patients a high standard of excellence across the board, and this is another example of our commitment to quality care and patient safety. Patients can rest assured knowing that their primary care physicians and specialists are getting the most accurate information with which to make a diagnosis,” says Dr. Paul Weiser, St. Mary Medical Center Director of Radiology.

Most insurance coverage is accepted at St. Mary Imaging, but pre-certification may be required. Walk-ins are accepted with insurance approval. To schedule an appointment, please call Centralized Scheduling at 215.710.2208.

About St. Mary Medical Center

St. Mary Medical Center in Langhorne, Pennsylvania, the most comprehensive medical center in the area, is celebrating 35 years of caring for our community. Its compassionate staff of more than 600 physicians, 2,400 colleagues, and 900 volunteers is committed to providing excellence in patient safety and quality care. St. Mary offers state-of-the-art technology and highly skilled physicians and clinical professionals in providing advanced care for complex cases. Services include a comprehensive cardiovascular program; the only state-accredited Trauma Center in Bucks County; Emergency Services with a dedicated Pediatric Emergency Care Center; a Joint Commission-certified Primary Stroke Center; specialized diagnostic imaging; obstetrics; a Joint Commission-certified joint replacement program; exceptional orthopedic surgical capabilities and rehabilitation; sleep disorders, pain management, and wound healing centers; the St. Mary Breast Center; and the St. Mary Regional Cancer Center.

St. Mary Medical Center

CONTACT: Kathleen Smith, +1-215-710-2090; or Patrick Donohue,+1-215-710-6908, both for St. Mary Medical Center

Cara Therapeutics Announces Issuance of U.S. Patent Covering Second Generation Kappa Opioid Receptor Agonists

SHELTON, Conn., July 22 /PRNewswire/ — Cara Therapeutics, Inc. announced today that The United States Patent and Trademark Office has issued U.S. Patent No. 7,402,564 entitled “Synthetic Peptide Amides” under its Accelerated Examination Program. The application was filed on November 12, 2007 and covers Cara’s second generation, peripherally-selective kappa opioid receptor agonist compounds. These compounds include CR845, currently completing a Phase I clinical trial and in development for injectable and oral delivery for the treatment of acute and chronic pain of visceral, inflammatory and neuropathic origin, and for the treatment of pruritis (itch), a common disorder associated with several diseases and conditions.

About CR845

In preclinical studies, CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibits analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneous, or oral administration. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus), impair breathing or elicit signs of addiction in animal models. Preclinical studies also indicate that CR845 possesses anti-itch activity. CR845 is currently completing Phase Ia studies.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara’s current pipeline includes near-term clinical drug candidates within multiple classes of peripherally-acting analgesics. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreenTM technology.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of Cara compounds and about Cara’s strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Cara’s research and clinical studies and Cara’s ability to obtain additional financing. These forward-looking statements represent Cara’s judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.

Cara Therapeutics, Inc.

CONTACT: Derek Chalmers, President & CEO of Cara Therapeutics,+1-914-347-4040, Ext. 201

Around Our Area Harnett County Deputies Find $12 Million Marijuana Field

By Cassidy Culbertson, Sanford Herald, N.C.

Jul. 22–BROADWAY — Harnett County deputies made their second major marijuana bust since June, spotting $ 12 million worth of plants in Broadway over the weekend.

The State Bureau of Investigation, U.S. Army National Guard and Harnett County Sheriff’s Department removed 5,000 plants spanning 11 plots on Monday. The plants were found off Cool Springs Road within a few miles of June’s marijuana bust, in which 35,000 marijuana plants were found, according to Harnett County Sheriff Larry Rollins.

The sheriff’s office contracted a private company to survey the county after June’s bust.

“This appears similar to what we found in June,” Rollins said. “There were some differences. The 11 plots were scattered through a remote wooded area. We were suspicious after what we found last time and concerned there could be some more large operations going on.

“We’ve got so many remote and desolate areas in Harnett County’s 600 square miles.”

No arrests have been made in either marijuana bust, and there are no suspects, Rollins said.

“For the last several years, a number of huge operations have been found in California, Oregon, Nevada and other places out west, where people got Mexican nationals to come in and operate marijuana fields,” Rollins added. “We’re pretty certain this is the type of operation (the Cool Springs road plot) is. The campsites had Hispanic foods and clothing with Mexican symbols and emblems.”

The sheriff’s department has no leads to indicate suspects, and Rollins urges anybody with information about suspicious activity to contact the department.

“Fortunately this operation wasn’t any bigger than it was. Hopefully the message is ‘don’t grow dope in this county, we will find it,'” Rollins said.

—–

To see more of The Sanford Herald or to subscribe to the newspaper, go to http://www.sanfordherald.com

Copyright (c) 2008, Sanford Herald, N.C.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Milliman Care Guidelines Offers National Client Award for Healthcare Leadership

SEATTLE, July 22 /PRNewswire/ — Milliman Care Guidelines LLC, A Milliman Company, has established an award for clients who are using the company’s evidence-based clinical guidelines and software to improve healthcare delivery.

The company will name the first recipients of The Richard L. Doyle Award for Innovation and Leadership in Healthcare during its next Client Forum, April 2009, in Miami. Dr. Doyle developed the first Milliman Care Guidelines(R) products in 1990.

The Care Guidelines were the first clinical guidelines to offer a proactive, “look-ahead,” approach to most conditions, allowing clinicians to see the entire continuum of care for a patient, and to identify milestones along the road to recovery. Today, Care Guidelines products and software are licensed by more than 1,000 clients, including six of the seven largest US health plans, as they strive to deliver optimal care to their patients and members.

The Doyle Award is intended to encourage clients to develop innovative ways to apply the Care Guidelines to improve healthcare management. Applicants are asked to demonstrate the positive effects of the Care Guidelines on healthcare quality or patient safety; on patient, member, payor or external quality agency satisfaction; on staff efficiency, or on healthcare cost.

The grand prize winner will receive two paid registrations to the Client Forum, including travel and lodging, and their accomplishments will be recognized in an opening-day plenary session. The organization will receive a crystal trophy for display, and Milliman Care Guidelines will host a reception for client employees at the winner’s location. All applicants will have the option to describe their work and share best practices in a general poster session during the Client Forum.

Doyle Award applications will be judged by a panel of healthcare experts who are familiar with the Care Guidelines, but are independent of Milliman. Judges include:

— Leah Binder, Chief Executive Officer of The Leapfrog Group

— Dr. Richard L. Doyle, Originator of the Milliman Care Guidelines (retired)

   --  Liza Greenberg, President of Health Project Consulting   --  Donna Merrick, Director of Standards Development for URAC   --  Michael Millenson, President of Health Quality Advisors   

Licensed users of the Care Guidelines may contact Milliman representatives or visit The Doyle Award web page at http://www.careguidelines.com/company/doyle for application details.

About Richard L. Doyle, MD

Dr. Doyle is the visionary behind the Milliman Care Guidelines. He began creating clinical guidelines as San Diego’s Mercy Hospital Chief of Staff in the 1980s to help improve hospital efficiency and quality. In 1990, Dr. Doyle joined Milliman (then Milliman & Robertson) to publish the company’s first clinical guidelines, then called Healthcare Management Guidelines. Before retiring in 1997, he had produced the original editions of four of the Care Guidelines products currently in use.

About Milliman Care Guidelines

Milliman Care Guidelines LLC, A Milliman Company, is located in Seattle, and independently develops and produces evidence-based clinical guidelines and a variety of software options that are used to support the care of almost two-thirds of US health plan members. Covering the continuum of care, the seven-product Care Guidelines series is updated annually by an experienced team of clinicians, and includes Ambulatory Care, Inpatient and Surgical Care, General Recovery Guidelines, Recovery Facility Care, Home Care, Chronic Care Guidelines and Behavioral Health Guidelines. For more information, visit http://www.careguidelines.com/.

About Milliman

Milliman Care Guidelines is a wholly owned subsidiary of Milliman, which serves the full spectrum of business, financial, government, and union organizations. Founded in 1947 as Milliman & Robertson, the company has 48 offices in principal cities in the United States and worldwide. Milliman employs more than 2,000 people, including a professional staff of more than 900 qualified consultants and actuaries. The firm has consulting practices in healthcare, employee benefits, life insurance/financial services, and property & casualty insurance. For more information, visit http://www.milliman.com/.

Milliman Care Guidelines LLC

CONTACT: Sherrie Dulworth, Vice President of Quality and Product Design,Milliman Care Guidelines, +1-914-244-0067, [email protected]

Web site: http://www.careguidelines.com/http://www.careguidelines.com/company/doylehttp://www.milliman.com/

Celebrity Designer and ADHD Spokesperson Ty Pennington Partners With Shire to Announce the Launch of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults

ATLANTA, July 22 /PRNewswire-FirstCall/ — Shire Limited , the global specialty biopharmaceutical company, today announced that it has launched VYVANSE(TM) (lisdexamfetamine dimesylate) for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD). This launch follows the recent FDA approval of VYVANSE to treat ADHD in the adult population. VYVANSE is now available in U.S. pharmacies nationwide in six once-daily dosage strengths. To raise awareness of ADHD in adults and recognize the launch of VYVANSE for adults, Shire has partnered with celebrity designer Ty Pennington to shine the spotlight on living as an adult with ADHD. Pennington takes VYVANSE as part of his treatment plan to manage his ADHD symptoms so he can focus and get work done.

Pennington returns today to his hometown of Atlanta, where he will visit the Savannah College of Art and Design-Atlanta (SCAD-Atlanta) and announce the Daily Successes with ADHD Scholarship for an adult with ADHD who is pursuing an education or career in a creative field at SCAD-Atlanta. The $10,000 scholarship, sponsored by Shire, the maker of VYVANSE, will benefit an adult with ADHD who is enrolled in, or applying to, a graduate program at the art institution. The objective of the scholarship is to recognize achievements, and to motivate a student to continue to focus and achieve daily successes.

“As an adult with ADHD, I know, firsthand, the importance of understanding and treating ADHD. I believe if I’d been diagnosed and treated earlier, I would have struggled less as a child,” said Ty Pennington, host of ABC’s Extreme Makeover: Home Edition(TM). “Today, I have a very demanding schedule with long production days and constant travel, and I take VYVANSE to help control my ADHD symptoms so that I can focus and organize.”

ADHD Can Affect Adults’ Daily Lives

In adults with ADHD, symptoms can impact their professional life, social life, relationships and personal finances. In a new survey conducted by Shire of adults who experienced ADHD symptoms in a typical week, 88 percent of 328 adults surveyed reported that they have difficulty organizing tasks and activities, while 89 percent of 381 of these adults had difficulty finishing things, such as projects or work at home. These adults reported that this has had a negative impact on their daily life and activities. Additionally, among the 347 adults surveyed who are currently employed, 66 percent felt that they would do a better job at work if they were more focused and organized.

“Although ADHD can affect children and adults, the core symptoms of the disorder, inattention, hyperactivity, and impulsivity, may present differently in these two patient groups. For example, hyperactivity may present in adults as inner restlessness and inattention may present as a lack of focus and organization, poor time management, and an inability to finish tasks,” said David W. Goodman, M.D., director of the Adult Attention Deficit Disorder Center of Maryland and assistant professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine. VYVANSE is one of several treatment options that may provide effective treatment control for adults with ADHD. In a clinical study, VYVANSE was shown to significantly improve ADHD symptoms within the first week: inattention — such as the ability to focus and organize — and hyperactivity and impulsivity — such as restlessness, and interrupting.”

Shire received approval in April 2008 from the FDA for VYVANSE for the treatment of ADHD in adults aged 18 to 55 years. VYVANSE was introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years. VYVANSE is available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. In its first year of availability, more than 2 million VYVANSE prescriptions have been filled.

VYVANSE works with the body’s natural metabolism to deliver active medication. VYVANSE is a once-a-day capsule that should be taken in the morning with or without food as prescribed by your doctor.

Additional information about VYVANSE and Full Prescribing Information are available at http://www.vyvanse.com/.

About VYVANSE

Vyvanse is indicated for the treatment of ADHD. Efficacy based on two controlled trials in children aged 6 to 12 and one controlled trial in adults.

Tell the doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform the doctor immediately if you or your child develops symptoms that suggest heart problems, such as chest pain or fainting.

Vyvanse should not be taken if you or your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.

Tell the doctor before taking Vyvanse if you or your child is being treated for or has symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; has abnormal thought or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell the doctor immediately if you or your child develops any of these conditions or symptoms while taking Vyvanse.

Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

Vyvanse was generally well tolerated in clinical studies. The most common side effects reported in studies of Vyvanse were: children — decreased appetite, difficulty falling asleep, stomachache, and irritability; adult — decreased appetite, difficulty falling asleep, and dry mouth.

Aggression, new abnormal thoughts/behaviors, mania, growth suppression, worsening of motion or verbal tics, and Tourette’s syndrome have been associated with use of drugs of this type. Tell the doctor if you or your child has blurred vision while taking Vyvanse.

About ADHD

ADHD is one of the most common psychiatric disorders in children and adolescents. Approximately 7.8 percent of all school-aged children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the Centers for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of U.S. adults aged 18-44 based on results from the National Comorbidity Survey Replication, a nationally representative household survey, which used a lay- administered diagnostic interview to access a wide range of DSM-IV disorders. When this percentage is extrapolated to the full U.S. population, approximately 9.8 million adults are believed to have ADHD. ADHD is a neurobiological disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic, or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no “cure” for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological, or behavioral modification, and medication.

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: http://www.shire.com/

“SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of and velaglucerase alfa (GA-GCB); manufacturing and JUVISTA(R) (Human TGF b3) commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder (“ADHD”)); the impact of competitive products, including, but not limited to, the impact of those on Shire’s ADHD franchise; patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire’s ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc’s filings with the Securities and Exchange Commission, including Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2007.

Shire Limited

CONTACT: Mindy Greene, +1-212-601-8330, or +1-917-653-6134 (mobile),[email protected], or Jacelyn Seng, +1-212-601-8385, or+1-917-392-0756 (mobile), [email protected], both for ShireLimited

Web site: http://www.shire.com/http://www.vyvanse.com/

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

SAN DIEGO, July 22 /PRNewswire-FirstCall/ — Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the presentation of positive pre-clinical animal efficacy data for its pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, CA. The study showed that treatment of hormone resistant human prostate cancer in tumor bearing mouse models with intravenous PEGPH20 in combination with the chemotherapeutic drugs, docetaxel (Taxotere(R)) or liposomal doxorubicin (Doxil(R)) resulted in a substantial increase in anti-tumor activity. The docetaxel combination treatment demonstrated significantly enhanced survival compared to treatment with the chemotherapeutic agent alone. The effects of PEGPH20 were selective to prostate tumors producing hyaluronan (HA), consistent with the selective reduction of tumor interstitial fluid pressure (IFP). Treatment with PEGPH20 was well tolerated in non tumor-bearing mice without significant increases in neutropenia (depletion of neutrophils, a type of white blood cell) compared to chemotherapy alone.

“These findings clearly demonstrate the activity of our long acting PEGPH20 enzyme candidate against HA-rich tumors in combination with chemotherapy,” said Gregory Frost, PhD, Halozyme’s Vice President and Chief Scientific Officer. “By targeting tumors that overproduce the HA matrix component, PEGPH20 may selectively attack tumor interstitial fluid pressure and combined with chemotherapy, reduce tumor burden for a significant number of patients.”

Halozyme is continuing its pharmacology, manufacturing and toxicology studies as part of its PEGPH20 development program in oncology. The company is making preparations for a pre-IND meeting with the FDA later this year to seek advice with regard to the design of its first-in-human clinical trial and plans to initiate studies in cancer patients with PEGPH20 during the first half of 2009.

Study Details and Background

This study utilized three widely accepted animal cancer models: xenograft PC3, xenograft Du145luc, and PC3-M-luc bone metastases. For the HA-producing xenograft PC3 model, animals received an intramuscular inoculation with PC3 prostate carcinoma cells in the hind leg in order to generate tumors with high IFP. When tumor volume reached 400-500 mm(3), a high tumor burden, animals were randomized to receive one of four possible treatments: PEGPH20 alone, chemotherapy alone, chemotherapy plus PEGPH20, or placebo. Two chemotherapeutic agents, docetaxel and liposomal doxorubicin, were tested in this model. The non-HA-producing xenograft Du145luc model was utilized in a similar manner with docetaxel. Finally, an HA-producing PC3-M-luc disseminated bone metastasis model was used to test PEGPH20 alone and in combination with docetaxel.

Xenograft PC3 results

— Tumor volume growth suppressed significantly. Tumor volume growth over time was significantly lower in the PEGPH20 plus docetaxel (p

— Survival for combination treatment was significantly increased. Docetaxel plus PEGPH20 increased life span by 225% while docetaxel alone increased life span by 59% relative to control. Furthermore, the survival benefit produced by the combination treatment was significantly better than docetaxel alone (p=0.003).

Xenograft Du145luc results

— Tumor volume growth unaffected by combination treatment, as expected. Human Du145luc prostate tumor cells do not produce hyaluronan, and no change in interstitial fluid pressure was observed following PEGPH20 treatment. Therefore, treatment with an HA-reducing treatment regimen would not be expected to provide a therapeutic benefit. Results demonstrated no meaningful difference in tumor volume between the docetaxel alone and PEGPH20 plus docetaxel treatment groups. In addition, unlike the HA-producing PC3 tumors, tumor growth curves in the control and the PEGPH20 groups were virtually superimposable. These findings support the proposed mechanism of action that only HA-producing tumors would be most susceptible to PEGPH20.

PC3-M-luc bone metastases results

— Survival benefit demonstrated. Two different combination dosage regimens of PEGPH20 plus docetaxel demonstrated improved survival compared to the control group. For this model, tumor cells are injected directly into the left ventricle and migrate to bone tissue.

Hyaluronan is a dominant constituent of the extracellular matrix in subsets of many solid tumor types, including prostate, breast, ovarian, pancreatic, and gastric, where it may increase the resistance to chemotherapeutic agents. Previous studies presented by Halozyme (Thompson et al. Proceedings AACR Annual Meeting, Volume 49, April 2008) demonstrated significant reductions of HA around the tumor, IFP, and tumor water content after intravenous administration of PEGPH20. Elevated tumor IFP is believed to limit the response to cytotoxic treatment regimens in many solid tumors. Removal of peritumoral HA and the lowering of IFP may potentially lead to improved responses to chemotherapy and a more rapid reduction of tumor volume that could potentially improve patient survival.

Pegylation refers to the covalent attachment of polyethylene glycol to a molecule, usually a drug or therapeutic protein. A pegylated molecule may be masked from the immune system and have a prolonged circulatory time due to a reduction in renal clearance. The pegylation of rHuPH20 increases its plasma half-life to greater than 24 hours compared to less than one minute for the unpegylated enzyme, therefore resulting in a longer duration of action.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology and dermatology markets. The company’s portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche’s biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the safety and efficacy of PEGPH20 in animal models) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words “believe,””enable,””may,””will,””could,””intends,””estimate,””anticipate,””plan,””predict,””probable,””potential,””possible,””should,””continue,” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company’s reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

    Halozyme Contact                     Media Contacts    Robert H. Uhl                        Karen Sparks / Joleen Schultz    Senior Director, Investor Relations  Mentus    (858) 704-8264                       (858) 455-5500, x275/x215    [email protected]                    [email protected]                                         [email protected]  

Halozyme Therapeutics, Inc.

CONTACT: Robert H. Uhl, Senior Director, Investor Relations of HalozymeTherapeutics, Inc., +1-858-704-8264, [email protected]; or media, KarenSparks, +1-858-455-5500, ext. 275, [email protected], or Joleen Schultz,+1-858-455-5500, ext. 215, [email protected], both of Mentus for HalozymeTherapeutics, Inc.

Response Biomedical Receives US FDA Clearance for RAMP(R) NT-proBNP Test for Diagnosis of Heart Failure

VANCOUVER, July 22 /PRNewswire-FirstCall/ — Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to market the RAMP(R) NT-proBNP Test as an aid to the rapid diagnosis of heart failure (HF).

“NT-proBNP is emerging as a superior marker for the diagnosis of heart failure,” said S. Wayne Kay, Chief Executive Officer. “The introduction of the point-of-care RAMP(R) NT-proBNP Test is a significant advance as it supports the drive for speed and accuracy of diagnosis for patients presenting in emergency rooms and for early detection in ambulatory care. Because the performance of our RAMP(R) NT-proBNP Test is clinically concordant with that of the Roche Elecsys proBNP Test, a hospital can have standardized clinical decision points for NT-proBNP in both their emergency rooms and central laboratories. The addition of the innovative NT-proBNP Test expands the menu of the RAMP200 analyzer for the rapid assessment of patients with symptoms of cardiovascular disease.”

Dr. James L. Januzzi, the Director of the Coronary Care Unit at Massachusetts General Hospital expressed his enthusiasm for the imminent introduction of the RAMP(R) NT-proBNP Test. “As the first full range point-of-care assay for NT-proBNP, the RAMP(R) Test will present a major step forward for rapid and confident diagnosis of heart failure using this important blood test. Clinical trials, including studies done at the Massachusetts General Hospital, have shown that the RAMP(R) result can be used interchangeably with results from automated NT-proBNP Tests done in the hospital laboratory. This harmony between the RAMP(R) and the automated NT-proBNP Tests represents a huge advantage over most point-of-care BNP assays, which have disappointing harmony with their automated counterparts.”

Response Biomedical recently announced a partnership granting rights to Roche Diagnostics, a world leader in clinical diagnostics, to market its line of cardiovascular point-of-care (POC) tests. Roche Diagnostics’ comprehensive sales and marketing infrastructure allows for broad worldwide penetration of Response Biomedical’s cardiovascular line.

About HF

HF impedes the ability of the heart to pump blood at a rate sufficient to support the body’s vital needs. HF affects nearly 17 million people worldwide, and is the single most frequent cause of hospitalization in people over 65ӚÓš years. The initial diagnosis of HF is problematic as symptoms can be associated with other pathologies such as respiratory disease and the secondary effects of obesity. According to the Canadian Heart and Stroke Foundation, doctors estimate that there are 200,000 – 300,000 Canadians with heart failure. Since 1970, the number of Canadians dying from congestive heart failure has increased sixty per cent. According to the American Heart Association, approximately five million Americans are currently afflicted with HF and 550,000 new cases are diagnosed each year. The prevalence of HF is expected to continue increasing due to the aging population and improved survival rates of patients with other cardiovascular diseases.

About NT-proBNP

NT-proBNP is widely recognized as a definitive marker for the diagnosis of HF. NT-proBNP is cleaved from the precursor peptide proBNP in quantities directly proportional to its biologically active counterpart BNP and in close correlation with the severity of heart failure. BNP is secreted primarily from the left ventricle in response to pressure overload and regulates blood pressure, electrolyte balance and fluid volume. BNP acts to reduce the pressure overload. Elevated levels of NT-proBNP indicate the presence of heart failure, and provide physicians with an important diagnostic tool in the early detection and management of HF. Independent published studies show that NT-proBNP is also valuable for: risk stratification of patients with stable coronary heart disease, as a prognostic marker across the entire spectrum of cardiovascular diseases, potentially detecting early stages of HF in the absence of clinically obvious symptoms, and for the assessment of prognosis for patients with HF and for patients who have previously had a myocardial infarction.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack and congestive heart failure.

In late 2006, the Company formed a strategic alliance with 3M Company to commercialize rapid infectious disease tests and in 2008 entered into a strategic alliance with Roche Diagnostics to commercialize cardiovascular POC tests worldwide.

In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking for its clinical products and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.

Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol “RBM” and quoted on the OTC Bulletin Board under the symbol “RPBIF”. For further information, please visit the Company’s website at http://www.responsebio.com/.

Statements contained in this press release relating to future results, events or developments, for example, statements containing the words “believes,””may,””could”, “plans,””will,””estimate,””continue,””anticipates,””intends,””expects”, “goal” and similar expressions, are “forward-looking statements” or “forward-looking information” under applicable United States and Canadian securities laws. Forward-looking statements or information may involve, but are not limited to, comments with respect to our planned activities, business plan and strategies and their future implementation, and our expectations for our financial condition and the results of, or outlook for, our business operations generally. Forward-looking statements or information are subject to the related assumptions made by us and involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such statements or information. Many of such risks, uncertainties and other factors form part of our underlying assumptions, and include, among other things, financial risks that would affect our operations such as our available working capital and cash flows and whether and for how long available funds will be sufficient to fund our operations and our ability to raise additional capital as and when needed; our need for substantial additional funding to conduct research and development and commercialization activities; our ability to establish, and our dependence upon, relationships with strategic alliance partners to develop and commercialize products; technological changes that impact our existing products or our ability to develop and commercialize our products; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; liability for patent, product liability and other claims asserted against us; commercialization limitations imposed by patents owned or controlled by third parties; our ability to retain, and our reliance upon, third party suppliers, manufacturers, distributors and alliance partners; our ability to effectively and efficiently manage the planned growth of our operations; our ability to profitably sell our products at prices that would be acceptable to third-party reimbursement programs; competition including competition from others with significantly more resources; market acceptance of our products and the size of our markets; changes in business strategy or development plans; changes in, or the failure to comply with, governmental regulations; and other factors referenced in our annual report, our Annual Information Form (AIF) (Form 40-F in the U.S.) and other filings with Canadian and United States securities regulatory authorities.

Given these uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward-looking statements or information. We disclaim any obligation to update, or to publicly announce any revisions to, any such statements or information to reflect future results, events or developments, except as required by law.

Response Biomedical Corp.

CONTACT: Response Biomedical Contacts: Bill Wickson, Manager, InvestorRelations, Response Biomedical Corporation, Tel (604) 456-6073, Email:[email protected]; Brian Korb, Vice President, The Trout Group LLC,Tel: (646) 378-2923, Email: [email protected]

OncoVista Innovative Therapies to Begin Enrolling Patients in a Phase I/II Study of Cordycepin in Patients With Refractory TdT-Positive Leukemia

OncoVista Innovative Therapies, Inc. (OTC BB: OVIT.OB), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics, announced today that patient recruitment has commenced in the company’s Phase I/II study of cordycepin for the treatment of patients with terminal deoxynucleotidyl transferase (TdT)-positive refractory leukemia. Participating clinical sites include the Dana Farber Cancer Institute (Boston, MA) and the Cancer Therapy and Research Center (San Antonio, TX).

“Initiation of this Phase I/II clinical trial of cordycepin is an important milestone for OncoVista. We believe cordycepin will prove to be an effective and well-tolerated treatment option for many leukemia patients who do not respond to other therapies. We are very excited to have the trial up and running.” stated Alexander L. Weis, Ph.D., President and Chief Executive Officer of OncoVista Innovative Therapies.

OncoVista has received Orphan Drug Designation from the FDA for cordycepin in this indication, which affords the company seven years of market exclusivity once the drug is approved for this indication.

The goals of the Phase I portion of the cordycepin study are to establish the recommended dose in the target population, determine drug-related dose-limiting toxicities, and assess pharmacokinetics. The goals of the Phase II portion of the study are to evaluate efficacy at the recommended dose and confirm the safety profile established in Phase I.

About cordycepin and TdT positive leukemias

Cordycepin (3′-deoxyadenosine) is a nucleoside analog that has been shown in preclinical studies to have activity against TdT-positive cells. Expression of TdT is one of the hallmarks of acute lymphoblastic leukemia (ALL). In addition to ALL patients, subsets of patients with acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) also express the TdT enzyme. Patients who have TdT-positive leukemia (ALL, AML, or blastic CML) whose disease has failed to respond to at least one standard treatment regimen and for which no standard therapies are expected to result in durable remission are eligible for enrollment in this trial.

About OncoVista Innovative Therapies

OncoVista is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies which are more efficacious and less toxic. Further information on OncoVista can be found at www.oncovista.com.

Forward-Looking Statements: A number of statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. These risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements.

Hope for Prostate Cancer Patients

A WONDER pill blocks the advance of prostate cancer with hardly any side effects, it is claimed.

Experts believe Abiraterone could treat eight out of 10 aggressive tumours that have resisted all other treatments.

Trials have shown the drug, taken as daily pills, cuts cancer levels by 30 per cent in 80 per cent of men in three months.

Patients in severe pain say they have been given a new lease of life by the drug.

That has led to a “stampede” of men wanting to take part in clinical trials.

The drug blocks production of hormones that drive the growth of prostate cancers.

It is effective even after the cancer has spread and could potentially be used to treat breast and bowel cancers.

Prostate cancer is the most common cancer in UK men.

Out of 35,000 diagnosed every year, 10,000 die.

If the drug is licensed in the UK, it could be available in Scotland by 2010.

It will need approval from the Scottish Medicines Consortium, who assess the cost-effectiveness of drugs.

But Dr Johann de Bono, who led the research, is optimistic the drug can transformlives.

He said: “Patients who started taking this drug in 2005 are still doing well two years, eight months later.”

Advanced prostate cancer patients are often given two years to live.

So far, 250 men have been treated with Abiraterone and a phase- three trial of 1200 men is under way.

Dr de Bono said: “This drug is spectacularly active.

“We believe we have made a major step forward in treating end- stage prostate cancer.

“My vision is to make chemotherapy obsolete.”

(c) 2008 Daily Record; Glasgow (UK). Provided by ProQuest Information and Learning. All rights Reserved.

Daycare Operator Provided Sweatshirt That Accidentally Strangled 2-Year-Old

SAN JOSE, Calif. _ As daycare provider Harold Taylor led the toddlers to the play structure in his chilly backyard, he asked his wife, Bertha, to grab the sweaters. She pulled out an old blue hooded sweatshirt that her grown son had worn 20 years ago, and put it on 2-year-old Coby Hofmann.

It had a drawstring at the hood — a drawstring that, while Coby was going down the slide, strangled him.

In dramatic and tearful testimony Monday, Harold Taylor spoke publicly for the first time about the May 21 death that led the state to shut down the center at the Taylors’ home off McKee Road in east San Jose, Calif. It had been operating for nearly 20 years.

“This was devastating,” Harold Taylor said. “They’re like my children. In my heart they are.”

Taylor, 73, and his wife are fighting to re-open their home, and the couple has received tremendous support from parents, including Coby’s mom and dad, who have all written letters on their behalf.

Jeff Hofmann, who plans to testify Wednesday, told the San Jose Mercury News on Monday that he and his wife fully support the Taylors and plan to send their newborn son to the daycare in the fall.

“We believe in them and know they are good people,” Hofmann said in a phone interview after the hearing. “It was an accident. Being angry with people, being enraged or suing, it’s not going to bring Coby back.”

Since Coby’s death, the state has alerted daycare providers to beware of the dangers of clothing with drawstrings. Even though it was Bertha Taylor who pulled out the old sweatshirt for Coby, Hofmann says he appreciates that “she gave him the jacket because he was cold.”

Besides, he said, some stores still sell hooded sweatshirts with cords.

“We consider them family and if it had been my father or mother, what are you going to do?” Hofmann said. “These people are family.”

At Monday’s hearing, two other parents and a grandparent sat through the daylong proceeding to show their support.

“They’re not fighting for themselves. They’re fighting for our babies,” said parent Julissa Melo. “My baby wants to go back and he doesn’t understand why he can’t.”

Nancy Miller, whose grandson attended the Taylors’ home day care, said, “it’s a tragedy that could happen anywhere to anyone.”

But Kimberly Kim, lawyer for the state Department of Social Services, told the administrative law judge that the Taylors’ daycare license should be revoked.

In her opening statement Monday, she said that Harold Taylor was “busy in the garden area of the backyard from which he could not see the slide part of the wooden structure.”

A 5-year-old girl told authorities shortly after Coby’s death that she first noticed the boy on the slide and “it looked like he was choking,” Kim recounted. The girl ran over to the wooden structure from a tree house about 25 feet away, Kim said, and “with help from the other kids, pulled Coby up the slide to the top of the structure.”

The girl said that Coby “was purple” and would not wake up, Kim said. That’s when she “yelled to Harold.”

Harold Taylor testified that he rushed to the structure — he was just 10 to 15 steps away — and lifted the 2-year-old’s limp body from the wooden platform. But he was stopped by the cord from the old blue sweatshirt that was caught between the slats. Taylor snapped the cord and ran into the house to perform CPR.

The child was pronounced dead at the hospital at 12:37 p.m. The cause of death was asphyxiation, according to the coroner.

“It’s two months later and I still cry every day,” Taylor said. “It’s hard for me to even go on. These kids are my kids. I’ve had Coby his whole life.”

___

(c) 2008, San Jose Mercury News (San Jose, Calif.).

Visit MercuryNews.com, the World Wide Web site of the Mercury News, at http://www.mercurynews.com.

Distributed by McClatchy-Tribune Information Services. For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Living Cell Technologies Reports Clinical Benefit for All Patients in Diabetes Trial

Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) today released further interim results describing clinical benefit in all patients who have received implants of DiabeCell(R), the Company’s encapsulated porcine islet cells for the treatment of type 1 diabetes.

Six patients with insulin dependent diabetes have now received DiabeCell(R) implants. Five patients in the first group received the lowest dose of 5,000 islet equivalents (IEQ/kg) and two of them have received a second implant of the same dose. To date, no remarkable adverse events have occurred during the trial, which has enabled LCT to meet clinical milestones in relation to safety for up to 12 months follow up.

The trial has been expanded to a second group of five patients and the sixth patient in the trial has been implanted with the higher dose of 10,000 IEQ/kg.

Professor Elliott, LCT Medical Director, said, “At this stage in the DiabeCell(R) trial clinical benefit has been observed in all five patients receiving the lowest dose which has far exceeded our expectations. In the first group, following DiabeCell(R) implants we have seen reductions in daily insulin requirements ranging from 23% to as much as 100% while maintaining good control of blood glucose levels in four out of five patients.”

“In patients who have had the longest follow-up period, we have seen reductions in insulin requirements of 24% and 54% being maintained at 12 and 11 months in the first two subjects respectively. We have also reported the detection of porcine insulin in blood samples of patients confirming that the implanted islets remained functional at 6 months and 11 months after the first implant.”

Improvement in blood glucose control in the group is reflected by the Mean glycated hemoglobin (HbA1c) level which fell from 8.5% pre-implant to 6.8% at the time of last measurement.

The lowest patient response was a 10% maximum reduction in daily insulin requirement. The patient’s HbA1c dropped markedly however, from 10.1 to 7.3 following the implant. This result indicates better blood glucose control after treatment with DiabeCell(R) and continuous glucose monitoring has confirmed this.

“The swings in blood glucose levels and his diabetes control have improved dramatically not with more but with a smaller insulin dose and the lowest dose of DiabeCell(R),” said Professor Elliott.

“The magnitude and duration of clinical responses observed with the lowest dose leads us to expect that higher doses of DiabeCell(R) will support greater and longer term reductions in the insulin needs of patients.”

Dr Paul Tan, LCT CEO, said, “The positive clinical results have prompted us to expand our pig breeding facilities to meet supplies of DiabeCell(R) for advancing our clinical and commercial programs internationally.”

About the trial

 --  The trial is under way in Moscow and is intended to enroll a total of     ten patients having type 1 diabetes who have given informed consent for     their participation --  The trial is being monitored by a U.S.-based contract research     organization (CRO) --  Patients receive one implantation of DiabeCell(R)  at the lowest dose     anticipated to demonstrate a measureable improvement in glucose control     and need for insulin (among other parameters) at the commencement of     the treatment and again following an additional implant six months     later --  The following parameters are being measured pre- and post-implant:         - Daily insulin dose         - Continuous glucose monitoring         - Haemoglobin A1c (to indicate average blood glucose over a           two-month period)         - Porcine insulin in blood after a standard stimulus         - Frequency of episodes of low blood glucose         - Patient satisfaction 

APPENDIX:

Trial Name: A Phase I/IIA, Open-Label Investigation of the Safety and Effectiveness of DiabeCell(R) (Immunoprotected alginate-encapsulated) Porcine Islets for Xenotransplantation in Patients with Type 1 Diabetes.

Protocols: LCT/DIA-07R and LCT/DIA-07R2

Trial Centre Details:

 --  Site: Sklifosovsky Institute      --  CRO: Monitoring by Contract Research Organization, Geny Research Group     (US)      

Clinical Trial Protocol:

Interim report of evaluable data as of 15 July 2008:

Six adult subjects have received implants and two have had a second implant.

 --  The human clinical trial of DiabeCell(R) in Russia has approval to     include 10 patients with Type 1 (insulin-dependent) diabetes. Subjects are     over 21 years old to 65 years of age. The candidates have had type 1     diabetes for at least 5 years with no other complications and provide full     consent for follow-up monitoring. In the first group, five patients     received an initial implant (a simple injection of encapsulated islets into     the peritoneal cavity of the patient) followed by a second implant six     months later. The first implant dose was equivalent to 5,000 IEQ (islet     equivalents/kg).  The second transplant was a further 5,000 IEQ/kg. The     procedure was minimally invasive and administered into the abdomen through     a laparoscope.      

In the second group, five more patients are to receive 10,000IEQ/kg

 Table 1: Patient demographics, implants received and adverse events                      Disease                               Adverse Events Patient             Duration  DiabeCell(R)   Follow-Up      Attributable  ID        Age Sex   (Years)    Implants      (Months)   to Trial Procedure ---------  --- --- ---------- ------------- ---------- --------------------                                                        Fever 38 degrees C                                                        for 3 days at 1 week    1        25   M         10 5,000 IEQ  x2         12  post first implant ---------  --- --- ---------- ------------- ---------- --------------------    2        38   F         15 5,000 IEQ  x2         10                  Nil ---------  --- --- ---------- ------------- ---------- --------------------    3        23   M          5 5,000 IEQ  x1          5                  Nil ---------  --- --- ---------- ------------- ---------- --------------------    4        36   F          7 5,000 IEQ  x1          4                  Nil ---------  --- --- ---------- ------------- ---------- --------------------    5        29   M          5 5,000 IEQ  x1          1                  Nil ---------  --- --- ---------- ------------- ---------- --------------------    6        23   M          6 10,000 IEQ x1          -                  Nil ---------  --- --- ---------- ------------- ---------- -------------------- Note: All Patients were treated with an insulin pump except Patient#4 

Primary Safety Endpoints

There were no remarkable adverse events.

 --  One patient had a transient fever following the first implant.      --  Two patients had transient non-specific upper respiratory symptoms one     at 2 weeks and the other at 12 weeks after the first implant.      --  No remarkable perioperative reactions were reported.      --  There have been no episodes before or after the implants meeting the     criteria for hypoglycaemic state.      --  Results from the first tests for porcine endogenous retroviral     infections are negative in all implant recipients.      

Report on Endpoints to follow are:

 --  Occurrence of hypoglycaemic episodes in the post-transplant period in     comparison with those occurring during the 8-week run-in period.      --  Occurrence of perioperative reactions (e.g. wound infections, local     tissue reactions to the alginate microcapsules at the time of     transplantation).      --  Occurrence of other adverse events or serious adverse events.      --  Abnormal laboratory test results, physical examination findings, or     ECG findings.      --  Psychological impact (as assessed by the ADDQoL quality-of-life     questionnaire).      --  Clinical and laboratory evidence of xenogeneic infection in transplant     recipients via regular monitoring at predefined time points (ongoing).      --  Clinical and laboratory evidence of xenogeneic infection in     partners/close contacts of the transplant recipients (ongoing).      

Primary Efficacy Endpoint

Insulin requirement was adjusted over the post-transplant period to maintain control of blood glucose levels and attain a targeted level of glycated haemoglobin [HbA1c] at or below 7%. Mean HbA1c fell from 8.5% pre-implant to 6.8% at last measurement. Reductions in HbA1c associated with reductions in daily insulin requirement, were noted in 4 of 5 patients (Table 2). In one patient, the HbA1c increased from 7.3% to 7.6% during a 4 month post-implant follow-up period.

 Table 2: Primary Outcome: Reduction in HbA1c                     HbA1c %            ---------------------------  Post-Implant  Patient                                 Follow-Up   ID       Pre-Implant   Post-Implant    (Months) ---------  ------------- ------------- ---------------    1                 7.1           6.9              11 ---------  ------------- ------------- ---------------    2                 8.2           6.5              10 ---------  ------------- ------------- ---------------    3                10.1           7.3               5 ---------  ------------- ------------- ---------------    4                 7.3           7.6               4 ---------  ------------- ------------- ---------------    5                 9.8           5.6               3 ---------  ------------- ------------- --------------- Table 3: Reduction in Insulin Dose                                                 Post-Implant                                           (Follow-Up in Months                  Pre-Implant               after First Implant)            ------------------------- --------------------------------------                           Average     Maximum %    Current %  Patient     Weight     Insulin Dose Reduction in Reduction in   Weight    ID         (Kg)      (Units/Day)  Insulin Dose Insulin Dose     Kg ---------  ------------ ------------ ------------ ------------ ------------    1                108          111      46 (8m)     24 (11m)     101 (9m) ---------  ------------ ------------ ------------ ------------ ------------    2                 66           23     100 (1m)     54 (12m)      65(10m) ---------  ------------ ------------ ------------ ------------ ------------    3                 90           60      10 (1m)       8 (5m)      94 (5m) ---------  ------------ ------------ ------------ ------------ ------------    4                 67           30      29 (2m)      10 (4m)      64 (4m) ---------  ------------ ------------ ------------ ------------ ------------    5                110           78      23 (2m)      23 (2m)     108 (1m) ---------  ------------ ------------ ------------ ------------ ------------ 

Secondary Efficacy Endpoints:

Reduction in daily insulin dose was noted in all patients as summarized in Table 3 with the average maximum reduction of 41.6% (range 10% – 100%) for the group at the current stage of the study. The accompanying current HbA1c ranged from 5.6% to 7.6%. For the same period of observations, none of the patients registered a change of body weight of > 10%.

The reduction in average daily insulin dose requirement was greater than 23% (range 23% – 100%) in four of five patients. One patient (Patient ID# 3) had a maximum reduction in daily insulin dose of 10% only but this was accompanied by a large fall of HbA1c from 10.1% to 7.3% indicating significant improvement in glycaemic control. This was confirmed by the continuous glucose monitoring device recording significant reduction in the amplitude of blood glucose excursions (Mean Amplitude of Glycaemic Excursion to be reported in detail).

Report on Endpoints to follow are:

 --  Glucose lability assessed using 72-hour continuous glucose monitoring     (CGMS(R), Medtronic Minimed, Northridge, CA) at 3, 6 and 12 months post-     transplant in comparison with baseline, reported as standard deviation of     glucose values at these times (Paty et al 2006).      --  Reductions in hypoglycemia and nocturnal hypoglycemia, as assessed by     a composite hypoglycaemic score (HYPO score) over the 12-month post-     transplant period compared with baseline (Ryan et al 2004).  Patients will     be asked to record the frequency, severity and degree of unawareness of the     hypoglycaemia on a scoring sheet.      --  Reductions in the average daily insulin dose of > 25% unaccompanied by     objective evidence of deterioration of diabetes control at 6 and 12 months     post-transplant compared with baseline, as measured by regular 7-point     blood glucose profiles and monthly HbA1C levels, in the absence of evidence     of major weight loss ( > 10%) or ketoacidosis.      --  Changes in endogenous insulin secretion as determined by the plasma     porcine insulin response to a Sustacal Meal at 3, 6 and 12 months post-     transplant.      --  Quality of life changes, as assessed by the ADDQoL quality-of-life     questionnaire, at 6 and 12 months post-transplant compared with baseline.      

Interim Summary and Conclusions

 --  Preliminary data shows that following DiabeCell(R) implantation,     clinical benefit was noted in all 5 patients in the first group who have     been implanted with the lowest dose of 5,000 IEQ/kg DiabeCell(R).      --  In four of the five patients, control of blood glucose levels improved     as reflected by the fall in HbA1c. The mean HbA1c for the group fell from     8.5% to 6.8%. In the patient whose HbA1c did not improve, the average daily     dose of insulin required was reduced by a maximum of 29%.      --  The maximum reduction in daily insulin dose for the five patients     ranged from 10% - 100% (mean 41.6%). In the patient with only 10% reduction     in daily insulin dose, control of blood glucose levels improved markedly as     reflected by the fall in HbA1c.      --  Porcine insulin was detected in blood samples from the first two     patients confirming that the implant remained functioning at 6 months and     11 months following the first implant.      --  There were no remarkable adverse events following implantation of the     lowest dose and the trial has been expanded to a further 5 patients who are     to be administered the higher dose of 10,000 IEQ/kg. The sixth patient in     the trial has been implanted with the higher dose.      

Scientific papers relating to DiabeCell(R) are available for download on the LCT website at www.lctglobal.com/scientificarticles.php

About Living Cell Technologies: www.lctglobal.com

Living Cell is developing cell-based products to treat life threatening human diseases. The Company owns a bio-certified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients having type 1 diabetes, the Company implants micro-encapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. The Company is developing treatments for Huntington’s disease and other neurological disorders that involve implantation of micro-encapsulated choroid plexus cells to deliver beneficial proteins and neurotrophic factors to the brain. Living Cell’s technology has the potential for allowing healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also is developing medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT’s business, which can be identified by the use of forward-looking terminology such as “promising,””plans,””anticipated,””will,””project,””believe,””forecast,””expected,””estimated,””targeting,””aiming,””set to,””potential,””seeking to,””goal,””could provide,””intends,””is being developed,””could be,””on track,” or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of July 22nd, 2008, and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

SOURCE: Living Cell Technologies

Illness of the Brain Worsens in Time

Dementia is a term used to describe symptoms which occur when the brain is affected by specific diseases and conditions, including Alzheimer’s disease and stroke.

It is progressive, which means the symptoms will gradually get worse, but how fast depends on the individual.

Symptoms of dementia include loss of memory, mood changes and communication problems.

In the later stages of dementia, the person affected will have problems carrying out everyday tasks and will become increasingly dependent on other people.

There are several diseases and conditions which cause dementia, including Alzheimer’s disease, which is the most common.

People suffering from multiple sclerosis, motor neurone disease, Parkinson’s disease and Huntington’s disease may also be more likely to develop dementia.

In the UK there are about 700,000 people sufferers, most of them older people.

Most forms of dementia cannot be cured, although research is continuing into the development of drugs, vaccines and treatments.

(c) 2008 South Wales Evening Post. Provided by ProQuest Information and Learning. All rights Reserved.

Sanford Man Accused of Molesting Two Girls

By Gary Taylor, The Orlando Sentinel, Fla.

Jul. 21–A Sanford man is in jail accused of molesting two girls, the Seminole County Sheriffs Office said Monday.

Greg Carter, 42, faces seven counts of lewd and lascivious behavior, five of them involving a child under the age of 12 at the time of the offenses. He listed his occupation on arrest records as a nurse at Central Florida Regional Hospital in Sanford.

The Sheriff’s office began its investigation on July 12 when two people came forward and said they were molested several years ago. Carter was arrested the next day.

Investigators said his wife, Jill Carter, 41, later killed herself at her home on Satsuma Drive. Deputy sheriffs went to the house Tuesday after friends and relatives could not reach the woman and found her dead from a gunshot wound. She was holding a handgun, the sheriff’s office said.

Greg Carter is being held without bail at the county jail in Sanford.

—–

To see more of The Orlando Sentinel or to subscribe to the newspaper, go to http://www.OrlandoSentinel.com.

Copyright (c) 2008, The Orlando Sentinel, Fla.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Healthation CEO Scott Kornhauser to Speak on Real Time Claims Adjudication in the Emerging Healthcare Retail Marketplace

DARIEN, Ill., July 21 /PRNewswire/ — Healthation, a healthcare software solutions company, today announced that their Chief Executive Officer, Scott Kornhauser will be speaking at the upcoming Claims Processing and Adjudication Conference held by California Association of Health Plans (CAHP) at the Marriot Burbank on July 23, 2008. Mr. Kornhauser will be discussing the future of the healthcare marketplace and the overall need for the application of newer technologies and business models to support the multiple point of service adjudication options offered to the consumer.

“In order for all of the stakeholders in our industry to truly realize the benefits of a transformed healthcare marketplace, Healthcare payers need to enable a real-time, workflow and value driven business model at the financial point of service between the consumer and provider,” emphasized Healthation CEO Scott Kornhauser.

About Healthation

Darien, IL- based Healthation is a healthcare claims processing software company helping health plans, third party administrators and self insured employers improve business performance with user-driven rules-based, open architected, benefits management and transaction processing solutions. Healthation’s goal is to accelerate a retail transformation in healthcare with a real-time, open exchange platform. The company’s AcceleHealth(R) solution is the industry’s only web-based payer system built to administer benefits in real-time across all lines of business under one master member record including medical, dental, vision, pharmacy, life and AD&D.

Healthation

CONTACT: Bryan R. Hebert of Healthation, +1-630-324-8818,[email protected]

Pasadena Golf Tournament for Young Cancer Patient

By AMANDA JEROSIMICH for The Maryland Gazette

Shawn Reichenberg Jr., a rising senior this fall at Northeast High School in the fall, is facing challenges beyond what most teens his age encounter.

Battling the stage III Hodgkin’s Lymphma he was recently diagnosed with, Shawn struggles each day to get better. His illness has forced him to sit out of the two sports he enjoys most – football and lacrosse – next season, while the medical expenses and extended hospital stays have put strains on his family.

To help out, Shawn’s family and friends have come together to sponsor a golf tournament at Bay Hills Golf Club, 545 Bay Hills Drive, in Arnold. The tournament will begin at 8 a.m. with a shot gun start at 9 a.m. Sept. 22.

The cost is $100 per golfer, or $400 per foursome. The fee includes a continental breakfast, lunch and beverages. There will be a silent auction, 50-50 and a bottle raffle. The group is also selling hole sponsorships for $150, where businesses can advertise at one of the 18 holes. The group is also seeking local businesses to donate items or services that will be given as prizes during the tournament.

Donations can be mailed to The Shawn Reichenberg Jr. Fund, 2932 Bristol Channel Court, Pasadena, MD 21122.

For more information, contact Seri Garrison at 443-986-4541 or Pat Hesse at 443-889-9307 or [email protected].

Movie night

Jenkins Memorial Church, 133 Riviera Drive, invites everyone to a free viewing of “Bee Movie” beginning at 5:30 p.m. today in the fellowship hall.

Activities for the entire family will include games and contests with prizes.

Popcorn, candy and beverages also will be provided.

For more information, call the church at 410-437-2846.

Monday bingo

Bingo players can get out their markers and head to Lake Shore Volunteer Fire Department, 4498 Mountain Road, starting at 7 p.m. Mondays for a fun evening of bingo.

Games start as low as $6. There is a large jackpot of $1,500 and a small jackpot of $500.

Contact Sandy Schloer at 410-768-0423 for more information.

Firefly fun

Everyone is invited to Fort Smallwood Park, 9500 Fort Smallwood Road, from 8:30 to 9:30 p.m. tonight to learn about fireflies and why they light up summer evenings.

The hour will include a short walk in search of fireflies. Participants should take a flashlight.

For more information, call the park office at 410-222-0087.

VFW dinner bingo

The Veterans of Foreign Wars Post 2462 Ladies Auxiliary, 1720 Bayside Beach Road, will hold a dinner bingo at 1 p.m. tomorrow.

Tickets are $20 and include 20 games, door prizes, dinner, desserts, drinks. There also will be an auction.

For details, call Rosemarie Billings-Briggs at 410-255-7101.

Vacation Bible school

Children ages 3 to 10 are invited to Magothy Chelsea Community Lutheran Church’s vacation Bible school.

The school will be held from 6 to 8 p.m. Monday through Friday at the church, 265 Beach Ave.

For more information, call the church at 410-255-1742.

Craft vendors needed

Community United Methodist Church , 8680 Fort Smallwood Road , is seeking crafters for its annual craft fair.

The event will be held from 9 a.m. to 2 p.m. Oct. 18.

The cost is $25 per space.

For details or to reserve a space, call Louise Stevens at 410- 360-0673 or Mary Lou Myers at 410-255-6058.

Clubs and organizations in the Pasadena area can contact Maryland Gazette correspondent Amanda Jerosimich at 410-437-3564 or [email protected] for publication of their news. {Corrections:} {Status:}

(c) 2008 Maryland Gazette. Provided by ProQuest Information and Learning. All rights Reserved.

CyGene Laboratories Launches StrokeScan(TM) DNA Analysis

CyGene Laboratories Inc. (OTC:CYGE) (“the Company”) announced today that it is introducing StrokeScan(TM), a genetic screening test aimed at identifying high risk individuals who have a family history of stroke, cardiovascular or kidney disease.

Offered at $499, StrokeScan(TM) analyzes genes that have been associated with the increased risk of stroke and the “alpha-galactosidase A” gene that is responsible for Fabry disease. Fabry disease is a genetic disorder that results in an enzyme deficiency that commonly causes death before age 55 by way of stroke, heart attack or kidney failure. Fabry disease was originally thought to occur in only one in 50,000 people. New scientific evidence, based on newborn screening, suggests that it may be over ten times more common as previously believed, and to occur in one in 3,500 people. Simple biochemical tests currently used to diagnose Fabry miss more than 70% of women and 15% of men having the disease. The average time to arrive at a medical diagnosis after the onset of symptoms presently takes over 10 years.

StrokeScan(TM) is based on know-how and intellectual properties that CyGene exclusively licensed from Prof. Dr. Arndt Rolfs of the University of Rostock, Germany. Prof. Rolfs is recognized as one of the leading authorities on Fabry disease and heads the largest global study on Stroke in Young Fabry Patients (sifap study, www.sifap.eu).

Martin Munzer, CyGene’s president and CEO, said, “StrokeScan(TM) has the ability to save lives. Genetic screening of people in high risk groups is essential in order to identify and then diagnose Fabry disease accurately and at an early stage. We believe that without this form of screening, over 90% of Fabry disease carriers will die undiagnosed, whereby many lives could be saved if the disease is identified and treated with approved drugs.”

For more information about CyGene Laboratories and its products and technologies, visit the Company’s Web site at www.CyGeneDirect.com.

About CyGene Laboratories Inc.

CyGene Laboratories Inc., based in Coral Springs, Florida, is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene’s scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets six DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene’s process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available.

Forward-Looking Statements:

The statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Additionally words such as “seek,””intend,””believe,””plan,””estimate,””expect,””anticipate” and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, when or whether the audits of our financial statements will be completed and audit opinions issued, due to unforeseen circumstances or unforeseen issues that may arise during the course of such audits. CyGene Laboratories Inc. has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions.

RACING into RETIREMENT ; My Husband’s Plan for His Golden Years? Not What I’D Expected

By Marcie Summerlin For the Journal

disagree a the am # recent not woman a sale , pushy but I tangled at most Macy person people ‘ with s . would Possibly will at tell you I’m very nice.

When it comes to my husband’s health, though, I can be the tiniest bit of a nag. I was adamant about his behavior shortly after his retirement. He wasn’t following the guidelines I’d read about preparing for that stage. Although I’d gently remind him each day that he wasn’t getting enough exercise, I didn’t receive a positive response. Before I left for work, I taped to the bathroom mirror articles on swimming and a map to our gym, but the cues went ignored, too.

Because he was now detached from the work world, I had another concern. Most males stay healthier in the long run when they have social connections. My male’s social group was the dog and me. How could we keep him engaged?

Neither of us excel at conversation when my husband expounds on topics dear to his heart, such as Civil War battles, beers of the world and the Atlanta Braves. I’d envisioned that when he retired he would join some group dedicated to one of these rarefied interests, say “Lee’s Modern-Day Lieutenants” or “Southwest Beer Fanciers.” I even looked forward to the annual dance or cruise the organization surely would sponsor each year.

What happened to our wellthought-out retirement plan for him? Had I not communicated it clearly?

Don’t get me wrong. He wasn’t idle. Our aging house was benefiting from his lavish attention. The floors and windows stayed spotless. The garden was infused weekly with rose bushes. Cabinets and metal chandeliers were painted. He got more done than Santa on Christmas Eve, but, according to articles about healthy older males, he wasn’t doing the right stuff.

That solitary activity wasn’t raising his heart rate. My concerns were understandable, right?

Out of the blue

But our lives hummed along. I rose at 5 a.m. to go to the gym before work; he climbed out of bed at 5 a.m. to start early at ignoring my hints.

I was resigned to put up with clean floors, great flowers and supper on the table when I arrived home. I can get used to anything after a while.

When his epiphany came, I was surprised. After a typical workday, I found my husband at home grinning like a turtle that has found a piece of melon. He handed me a brightly colored brochure with bicyclists pedalling on the front. “Look! I’ve signed up to do a 100- mile bike ride!”

I couldn’t believe my ears. I fired off challenges, including that he didn’t own a bike, hadn’t ridden in years and couldn’t ride 100 miles.

He was ready. He now had a bicycle and knew of a national charity that would train him for five months to go the distance.

The event was a fundraiser for cancer research, and in exchange for the training he’d raise money for the organization by asking people for donations.

I begged him not to solicit anyone I knew. Not to worry, he said. He’d already drafted a letter sure to make people thrilled to contribute. Who was this person?

Apparently, he’s the retiree I’d imagined. I had to admit he’d nailed it — social group, exercise and all for a good cause.

My Lance Armstrong clone started training immediately for the century. That’s the term for a 100-mile bike ride. His typical morning regimen before a ride involved loading up on carbs (formerly known as bagels), hydration and — Holy Toledo — spandex. Also, many energy gels and bars were stuffed into his jersey pockets.

Note to fashion industry: Why can’t all my blouses have fabulous elastic pockets on them like cycling jerseys do? I could dispense with purses.

As the training miles increased, the weather forecast took on supreme importance. Before long, the Weather Channel announcers seemed to be part of our family.

The weekend rides jolted me. I resented being left behind. But how could I complain when it was for charity?

Getting involved

Well, easy. The charity’s director had heard this from participants’ spouses, and she had a solution: Drive the support and gear vehicle.

The SAG vehicle carries the food, water, air pump and extra clothes the cyclists need. I followed her suggestion. Driving was better than sitting at home as a cyclist’s widow.

Amid the flat tires, steep climbs, wind and heat, I began to realize how tough a century ride is. Occasionally the people with cancer accompanied me to cheer on the riders, and I saw why the riders made the commitment.

After my husband rode his first century (yep, he did it!) he became a program mentor and then a team coach. He helped novice cyclists complete an endurance challenge while making a huge difference to people.

On one trip, an 8-year-old patient, her mom and her little brother joined me in the SAG vehicle. They yelled their hearts out for the team. The mom and I found that neither of us had any sense of direction, which occasionally caused us to become lost. We quickly rejoined our riders, and they seemed to forgive us.

Despite the seriousness of the cause, we shared plenty of laughs. On one of my favorite rides, a participant’s husband brought spray paint and rolls of banner paper. He painted jokes for the cyclists to read as they pedaled by us. At the end, riders called out “It’s the Sign Guy!” and thanked him, saying the anticipated comic relief encouraged them.

We incorporated many rides into vacations. By the time my husband became a cyclist, I’d forgotten about my retirement plans for him. None of my schemes of group Civil War re-enactment dinners or chess club cruises came to fruition. But he found an opportunity to get in shape and improve the world.

Marcie Summerlin became a staff member at The Leukemia & Lymphoma Society after her husband’s first bike ride with its Team In Training program.

(c) 2008 Albuquerque Journal. Provided by ProQuest Information and Learning. All rights Reserved.

Dover-Foxcroft Plans Homecoming Events

DOVER-FOXCROFT – The Shiretown Homecoming Celebration will begin with a free barbecue from 11 a.m. to 1 p.m. Friday, Aug. 1, sponsored by WDME-FM 103.1 and the Piscataquis Observer in front of their two buildings on Main Street.

On the same day, Mayo Regional Hospital will hold its health fair from 2 to 4 p.m.

A parade at 10 a.m. will be followed by music, craft sales, a chicken barbecue, games for children and fireworks at dusk Aug. 2.

(c) 2008 Bangor Daily News. Provided by ProQuest Information and Learning. All rights Reserved.

Mission Man Meets Donor Who Saved His Life

By Lynnea Olivarez, The Monitor, McAllen, Texas

Jul. 19–MCALLEN — More than 35,000 non-Hodgkin lymphoma patients search for a bone marrow transplant every year.

“Right now, only about two in five patients are finding matches,” said Yvonne Ybarra, a director at the National Marrow Donor Program.

Tim Shepard, 19, of Mission, beat the odds.

At United Blood Services in McAllen on Friday, Shepard met the man who saved his life, Terence Johns, a Boston police officer.

“Thanks to Terence, … I’m here today with you all,” Shepard said.

Shepard was initially diagnosed with non-Hodgkin lymphoma in 2003, when he received chemotherapy for a year. He went into remission until shortly after his high school graduation in the summer of 2006. Then his doctors told him that his cancer had come back.

“Terence was Tim’s only match,” said Roland Guerra, Shepard’s uncle and legal guardian. “Without him, he would not be alive.”

In 2008 alone, 66,120 patients have been diagnosed with non-Hodgkin lymphoma, and 19,160 patients have died as a result of this cancer, estimates the National Cancer Institute.

Shepard’s chances of being added to the latter statistic were significantly increased because of his Hispanic and African-American ancestry. (I know correct AP style is “black,” but this is the way that Tim has been described…) Less than 25 percent of the 6 million registered marrow and stem cell donors are of minority racial or ethnic backgrounds, according to the donor program.

Johns, however, said that he “jumped at the chance” to become a donor.

“I dropped what I was doing and was there in the next 30 minutes,” Johns said about his reaction to a message left on his home answering machine informing him that he was a potential match to Shepard.

“When they finally told me I was a match,” Johns said, “it was like one of those television commercials and then they told me the side effects (of donating).”

Guerra said that so many registrants fail to follow through in donating their bone marrow in fear of the physical pain associated with the procedure.

For Johns, the procedure “was the easiest thing I’ve ever done.” He said that he even threw away five out of the six doses of pain medication doctors prescribed.

To help raise awareness of and money for non-Hodgkin lymphoma research and the donor program, nearly 50 bicyclists from the area gathered at Friday’s celebration to participate in a “Hero Ride,” in which participants biked the 250 miles from McAllen to San Antonio.

“As long as we continue fighting, we’re always going to come out on top,” said Letty Zavala, president of Team McAllen Cycling.

For now, Shepard’s own battle has ceased.

He has been in remission for more than a year, and has just completed his first year as a student at South Texas College. Shepard plans to become a pediatric oncologist.

—–

To see more of The Monitor, or to subscribe to the newspaper, go to http://www.themonitor.com.

Copyright (c) 2008, The Monitor, McAllen, Texas

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Global Thought Leaders Outline Unmet Needs, Opportunities in Anxiety and Depression Market in New MedPredict Report

SCOTTSDALE, Ariz., July 21 /PRNewswire/ — MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for anxiety and depression therapies.

In this report, entitled “MedPredict Thought Leader Insight & Analysis: Anxiety & Depression Q3 2008,” a panel of physician experts from North America and Europe discuss the strengths and weaknesses of a variety of branded and near-market antidepressants and anxiolytics.

“In our last report we highlighted three key unmet needs — higher core efficacy, more durable remissions and lower side effects,” said Dr. Jeffery Berk, MedPredict’s president and one of the authors of the report. “This new report identifies the characteristics that next-generation therapeutics will need to go beyond those benefits and deliver enhanced cognition, reduced anhedonia, and relief from pain and fatigue.” Some of the questions addressed by MedPredict’s panel:

— How will FDA’s approval of Lilly’s Cymbalta for neuropathic diabetic pain and fibromyalgia impact its use in depression? How important is a pain indication in treatment of depression?

— In this challenging regulatory and economic environment, what will new therapeutics need to demonstrate to displace current usage of SSRIs, SRNIs and generic antidepressants? How should these studies be designed?

— How do thought leaders view the strengths and weaknesses of Lilly’s Cymbalta vs. Wyeth’s Pristiq?

— What are the differences in prescribing trends among psychiatrists compared with primary care physicians?

— Which of the new molecules and mechanisms in development are most promising? The panel covers triple reuptake inhibitors, antipsychotics, MAOIs, Beta-3 agonists, nicotinic acetylcholine receptor agonists, NMDA/glutamatergics, GABA, CRH and more.

Companies/Partnerships discussed include: Abbott, AstraZeneca, Bristol-Myers Squibb, Forest/Lundbeck, Forest/Cypress/Pierre Fabre, Lilly, Lilly/Boehringer Ingelheim, Lundbeck/Takeda, Merck-Serono, Ono, Novartis/Servier, Pfizer, Sanofi-Aventis, Sepracor, Targacept/AstraZeneca, Wyeth, and others.

   This report can be purchased by contacting MedPredict.    About MedPredict  

MedPredict (http://www.medpredict.com/) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

MedPredict

CONTACT: Elizabeth Mathews of MedPredict, +1-513-271-1924,[email protected]

Web site: http://www.medpredict.com/

FDA Clears Osmetech’s Warfarin Sensitivity Test and New eSensor(R) XT-8 Platform

Osmetech plc (AIM:OMH), the fast growing international molecular diagnostics company, announces that it has received 510(k) clearance from the US Food & Drug Administration (‘FDA’) for its eSensor Warfarin Sensitivity Test to be used as an aid in the identification of patients at risk for increased sensitivity to the widely used blood-thinning drug, warfarin. The Company also announces that the FDA clearance includes its second generation eSensor XT-8 molecular diagnostics platform.

James White, Chief Executive, Osmetech plc, said:

“The FDA clearance is an important milestone for Osmetech. As we gear up the launch of our warfarin sensitivity test in the US this clearance provides further validation of our strategy of targeting the exciting opportunities in the rapidly developing molecular diagnostics market.

“With key technological and regulatory challenges having now been met, we are confident of further commercial success with the launch of our new eSensor XT-8 platform supported by a growing menu of tests planned to include pharmacogenetics, genetic diseases and infectious diseases.”

Warfarin sensitivity test

Warfarin is the most widely prescribed oral anticoagulant in North America and Europe with an estimated 2 million new patients in the US each year. Warfarin is the second-most-likely drug, after Digoxin, to cause adverse events requiring hospitalization. A recent economic study (Brookings Institute, November 2006) concluded that widespread use of warfarin sensitivity testing in the U.S. could avoid 85,000 serious-bleeding events and 17,000 strokes a year, saving healthcare costs of approximately $1.1 billion annually and improving patient care.

Our eSensor Warfarin Sensitivity Test detects the three genetic markers that are known to play a critical role in metabolism of, and sensitivity to, warfarin. Through detection of these genetic markers, doctors are better able to accurately and efficiently determine the appropriate warfarin dosage level. Individuals respond to warfarin differently, and if its administration is not managed carefully, life threatening side effects may occur. Last year, the FDA cleared updated labeling for Coumadin(R) (generic name warfarin) recognizing the role of CYP2C9 and VCORC1 genes in warfarin metabolism.

eSensor XT-8

Our second generation platform, the eSensor XT-8, is designed to support a broad menu of tests and provide accurate results while minimizing technician involvement. We believe that the features of our eSensor XT-8 System compare favorably to those of other molecular detection systems and that its ease of use, readily interpretable results, speed and low maintenance are particularly suited to the needs of the decentralizing market.

About Osmetech plc (www.osmetech.com)

Osmetech plc is an AIM-listed public company on the London Stock Exchange. The company is a fast developing, international diagnostics business with operations in Boston and Pasadena in the US, serving the high growth molecular diagnostic market targeting hospitals and reference laboratories. Osmetech has a strong portfolio of over 200 issued and pending patents and has launched its first generation eSensor 4800 platform, an electrochemistry-based array system, together with an FDA cleared in vitro diagnostic test for Cystic Fibrosis carrier detection.

In an Out-of-Shape Economy, Gym Memberships Decline

By Larissa Theodore, Beaver County Times, Pa.

Jul. 21–SPAS and SALONS

Audrey Guskey, professor of marketing at Duquesne University, said spas and salons are not hurting as much as fitness centers because they are more affordable, convenient and close by.

“People scrimp on certain things like vacations, but they’ll splurge on a tanning center or spa treatment or getting their nails done,” Guskey said. “People will be thrifty, cut coupons for food, or do buy-one-get-one, but they’re not going to not get their nails done, or go tanning or get a massage.”

In the past three years, John DiNardo has seen a decline in gym membership at his Hopewell Township fitness center.

While people quit coming to gyms for various reasons, DiNardo, owner of DiNardo Fitness at 2284 Brodhead Road, is sure the economy can be blamed for many of the departures.

“People are saving for other things instead of spending it on gym memberships … I believe it’s strongly the economy and job situations. There’s not enough good job opportunities in the area,” DiNardo said.

As economic pressures mount, people aren’t giving up exercise, but they are letting go of the extra cost of gym memberships.

“With the gas prices being so high and people being really pressed for money, one of the things that may go is their fitness center memberships, especially in the summertime,” said Audrey Guskey, professor of marketing at Duquesne University.

Fred Kaminski, 75, of Conway is one of them. In shorts, sneakers and a T-shirt, Kaminski walked laps at the Beaver Valley Mall on Friday morning to get in his daily workout. Kaminski used to belong to a gym in Baden, but said he gave it up because he wasn’t interested in the weightlifting equipment, and paying to belong to a gym didn’t add up when he can walk his neighborhood or the mall and get the same results for free.

Now Kaminski, who has had two hip replacements, walks his neighborhood almost daily and goes to the mall when it’s exceptionally hot.

BELT TIGHTENING

Rising prices on everything from food to gasoline are pushing consumers to tighten their belts rather than their abs.

The sluggish economy has caused the first nationwide decrease in gym memberships in more than a decade, according to the International Health, Racquet and Sportsclub Association’s June report.

“While the health and fitness industry historically has been fairly recession-resilient, it is certainly not immune to economic factors that affect the global fitness market — among these factors are the current credit crunch, increased competition and rising expenses,” Katie Rollauer, the association’s senior manager of research, wrote regarding the most recent findings.

The association, which represents the health industry, had projected memberships would increase by 1.5 million from 2006 to 2007, but instead the rate slumped off by about 1 million.

The median cost for monthly gym memberships is $55 for commercial health clubs, with monthly fees ranging from $30 to hundreds of dollars, according to IHRSA figures.

ATTRACTING MEMBERS

Mary Beth Anderson, 47, of Chippewa Township was a member of Curves, but canceled in early spring because she’d rather exercise outside.

“I couldn’t see continuing to go during the summer,” said Anderson as she walked at the Bradys Run walking trail in Brighton Township.

To make up for lost income, some gyms are reducing initial fees or running specials to attract would-be members.

“We run a few specials here,” said DiNardo, who said first-timers are given a chance to join with no money down.

The gym also offers free tours and payment options. Members can opt to pay $58 on the month-to-month basis without a contract, or $48 a month with an annual contract.

DiNardo said memberships tend to drop more during the summer, when many can exercise outside, plan vacations or have children out of school. It’s also hard to entice someone who is already biking or walking to save on gas to come to the gym and use a treadmill.

“People are prioritizing things,” DiNardo said. “What’s most important, spending $40 a day on gas or $40 a month on a gym membership?”

GROWING MEMBERS

Mary Jane Tillia, an employee at Femlines Fitness for Women in Big Beaver, said membership has held fairly steady despite a nationwide decline, although the membership base isn’t huge.

“I just signed up a new member on Monday, so that’s a good sign,” Tillia said.

Bill Parise, director of the Beaver County YMCA, said membership grew by seven members last month to 10,241.

“Our membership is really very steady,” he said.

On Wednesday alone, the Rochester Township facility hit 1,800 visits.

“That’s large for us in the summer,” Parise said. “Part of it is, it’s very hot, and our building is nice and cool. Our numbers have actually been very, very good.”

The Y charges $13 for youth members and about $53 a month for a family. Still, Parise said, the Y always has cancellations, mainly because someone moves out of town. Sometimes people lose their jobs and can’t afford the costs, but in those cases, scholarships to the Y are offered, Parise said.

While canceling may not add much extra to a person’s budget, old-fashioned alternatives, such as parks and bike trails, are free.

“There are a lot of opportunities for Pittsburghers to run, walk, go to the park, go swimming, which may cost $5 per person, rather $100 per month for a family. There are a lot of options that people do have,” said Duquesne University’s Guskey.

Consumers who would rather work out in a gym can ask for a trial membership before joining. Some might find it’s cheaper to pay each time they visit.

Guskey also suggested checking out local high schools, which sometimes have swimming pools at low cost, if not free, or fitness centers that are open to residents.

Larissa Theodore can be reached online at [email protected].

—–

To see more of Beaver County Times, Pa., or to subscribe to the newspaper, go to http://www.timesonline.com.

Copyright (c) 2008, Beaver County Times, Pa.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

TorontoVE:DOC,

Destruction Of Wetlands May Cause "Carbon Bomb"

Threatened by climate change, development and dehydration, wetlands throughout the world could release a “carbon bomb” if they are destroyed, scientists reported Sunday.

These wetlands contain 771 billion tons of greenhouse gases, 20 percent of all the carbon on Earth and about the same amount of carbon as is now in the atmosphere, the ecologists told an international conference.

If all the wetlands on the planet released their carbon, it would substantially increase the climate-warming greenhouse effect, according to Paulo Teixeira, coordinator of the Pantanal Regional Environment Program in Brazil.

“We could call it the carbon bomb,” Teixeira told Reuters during a telephone interview from Cuiaba, Brazil, where the conference is being held.

“It’s a very tricky situation.”

Nearly 700 scientists from 28 countries are convening this week at the INTECOL International Wetlands Conference to search for ways to protect the endangered wetlands.

The wetlands are not merely swamps, but also include river deltas, marshes, mangroves, peat bogs, tundra, lagoons and river flood plains, which together account for 6 percent of the planet’s land surface and store 20 percent of its carbon.   Furthermore, they produce one quarter of the world’s food, purify water, recharge aquifers and buffer violent coastal storms.

Wetlands have traditionally have been viewed as an impediment to civilization.  Indeed, nearly 60 percent of the planet’s wetlands have been destroyed in the past 100 years, mostly due to agriculture draining.   Dams, Pollution, urban development, canals, groundwater pumping and peat extraction have each contributed to the destruction.

“Too often in the past, people have unwittingly considered wetlands to be problems in need of a solution, yet wetlands are essential to the planet’s health,” Konrad Osterwalder, UN Under Secretary-General and director of UN University, told Reuters.

In a statement, the ecologists said the impacts of climate change, to date, are minor compared to human depredations.  As with other environmental challenges, it is far better to maintain the wetlands than attempt to rebuild them later, they said.

As the planet warms, water from wetlands will likely evaporate, and rising sea levels could change the salinity of the wetlands or completely overwhelm them. Nevertheless, wetland rehabilitation is a viable alternative to artificial flood control for managing the larger, more frequent floods and severe storms predicted for a warmer planet.

Northern wetlands, where billions of tons of carbon are stored in permanently frozen soil, are at risk as global warming is thought to be more extreme at high latitudes, according to conference participant Eugene Turner of Louisiana State University.

The melting of Arctic wetland permafrost and the subsequent release of carbon into the atmosphere may be “unstoppable” in the next two decades. However,  wetlands closer to the equator, such as those in Louisiana, can be restored, Turner told Reuters.

Teixeira acknowledged wetlands have a public image problem, and that people generally favor saving the rainforest but not the swamp.

“People don’t have a good impression about wetlands, because they don’t know about the environmental service that wetlands provide to us,” he said.

On the Net: